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Summary
The majority of advanced prostate cancers metastasise to the bone. Mediators o f bone 
remodelling, the bone morphogenetic proteins (BMPs) have extensively been implicated in 
the progression and metastasis o f prostate cancer. Due to the clear importance of BMPs in 
prostate cancer, this study aims to investigate the effects of GDF-9, a relatively unstudied 
member of this family, on prostate cancer cells.
Endogenous GDF-9 expression was altered by over-expression using cloning in PC-3 cells, 
and gene silencing using ribozyme transgenes, in both PC-3 and DU-145 cells. Functional 
assays were then carried out on these cells to determine any changes in their biological 
properties. Furthermore, recombinant GDF-9 (rh-GDF-9) was generated in order to treat the 
cells and confirm the effect it has on prostate cancer cell biological properties as well as any 
as any mechanisms and downstream signalling.
Both endogenous and exogenous GDF-9 led to a promotion in prostate cancer cell adhesion, 
invasion, motility, and growth. GDF-9 mediated growth promotion was shown to correlate 
with an increase in cell cycle progression via up-regulation o f Cyclin D l, and protection 
from caspase 3 mediated apoptosis in a Smad-independent manner. Furthermore, GDF-9 
associated cell adhesion, motility, and invasion, was shown to involve FAK, paxillin, and 
EMT and its associated inducers. These effects act to promote the aggressiveness of PC-3 
cells, aiding in their progression and possibly metastasis.
These results suggest that GDF-9 is involved in prostate cancer progression via activation of 
a complex network of signalling pathways and molecules. This provides further proof of the 
importance of BMP signalling and suggests that perhaps novel treatments for prostate cancer 
based on BMPs should be investigated. In addition, it sheds some light on the use of BMPs 
as prognostic indicators o f disease, aiding in diagnosis and treatment. Whether or not this 
would include GDF-9 requires further investigation.
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Chapter 1 
Introduction
1.1 Prostate Cancer
1.1.1 Epidemiology and risk factors
Prostate cancer is the primary male cancer in the developed world, accounting for 24% of all 
diagnosed male cancers, and is the second leading cause of death from cancer after lung cancer 
(Jemal et al., 2009). Several risk factors have been recognized in the development of prostate 
cancer, the most significant of which include; age, race, diet, family history and place of birth 
(Wynder et al., 1971).
Age is undoubtedly the most important and clear-cut of these factors with prostate cancer being 
most prevalent in men aged over 50. A consistent trend is present where clinical diagnosis of 
the disease increases directly with age. In the US for example, the probability of developing 
invasive prostate cancer is rare in men under the age of 39, with odds of only 0.01%, whereas 
this percentage increases to 2.43% in 40-59 year olds, 6.42% in 60-69 year olds and 15.78% in 
over 70 year olds (Jemal et al., 2009). This trend remains in respect to mortality rates where 
93% of prostate cancer deaths occur in men aged 65 and over, so much so that in men over the 
age of 85, the mortality rate even exceeds that of lung cancer (CR-UK, 2007) (Figure 1.1).
In terms of race, the highest incidence rates are seen in African American men with 60% more 
cases and double the mortality rate compared to that reported in white men of a similar age 
(DeChello et al., 2006). Geographically, a variation is seen in the incidence rates of prostate 
cancer, with rates being far higher in the more developed countries as opposed to the less 
developed ones. North America has the highest prevalence with a rate of 119.9 per 100,000, 
followed by Australia and Western Europe with rates of 79.9 and 61.6, respectively. This is in 
comparison to the rates seen in places like Western Africa and Eastern Asia, where they reach
19.3 and 4.4 cases per 100,000, respectively. Despite this tendency, the more developed 
countries have much higher survival rates due to the larger proportion of early stage diagnoses 
and PSA testing that is performed (CR-UK, 2007). This geographical disparity is mainly
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present due to dietary, racial, and environmental factors, as well as differences in cancer 
detection programmes and medical care in these countries.
Environmental and lifestyle factors found to be capable of contributing to prostate 
cancer development include diet. Several reports have found that high fat intake, dairy 
products, and butter, have a positive association with the risk of developing prostate cancer. 
This is thought to be due to the energy released from saturated fats (Whittemore et a l,  1995). 
Meanwhile, vitamins D and E, soy milk, selenium, and lycopene, a carotenoid found in 
tomatoes, have been reported to modify levels of male sex hormones, and hence inversely 
correlate with prostate cancer risk (Dagnelie et a l,  2004). This is one of the reasons why Asian 
populations with lower fat and higher soy protein intake than western populations, have lower 
incidence rates of prostate cancer.
Finally, there are also hereditary factors that have been found to influence the 
development of prostate cancer. A recent study demonstrated that early onset of prostate cancer 
risk was increased 2.3 fold in men who reported a history of the disease in either a father or 
brother (Chen et a l ,  2008). Several candidate genes have been investigated in order to 
determine their role in hereditary prostate cancer development. Polymorphisms in genes such 
as E-cadherin, CDKN1B, CYP17 and the androgen receptor have been reported to have some 
influence on the risk of developing hereditary prostate cancer (Chang et a l, 2001; Chang et a l, 
2002; Chang et a l,  2004; Jonsson et a l ,  2004).
Although the BRCA genes have been identified as genetic markers for breast cancer, men 
carrying BRCA1/2 mutations were found to have more aggressive forms of prostate cancer of a 
higher Gleason score. For example, men with prostate cancer who carry BRCA2 mutations 
have been shown to have a shorter life expectancy than men with prostate cancer in the general 
population. It would therefore follow that BRCA1/2 mutations are prognostic indicators of
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aggressive prostate cancer, and hence screening male carriers of these mutations for prostate 
cancer, would be of diagnostic use (Mitra et al., 2008).
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Figure 1.1: Number of deaths and age-specific mortality rates, prostate cancer, UK (taken 
from CR-UK, 2007).
1.1.2 Biology, histology, and function of the prostate
The prostate is a composite tubuloalveolar walnut-sized gland of the male reproductive system, 
which is situated within the pelvis at the base of the bladder, surrounding the urethra. The 
prostate is also surrounded posteriorly by the rectum, through which it can be felt, particularly 
when enlarged, during rectal examinations for prostate irregularities.
The prostate is covered by a capsule made up of collagen, elastin, and copious amounts 
of smooth muscle, involved in aiding the mechanical expulsion of semen during ejaculation 
following neural stimulation. Along with this function, the prostate also acts as a sex accessory
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tissue by being responsible for storing and secreting a translucent, somewhat alkali fluid which 
acts to aid sperm motility by liquefying and protecting the sperm when passing through the 
hostile acidic conditions of the female vagina.
The prostate is mainly composed of glandular epithelium which is deposited in a 
fibromuscular stroma. This non-glandular fibromuscular stroma makes up around a third of the 
gland, and stretches from the bladder neck to the striated sphincter. It comprises of fibroblasts, 
smooth muscle, nerves, and lymphatics. The stroma is immediately continuous with the 
capsule, and progressively lengthens into fibrous tissue that terminates in loose connective and 
adipose tissue (McNeal, 1988)
The glandular epithelium meanwhile is made up of three major zones, a concept that 
was defined by Mcneal and his colleagues in 1981. The largest of these zones which makes up 
around 70% of the glandular tissue, is the peripheral zone that stretches to the side and towards 
the posterior of the prostate. This is the site where the majority of prostatic cancers arise. The 
central zone meanwhile, constitutes only 25% of the gland but makes up the majority of the 
prostatic base, and spreads cone-shaped around the ejaculatory ducts to the bladder base. 
Unlike the peripheral zone, only 1-5% of adenocarcinomas develop in the central zone. Finally, 
the transition zone makes up the smallest region at only 5% of total prostate volume, and is 
comprised of two small lobules that lie alongside the prostatic urethra. It is here where the bulk 
of Benign Prostatic Hyperplasia (BPH) originate, which are commonly of lower malignancy 
(McNeal, 1981).
On the whole, the prostatic glands are simply branched and tubuloalveolar in structure, lined 
with both cuboidal and columnar secretory epithelial cells, androgen-dependent for their 
growth. These terminally differentiated columnar cells are rich in secretory granules, keratin, 
and enzymes such as prostatic acid phosphatase, leucine amino peptidase, and PSA. They are 
tightly packed together via cellular adhesion molecules (CAMS), and attached to a basement
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membrane through integrin receptors which connect them to the stromal cells via an 
extracellular matrix, enhancing epithelial cell growth. The apical luminal side of the cells 
contain microvilli, which aid in the secretion and drainage of seminal fluid from the acini into 
ducts linked to the urethra (Hallstrom and Laiho, 2008). Figure 1.2 is a schematic 
representation of the cell types present in the prostatic epithelium.
Along with these cells, the prostatic epithelium is made up of three other cell types; basal cells, 
transient amplifying epithelial cells, and neuroendocrine cells. The basal cells lie between the 
secretory cell layer and the basement membrane. Like the secretory epithelial cells, basal cells 
are also abundant in keratin but are much smaller and less plentiful. They are rounder and less 
differentiated with barely any secretory enzymes, and are independent of androgen for their 
growth. They do however contain large amounts of ATPase, implying that they may play a role 
in active transport. It has been shown that active DNA synthesis occurs only in this basal cell 
layer and so it is this layer that is thought to include the pluripotent prostate stem cells, which 
due to their high regenerative capacity, can act as progenitors for many neoplasms (Dermer, 
1978).
Finally, neuroendorcrine cells are scattered among the basal and secretory epithelial cell layers 
in the acini and ducts of the prostate. It is thought that there are three types of these 
neuroendocrine cells and that they may transmit narrow apical extensions into the lumen 
(McNeal, 1997). These cells can be characterised by their secretion of peptide hormones such 
as serotonin, somatostatin, and calcitonin (McNeal, 1997; Long et al., 2005). The role they 
play in the prostate is still unclear, however it is believed that the cytokines they secrete may be 
involved in the growth and differentiation of the prostatic epithelium. They have also recently 
been linked to prostate carcinogenesis and may give rise to small cell carcinomas in the prostate 
(di SantAgnese, 1998).
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Interactions between the stroma and the epithelium remain elusive but it has been recently 
suggested that the stroma is responsible for producing several growth factors vital for the 
growth and development of the normal as well as malignant prostate. Epidermal growth factor 
(EGF), basic fibroblast growth factor (bFGF), and transforming growth factor beta (TGF-P) for 
example, have been implicated in growth regulation of both the normal and benign prostate 
(Ware, 1993). It has been shown that prostatic epithelial cells but not stromal cells, express 
high levels of the EGF receptor. The TGF-p receptor on the other hand has the opposite 
expression pattern (Scher et al., 1995). In addition, it has been demonstrated that the addition 
of fibroblasts to epithelial tumour cells, promotes their growth in vivo (Camps et al., 1990). 
This suggests that it is indeed the stromal cells that act in a paracrine fashion to regulate the 
biological properties of the epithelial cells, and that cancer cells are capable of exploiting these 
pathways, and along with complex interactions between androgens and cellular communication, 
can lead to the progression and metastasis of prostate cancer. It is therefore of utter importance 
to understand the crosstalk between the epithelial and stromal components of the prostate in 
order to determine cancer aggressiveness.
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Figure 1.2: schematic diagram of the different cell types present in the prostatic epithelium 
(adapted from Hallstrom and Laiho, 2008).
1.1.3 The biology of prostate cancer
Around 95% of all prostate cancers are adenocarcinomas that arise from the prostatic 
epithelium. The remaining 5% of prostate cancers are very rare but are generally of the 
following types; sarcoma, squamous cell carcinoma, transitional carcinoma, signet-ring 
carcinoma, and neuroendocrine carcinoma. These rarer cancers are sometimes more difficult to 
distinguish between, and are usually less responsive to hormonal therapy (McWilliam et al., 
1997).
In prostate cancer, the genetic and epigenetic events that need to occur in order for a cell to 
become cancerous are elusive. However, it is believed that premalignant lesions are present 
that long precede prostate cancer development, as they are often found adjacent to prostate 
adenocarcinomas. There are several types of pre-malignant lesions, the most common being 
Prostatic Intraepithelial Neoplasia (PIN), which is a term that covers the expressions prostatic 
epithelial dysplasia and atypia (Haggman et al., 1997). PIN is described as the appearance of 
morphological atypical or dysplastic epithelial cells surrounded by benign seeming glands and
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acini, with a cell morphology that lies somewhere between that of a benign and a malignant 
cell. PIN is graded depending on the degree of basal cell layer disruption (with more disruption 
being present in high grade PIN) and a gradual reduction in keratin expression, and ranges from 
grade 1 (mild) to grades 2 and 3 (high grade or severe) (Bostwick, 1999).
Proliferative Inflammatory atrophy (PLA) is another form of premalignant lesion that is also 
found near adenocarcinomas and can fuse with high-grade PIN areas. PIA is normally triggered 
in response to tissue-detrimental chronic inflammation that causes oxidative stress, and is linked 
with rapid regenerative cell proliferation (Coussens and Werb, 2002; Palapattu et al., 2005). 
Finally, BPH is a lesion associated with deregulated proliferation of stromal cells but is 
generally not believed to be a precursor of malignant transformation (McNeal, 1984).
1.1.4 Prostate cancer detection
The incidence of prostate cancer increases with age, with an incidence percentage of over 30% 
in men over the age of 50, and up to 80% by the age of 80. However, prostate cancer is 
typically a slow growing cancer, so much so that most never grow to the point where they cause 
symptoms, and the majority of men with prostate cancer die of other causes before the disease 
even impacts their lives. This lack of symptoms becomes problematic, as at the point of 
diagnosis around 75% of patients exhibit locally extensive or metastatic disease, resulting in a 
poor diagnosis of less than 15% 5 year survival rate (Foster, 1990).
Those that do display symptoms however, most commonly present with bladder outlet 
obstruction, nocturia, reduced urinary flow, and deficient bladder emptying-symptoms known 
as prostatism. However, these symptoms are more commonly associated with BPH, and this 
makes it difficult to distinguish between cancers of differing aggressiveness, adding another 
dilemma to the management of prostate cancer. In addition, there are currently no independent 
markers or cellular features that exist to aid in the prediction of the behavior of prostate cancer 
in a specific patient. However, patients with advanced prostate cancer present with symptoms
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such as perineal pain, impotence, and hematuria, while those with metastatic disease exhibit 
symptoms of bone pain and fatigue (Foster and Abel, 1992).
Three main strategies exist in the detection of prostate cancer; serum prostate specific 
antigen (PSA) analysis, digital rectal examination (DRE), and trans-rectal ultrasound (TRUS) 
detection. It has been shown that if a combination of these methods are used, that higher 
prostate cancer detection rates can be achieved. PSA in combination with DRE for example, 
leads to a doubling in detection rates, in comparison to DRE alone (Littrup and Goodman, 
1994).
1.1.4.1 PSA serum test
Prostate specific antigen (PSA) is a glycoprotein with serine protease activity which is located 
within the cytoplasm of both benign and malignant prostate cancers, and secreted exclusively 
by the prostatic epithelial cells. It generally functions as a liquefying agent in semen following 
ejaculation so as to aid sperm when traversing through the uterus (Catalona et al., 1991).
Before the days of PSA testing, most prostate cancers were detected during DREs and TRUS, 
with prostatic acid phosphatase (PAP) being used as the main serum biomarker. PSA was first 
described in 1966, and was later found to be measurable, with increased levels demonstrated in 
clinical disorders of the prostate, such as; BPH, prostatitis, and prostate cancer (Habara et al., 
1966). However, it was only in 1991 that Catalona et al. first assessed PSA as a prostate cancer 
screening test (Catalona et a l,  1991).
PSA circulates in the blood stream in the form of three isoforms, both complexed and free, each 
of which can be measured separately. The lower the ratio of free-PSA:bound-PSA in the blood 
of a patient, the higher the risk of prostate cancer, with a ratio of 25% and less being used as a 
threshold for for instigating biopsies. There are three isoforms of free PSA, including: BPH- 
PSA, inactive PSA, and proenzyme-PSA, or pro-PSA. It has been demonstrated that in benign 
prostatic tissues, levels of both BPH-PSA and inactive PSA are more copious than pro-PSA,
10
whereas in prostate cancer tissues, there is 1.3-1.4 times more pro-PSA than BPH-PSA and 
inactive PSA (Loeb and Catalona, 2008). A PSA level of 4.0 ng/ml and above was believed to 
be indicative of possible prostate cancer, and hence was chosen as the threshold for initiating 
biopsies in prostate cancer diagnoses. Patients with PSA levels of between 0 and 3.99ng/ml 
were referred to as being within the normal range, and hence were normally not biopsied (Gann 
etal., 1995).
The use of PSA serum testing altered the world of prostate cancer diagnosis and it become the 
most commonly used non-invasive method of screening for solid tumours of the prostate. 
Recently however, PSA testing has been shrouded with controversy as limitations to its 
specificity are being questioned. This is mainly due to data from several groups which showed 
that a significant number of men with PSA levels within the ‘normal range’ actually had 
prostate cancer, some even of a high grade. In addition, as BPH, prostatis, and ejaculation can 
also cause an increase in PSA levels, patients who have PSA levels in the range of 4ng/ml- 
lOng/ml, sometimes have to undergo unnecessary and painful biopsies (Thompson et al., 2005; 
De Angelis et al., 2007).
For these reasons, several modifications have been made to PSA testing, including; age-specific 
PSA ranges (Dalkin et al., 1993), transition zone PSA density (Catalona et al., 1998), free to 
total PSA ratios (Catalona et al., 1999), and PSA velocity (Carter et al., 1992). In addition, 
extensive research is being carried out in order to find novel biomarkers for use in protein 
cancer detection. Some of these include; prostate cancer gene 3 (PCA3), and early prostate 
cancer antigen (EPCA and EPCA-2), which are briefly mentioned below.
1.1.4.2 Novel potential biomarkers for prostate cancer
Due to the obvious flaws in PSA testing, research into improved biomarkers for the detection of 
prostate cancer has expanded and yielded numerous feasible candidates. An ideal biomarker 
would require several characteristics in order to be viable, the most important of which are;
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disease specificity, high sensitivity, cost-effectiveness, user-friendliness, and having some sort 
of association to disease outcome.
Most of the targets that meet some of these requirements represent genes with altered 
expression levels in prostate cancer or epigenetic changes that lead to transcriptional changes in 
genes involved in prostate cancer progression (Lin, 2009). The most promising candidates 
include prostate-specific membrane antigen (PSMA), prostate cancer gene 3 (PCA3), and early 
prostate cancer antigen (EPCA).
PSMA is an essential cell-surface marker of prostate cancer, where its expression is specific and 
abundant. Recent development of PSMA-targeted prostate cancer therapies such as vaccines 
have entered clinical trials, demonstrating some promising results (Olson et al., 2007). PCA3 
meanwhile, was discovered in 1999 as a non-coding prostate-specific mRNA highly over­
expressed in prostate cancer tissue compared to normal tissue (Bussemakers et al., 1999). 
Recently, a non-invasive test called the Progensa™ PCA3 test (Gen-probe, San Diego, CA, 
USA) has been developed, which uses PCR to amplify and quantify the ratio of PCA3 to PSA 
mRNA levels, following a DRE. This ratio gives a PCA3 score, which has been used to aid in 
better decision making when contemplating initial and secondary biopsies in patients with 
serum PSA levels between 2.5ng/ml and lOng/ml (Kirby et al., 2009).
Finally, EPCA and its isoform EPCA-2, are nuclear structural proteins specific to prostate 
cancer tissue which can be accurately measured with an ELISA assay that appears to be very 
precise in distinguishing between localized and high grade cancers (Getzenberg et al., 1991). 
However, despite the promising advances seen in these novel biomarkers, a lot more work 
needs to be carried out before they can replace PSA testing in the detection of prostate cancer.
1.1.4.3 Digital rectal examination (DRE)
DRE was the first conventional method used in the detection of prostate cancer, popular in the 
days before PSA testing came about. The process involves an examiner inserting a gloved,
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lubricated finger into the rectum in order to inspect the size, shape, and texture of the prostate, 
and any lumps or nodules that may be present. Areas deemed irregular then go through further 
evaluation to determine whether they are cancerous or not.
However, DRE only evaluates the posterior and lateral aspects of the prostate, and although the 
majority of cancers usually arise in this area, around 25-30% of cancers are not accessible to the 
examining finger and can be missed, therefore making the method insufficiently sensitive 
(McNeal et al., 1986). The method also lacks in specificity, as a large proportion of 
examinations result in false-positives, with around 6-33% of asymptomatic men reporting 
positive values (Richie et al., 1993). In addition, only prostate cancers which are more 
advanced can be felt by DRE, with only about 30% of those detected being organ confined and 
hence potentially curable. Any consequential treatment following DRE therefore typically 
proves less effective and for this reason the method is rarely used as a form of prostate cancer 
detection on its own (Narain et al., 2002).
1.1.4.4 Trans-rectal ultrasonography (TRUS)
Trans-rectal ultrasonography was presented over 20 years ago and is the preferred method by 
which to obtain prostate needle biopsies. The process involves inserting an ultrasound probe 
into the rectum of the patient, and using the resulting image to direct spring loaded 18-gauge 
biopsy needles into abnormal areas of the prostate. The most commonly used technique is the 
six-core or sextant biopsy, with 8 to 10 being carried out to sample the prostate as it leads to 
significantly improved cancer detection rates (Chang et al., 1998).
In TRUS, the typical prostate cancer appears as a hypoechoic nodule, with the larger ones being 
more visible on a sonogram. However, the method provides with very little information as a lot 
of cancers are not visible by sonography, and the 10-15% which are are not blatant, despite the 
majority of the patients having an elevated PSA. Therefore, the low yield, high cost, difficulty,
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and its rare detection of cancers, has led to the omission of TRUS as a screening test (Narain et 
al., 2002).
1.1.5 Prostate cancer grading and staging system
In order to establish which treatment to provide a prostate cancer patient with, the cancer needs 
to be classified and graded using established grading systems such as the TNM staging system 
and the Gleason grading system.
1.1.5.1 The Gleason grading system
The most widely used grading system for prostate carcinomas is the Gleason grading system, 
which was initially described by Gleason and Mellinger in 1974. The grading is based on the 
histological pattern of the distribution and growth of the tumour cells in the prostatic stroma, as 
well as the degree of glandular differentiation in H&E stained prostatic tissue samples from 
either a biopsy, or if after radical prostatectomy, a whole prostate (Gleason and Mellinger, 
1974).
The various growth patterns (shown in Figure 1.3) are combined to form 5 basic grade patterns 
ranging from 1 (least aggressive) to 5 (most aggressive). A histological score ranging from 2- 
10 is then generated, by the addition of the primary grade pattern; the prevailing one in that 
area, to the secondary pattern, which is the subsequently most widespread pattern. However, if 
only one grade is present, or if the second grade covers less than 3% of the total tumour, its 
value is doubled in order to give a corresponding Gleason score.
The most frequently observed pattern of prostatic adenocarcinoma growth is pattern 3, which is 
divided into three distinctive manifestations; A, B, and C. Patterns 4 and 5 meanwhile are only 
presented as forms A and B, whereas patterns 1 and 2 reveal only one outline. The cell 
arrangement seen in each Gleason pattern is described in Table 1.1, and ranges from the closely
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packed well-differentiated carcinoma cells seen in pattern 1, to smooth rounded masses of 
necrotic and very poorly differentiated carcinoma cells in pattern 5 (Humphrey, 2004).
Prostatic  Ad e n o c a r c in o m a  
(Histologic G ra d es )
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Figure 13: Schematic drawing o f Gleason histological grading (Taken from Humphrey at al., 
2004).
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Pattern Tumour shape Stromal Invasion Tumour cell distribution Gland
size
1 Nodular with well 
defined smooth edges
Pushing Single, oval and closely packed 
cells, but detached glands
Medium
2 Less defined and 
constrained masses
Some gland 
separation at 
tumour peripheries
Single, separated, loosely 
packed oval glands, with more 
variation in their size and shape
Medium
3A Indefinable 
infiltrating edges
Irregular extension
variable shape and size, with 
elongated and twisted forms and 
wide stromal separation
Medium
3B Indefinable 
infiltrating edges
Irregular extension As with 3A except with smaller 
glands
Small to 
very 
small
3C Masses and cylinders 
with smooth round 
edges
Expansile Papillary and cribriform 
epithelium without necrosis
Medium 
to large
4A Raggedly infiltrative Disseminated and 
permeative
Amalgamated glands in masses, 
cords, or chains
Variable
4B Raggedly infiltrative Disseminated and 
permeative
As 4A, but cells have cleared 
cytoplasm (hypernephromatoid)
Variable
5A Smooth and rounded 
cylinders
Expansile Papillary, cribiform or solid 
masses with central necrosis 
(comedocarcinoma)
Variable
5B Raggedly infiltrative Disseminated and 
permeative
Masses and sheets of anaplastic 
carcinoma, with some tiny 
glands or signet cells
Variable
Table 1.1: Gleason grading system for prostate cancer (adapted from Humphrey et al., 2004).
1.1.5.2 Tum our Nodal M etastasis (TNM) Classification
The TNM classification of the prostate was first established in the 1940s by Pierre Denoix, but 
was updated by the American Joint Committee on Cancer and International Union against 
Cancer (UICC), in 2002. The system is based on primary tumour (T), lymph node (N), and 
metastases (M) categories, with each one being built on a series of clinical examinations, 
radiological imaging, biopsies, and biochemical analyses (Greene and Sobin, 2002). Clinical T 
staging is the most important prognostic factor for clinically localised prostate cancer, and is
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usually carried out using DRE. Regional lymph node metastases meanwhile are strong 
predictors of progression, and imaging using nomograms is essential for men who have a 
greater risk of developing metastases. Finally, staging for bone metastases has been widely 
used as the established norm for distinguishing outlying metastases of the axial skeleton, with 
MRI being the most reliable means of detection (Borley and Feneley, 2009). The staging is 
described in full detail in Table 1.2, and represented in diagram form in Figure 1.4 below.
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T1 Clinically inapparert; tumor not 
palpable or visible by imaging
T1 a Incidental finding during 
transurethral resection of prostate; 
< 5% oftissue  resected
T1b Incidental finding during 
transurethral resection of prostate; 
> 5% oftissue resected 
T1c Tumor identified by needle 
biopsy (e.g. because of elevated 
P S*)
T3 Tumor extendsthrough prostatic 
capsule, bladder neck or seminal 
capsule
T3a Unilateral extracapsular 
extension
T3b Bilateral extracapsular 
extension
T3c Tumor invades seminal 
vesicle(s)
T4 The tum or has spread or 
attached to  tissues next to the 
prostate (o therthan the seminal 
vesicles).
T4a The tum or h as  spread to the 
neck of the bladder, the external 
sphincter (m usclesthat help control 
urination), or the rectum
T4b The tumor has spread to 
the floor and/to the wall of the 
pelvis.
NO-3 MO-1
12  Tumor confined within prostate 
(palpable or visible on TRUS)
1 2 a  Involves half of a lobe or less
12b  Involves more than  half of a 
lobe one lobe but not both lobes
1 2 c  Tumor involves both lobes
NO C ancer has not spread to any lymph nodes.
N1 C ancer has spread to a single regional lymph node (inside the pelvis) 
and is not larger than 2 centimeters
N2 Cancer has spread to one or more regional lymph nodes and is 
larger than 2 centimeters (% inch), but not larger than 5 centimeters 
N3 Cancer has spread to a lymph node and is larger than 5 centimeters
MO The cancer has not m etastasized (spread) beyond the regional 
lymph nodes
M1 The cancer has m etastasized to  distart lymph nodes (outside of the 
pelvis), bones, or other distant organs such a s  lungs, liver, or brain
Figure 1.4: Diagram showing and explaining the three categories of TNM staging of prostate 
cancer (Simon Kaiser, 2004).
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Stage Characterisation
Primary Tum our (T)
TX Primary tumour cannot be assessed
TO Primary tumour not evident
T1 Tumour clinically inapparent, not palpable or visible by imaging
T la Tumour (non-palpable) as incidental histological finding at transurethral 
resection of prostate in 5% tissue resected.
T ib Tumour (non-palpable) as incidental histological finding at transurethral 
resection of prostate in >5% tissue resected.
T ic Tumour (non-palpable) identified by needle biopsy (for elevated serum 
PSA) includes bilateral non-palpable tumour on needle biopsy.
T2 Tumour confined within prostate (including prostatic apex and prostatic 
capsule) that is either palpable or visible on imaging, or (p-prefix) 
demonstrated in radical prostatectomy specimen.
T2a Tumour involving one-half of one lobe or less.
T2b Tumour involving more than one-half of one lobe or less.
T2c Tumour involving both lobes.
T3 Tumour extends through prostatic capsule.
T3a Extra-capsular extension (ECE).
T3b Invasion of seminal vesicle(s)
T4 Tumour fixed, or invades adjacent structures: bladder neck, external 
sphincter, rectum, levator muscles, and pelvic wall.
Regional lymph nodes (N)
NX Regional lymph nodes cannot be assessed.
NO No regional lymph node metastases.
N1 Regional lymph node metastases within true pelvis, below common iliac 
artery bifurcation, either unilateral or bilateral.
....
Metastases (M)
MX Distant metastases cannot be assessed.
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M0 No distant metastases.
M ia Non-regional lymph node metastasis.
M lb Metastasis to bone(s).
M lc Metastasis to other site(s).
Table 1.2: The 2002 TNM classification for adenocarcinoma of the prostate (adapted from 
Borley et al., 2009).
1.1.6 T reatm ent and m anagem ent of prostate cancer
1.1.6.1 Active surveillance
This method, also known as watchful waiting or expectant management, is the standard 
treatment for patients with T1 or T2 localised prostate cancer. Due to the fact that the natural 
history of patients with localised prostate cancer shows that few of them ever develop 
metastases or die from the disease, and that at present all active treatments for prostate cancer 
result in adverse effects, active surveillance can instead be employed as a less invasive form of 
treatment. This entails strict monitoring o f a patient’s progression by carrying out PSA serum 
tests, DREs, and tissue biopsies, until further action is carried out, if required (Wu et al., 2004). 
The decision to undertake this method however, depends on several crucial factors including 
patient life expectancy, where active surveillance remains a reasonable option in older men with 
a life expectancy of less than 10 years. In the case of younger men however, this method is 
usually only undertaken for a period of around three years as the risk of metastasis increases. 
Other factors to consider include; tumour characteristics and aggressiveness, as well as the 
preference of the patient for a particular treatment regime after being informed of any possible 
adverse effects, efficiency, and issues concerning quality of life (Chodak et al., 1994).
1.1.6.2 Radical prostatectom y
Complete surgical removal of the prostate, or prostatectomy, has been used as a treatment for 
prostate cancer for over a century, and is usually carried out on patients with either early stage
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disease (Tl-T2b), where the tumour is clinically confined to the prostate, or on those who have 
failed to respond to radiation therapy. However, it has also been advocated that its use in 
patients with locally advanced disease (T3-T4) alongside adjuvant radiation therapy, can prove 
beneficial. In contrast, the operation is rarely recommended for older men with a life 
expectancy of less than 10 years, as it proves to offer little benefit and can impose significant 
complications (Bill-Axelson et al., 2005).
In the past, methods included a perineal approach, which was succeeded by the radical perineal 
tactic, where the surgeon removes the prostate through an incision in the perineum. In the 
1940s however, this method was replaced by Millin’s radical retropubic approach which, 
although slightly technically improved, remains the most commonly used form of 
prostatectomy to this day. The method entails the removal of the prostate through the pelvis 
above the pubic bone via an abdominal incision, and offers a considerable advantage over its 
perineal counterpart, as it is simpler to teach, and allows access to the pelvic lymph nodes, 
which is valuable for tumour staging (Millin et al., 1949).
Other more modern methods include the less invasive Laparoscopic radical prostatectomy 
(LRP), or robotic assisted laparoscopic radical prostatectomy (RALP), which unlike the 
previously mentioned methods, do not require a large incision, and rely on modern technology 
such as fibre optics and miniaturisation (Smith et al., 2007).
Prostatectomy is deemed curative only if the entire tumour is removed. However, it can come 
with several complications. In the past these included; impotence, incontinence, morbidity, and 
loss of erectile function. However, due to improved surgical techniques, these complications 
are less common, and morbidity for this procedure is low. The only time treatment failures can 
occur is when the cancer has previously spread to distant sites before the operation has taken 
place, or if the local tumour is not completely excised. For these patients, close monitoring is 
required in order to detect any recurrence (Garnick, 1993).
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1.1.6.3 Radiation therapy
Radiotherapy is commonly used to treat all stages of prostate cancer or when surgery has failed. 
The method uses ionising radiation to damage cellular DNA, and although this occurs in both 
normal and cancer cells, the cancer cells are less capable of repairing the damage and therefore 
undergo apoptosis. Although initially attempted in the early twentieth century, radiotherapy 
only emerged as a principal treatment for prostate cancer in the 1950s. Nowadays, computer 
technology and advanced imaging has revolutionised the preparation and implementation of 
radiotherapy (Hanks et a l ,  1997).
Two types of radiotherapy exist; external-beam radiotherapy, where the radiation is applied 
from an external source, or brachytherapy, where the radioactive source is implanted into the 
prostate. The development of treatment techniques for external-beam radiotherapy began in the 
1950s by Bagshaw and colleagues (Bagshaw, 1969). They instigated the use of megavoltage 
linear accelerators as a means of directing a beam of high dose radiation (4,500-5,400 cGy) 
towards the prostate, with lower doses being applied to the surrounding tissue. The procedure 
is usually delivered using techniques such as intensity modulated (IMRT) or proton beam 
radiotherapy (PBRT), which act to amend the radiation beam to coincide with the shape of the 
tumour, so as to allow for higher doses to be applied to the prostate and seminal vesicles, while 
protecting the bladder and rectum from considerable damage (Zelefsky et a l,  2006). Treatment 
is generally given over a period several weeks, with daily 180 to 200 cGy portions 5 days per 
week, succeeded by a boost to the prostate to a total dose of 6600-7000 cGy. Possible side 
effects include inflammation of the bladder, rectum, and urethra, as well diarrhoea and dysuria 
(Bagshaw et a l, 1977).
Brachytherapy meanwhile, was introduced in 1983 by Holm and colleagues, who 
implemented the stereotactic perineal approach using TRUS guidance. The procedure involves 
the insertion of approximately 100 small radioactive rods (‘seeds’) with the use of a TRUS
22
guided needle through the perineum skin, directly into predetermined positions within the 
tumour, using catheters. The patient is placed in the dorsal lithomy position, and remains under 
general or spinal anaesthesia throughout the whole procedure. The radioactive source of the 
rods can either be of the low-dose rate (LDR), using Iodine-125 or palladium-103 as the source 
of energy, or as a high-dose rate (HDR) with Iridium-192. Currently, LDR is the most 
commonly used form of brachytherapy, with the seeds remaining permanently inserted within 
the prostate, until they eventually become inert and hence not posing a risk of radioactive 
exposure to any surrounding patients (Perez et al., 1993).
Brachytherapy has been shown to cause less damage to external tissues when compared to 
external beam radiotherapy, but is also not as efficient at killing cancer cells that are situated 
outside the prostatic capsule. However, either one of the techniques can be used as a form of 
prostate cancer treatment instead or after surgery of early stage disease, or as a means of 
palliative treatment for painful bone metastases in metastatic prostate cancer patients. 
Hormonal therapy can sometimes be combined with either one, or both types of radiotherapy in 
patients with advanced prostate cancer, as this synergistic effect appears to improve patient 
survival (D'Amico et al., 2004).
1.1.6.4 Androgen ablation therapy
The male sex hormones, or androgens, are essential for both normal prostate growth and 
maintenance, as well as for the development of early stage prostate cancer. Androgens are 
particularly important for the survival and growth of prostate cancer cells, and many groups 
have shown that their suppression results in an inhibition of tumour cell proliferation, activation 
of apoptosis, and a decrease in tumour size (Kyprianou et al., 1990). The concept of using 
androgen ablation for prostate cancer treatment has been around for more than a century and is 
now used as a means for treating advanced and metastatic prostate cancer. However, androgen 
therapy is rarely curative. This is due to the androgen insensitive cells that are present within
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the tumour, and although initial therapy will reduce tumour size, prolonged therapy can act as a 
selective pressure for the androgen independent cancer cells to thrive. These cells can then 
induce re-growth of a tumour which will no longer respond to hormonal therapy (Robson and 
Dawson, 1996).
In order to understand how androgen ablation therapy works, the complex feedback 
loops involved in androgen production need to first be explained (Figure 1.5). The vast 
majority of androgen production (95%) is produced by the testicles, with the remaining 5% 
being produced by the adrenal glands. Androgens are produced by a feedback loop that 
involves the testicles, hypothalamus, pituitary, as well as the adrenal and prostate glands. 
Androgens bind to androgen receptors (AR) within the hypothalamus, resulting in the 
stimulation of Luteinising-hormone-releasing-hormone (LHRH) production, which in turn 
travels to the pituitary where it binds to LHRH receptors, in order to produce Luteinising 
hormone (LH). LH then interacts with its receptors in the testes to induce the synthesis of 
testosterone from cholesterol.
Testosterone finally enters the prostate cells, where the enzyme 5a-reductase converts it to 
Dihydrotestosterone (DHT), which binds with high affinity to ARs. This complex then 
translocates to the nucleus of the prostate cells to activate the transcription of survival and 
growth genes. The whole process acts as a negative feedback loop, as high levels of 
testosterone inhibit production of LH and LHRH in order to maintain a balance of androgen 
levels in the blood. The adrenal glands also produce androgens which feed into the testicular 
androgen production loop (Denmeade and Isaacs, 2002).
Hormonal therapy acts to block testicular androgen production in order to prevent prostate 
cancer cells from using them for continued growth and survival, and this is carried out in one of 
two ways; surgical or chemical castration. Orchiectomy is the surgical procedure, in which 
either one or both (bilateral orchietomy) of the testicals are removed. As the testicles are
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responsible for the majority of androgen production, this results in a massive drop in 
testosterone levels, thereby preventing the prostate from producing DHT, and inhibits prostate 
cancer cell growth (Denmeade and Isaacs, 2002).
However, due to the obvious psychological effects this can have on a patient, there are 
alternative chemical methods available in order to induce castration. The first drug that was 
produced for chemical castration was the synthetic estrogen, diethylstilbestrol (DES). 
However, due to the toxicity issues and cardiovascular complications associated with this drug, 
other drugs were developed. The most commonly used are LHRH agonists, such as leuprolide 
and goserelin, which for the initial 7 days induce a transient increase in testosterone levels- 
referred to as ‘testerone flare’- which can cause considerable bone pain in 5-10% of patients.
However, with continued use, after around 2-3 weeks, the high levels of testosterone act to 
down-regulate LHRH receptors of the pituitary, resulting in a reduction in LH and testosterone 
levels (Vilchez-Martinez et a l,  1979). Side effects are rather mild and include; hot flashes, 
fatigue, reduced libido, impotence, and weight gain. This method therefore proves to be a 
successful form of chemical castration, and results compare to surgical and DES castration with 
significant reductions in PSA levels in 70-80% of patients, and a decrease in pain in 60-80% 
(Tolis et al., 1982).
At the other side of the spectrum is the use of LHRH antagonists which include; Cetrocide, 
Abarelix, and Ganirelix that directly inhibit the LHRH receptor, resulting in a reduction of LH 
and testosterone levels comparable to that caused by LHRH agonists. However, they have an 
added benefit in that they do not cause the painful testosterone flare, characteristic of LHRH 
agonists (Schally et a l,  2000).
The final form of drugs for chemical castration is the anti-androgens, which 
competitively inhibit circulating androgens and DHT from binding to ARs, thereby preventing 
the downstream effects. Initially, the steroidal drug cyproterone acetate was used due to its bi­
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functionality of acting as both an anti-androgen and a progesterone agonist, capable of binding 
the progesterone receptor in the pituitary in order to prevent the release of LH, and the 
corresponding increase in testosterone levels. The resulting effect proved to be equally 
effective as medical castration (Varenhorst et al., 1982). However, due to its considerable side 
effects, novel non-steroidal drugs such as Flutamide, Bicalutamide, and Nilutamide were 
developed, due to their increased tolerance and lack of effect on libido. However, they were 
later found to be capable of crossing the blood-brain barrier and increasing LH and testosterone 
levels, making them a less effective therapy than conventional castration methods, in terms of 
overall patient survival (Chodak et a l , 1995).
As all these new agents were being developed, it became apparent that none of the castration 
methods alone were capable of curing patients with advanced prostate cancer. As mentioned 
above, the adrenal glands are also capable of secreting low levels of androgens alongside the 
testicles, and despite its controversial role in prostate cancer, it was thought that adrenal 
androgen production should be inhibited alongside testicular castration, resulting in a total 
androgen blockade. Adrenelectomy, the surgical removal of the adrenal glands, and 
hypophysectomy, the surgical removal of the pituitary, act as successful ways of inhibiting 
adrenal androgen synthesis, and have been shown to improve survival in prostate cancer 
patients who showed no improvement with testicular androgen ablation alone. Chemical 
methods to inhibit adrenal androgen production come in the form of drugs such as 
Aminoglutehimide and Ketoconazole (Labrie et al., 1982).
When combined with LHRH-agonists, these anti-adrenal androgens prevent the testosterone 
flare reaction seen when LHRH-agonists are used on their own, and the gradual increase of 
testosterone seen when using anti-androgen drugs. This combined therapy showed reports of 
patients with slightly longer progression-free survival (Crawford et al., 1989). In conclusion, 
while androgen-ablation presents patients with a means of significant palliative therapy, due to
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the presence o f androgen-independent cancer cells within the tumour, it is never curative, no 
matter how completely or early it is given.
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Figure 1.5: Schematic diagram of the negative feedback loop in androgen production. (Adapted 
from Denmeade et al., 2002).
1.1.6.5 Cytotoxic chem otherapy (for horm one-refractory prostate cancers)
As mentioned in the previous section, androgen insensitivity poses problems when treating 
advanced prostate cancers. It has been proposed to occur by various mechanisms, including 
hypermethlyation of the androgen receptor and hence silencing of androgen receptor gene 
expression, and during androgen ablation, through amplification o f the AR gene, allowing the 
cancer cells to remain functional at lower concentrations of androgen (Kaarbo et al., 2007). 
Despite this, some androgen-independent tumours will still respond to subsequent hormonal 
therapies. However, there exist some tumours which are hormone-refractory, and hence 
become completely unresponsive to continued hormonal manipulation.
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For these tumours, treatment is possible in the form of cytotoxic chemotherapy. However, as 
these drugs are cytotoxic, they lead to the death of both cancer and normal cells, resulting in 
considerable toxicity and undesirable side effects. However, due to extensive research, 
several newer combination therapies with lower toxicity have been developed. These drugs 
include; Estramustine, Vincristine, Etoposide, Doxorubicin, and the taxanes, Paclitaxel and 
Docetaxel (Hudes et al., 1997). Use of these drugs has demonstrated an increase in patient 
survival, and a significant reduction of 50-75% in PSA levels (Scher et al., 1999). Other drugs 
such as Mitoxantrone in combination with corticosteroid are mainly used as a means of 
palliative treatment in patients with metastatic prostate cancer (Tannock et al., 1996).
In addition, a relatively new drug known as Arbiraterone is currently undergoing placebo 
randomised phase III clinical trials, in patients with hormone-refractory prostate cancers. 
Abiraterone is a potent and highly specific permanent inhibitor of cytochrome p-17 (17a- 
hydroxylyase), a dual enzyme that prevents adrenal enzyme production. 17a-hydroxylyase is 
involved in the production of 5-Dehydroepiandrosterone (5-DHEA) and androstenedione, 
which ultimately end up being metabolised into testosterone. Previous trials have shown that 
hormone-refractory patients treated with Abiraterone presented with a >50% reduction in their 
serum PSA levels, and shrinkage in tumour size. MDV3100 is another novel AR antagonist 
that blocks nuclear translocation of AR and has shown promising results during clinical trials 
(Vishnu and Tan, 2010).
1.2 Cancer m etastasis
Metastatic prostate cancer is responsible for the bulk of deaths associated with the disease, and 
as of yet no curative treatment has been discovered. For this reason the phenomenon of 
metastasis has become an intensively studied area, and it is anticipated that a more thorough 
understanding of the mechanisms behind the process will give rise to novel therapeutic targets, 
capable of delaying or preventing prostate cancer from metastasising.
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Metastasis occurs as a multistage process in which cancer cells migrate from their site of origin, 
and colonise a secondary site in distant organs. The basic steps of the process include; local 
invasion, intravasation, survival in the circulation, adhesion and extravasation, and finally, 
colonisation of a secondary site (Figure 1.6). However, in order for cells to obtain metastatic 
abilities, they must undergo a series of genetic and epigenetic events to help them along this 
metastatic path. Firstly, in order for a primary tumour to develop, a normal cell needs to 
acquire initiating mutations bestowing it with unlimited proliferative potential, tolerance for 
replicative defects, and maintenance of progenitor phenotypes. The tumour slowly grows, but 
these mutations are not sufficient for metastatic competence and hence the cells need to undergo 
further transition (Nguyen et al., 2009).
1.2.1 Local invasion
Local invasion is one of the most essential early steps of the metastatic process, as without it, 
the malignant cells are incapable of migrating from their site of origin. The cells need to 
acquire invasive and motile potential by down-regulating cell-cell, and cell-matrix adhesive 
components. The former, is mediated by cadherin-catenin complexes, the most important of 
which in the case of prostate cancer include, E-cadherin and P-catenin.
E-cadherin is a common tumour suppressor gene, and its loss induces cell detachment and 
invasive potential. Indeed, its expression has been found to be reduced in primary prostate 
cancers, and has been correlated with increased tumour grade, poor prognosis, and bone 
metastasis (Cheng et al., 1996). In addition, it plays a critical role in the process of epithelial to 
mesechymal transition (EMT), which cells are required to undergo in order to progress and 
metastasise. The transition involves the loss of cell polarity, and cell-cell binding, as the cells 
take on a mesenchymal phenotype and increase their expression of N-cadherin, granting them 
with the ability of invading the extracellular matrix (ECM) and migrating to remote sites. P- 
catenin meanwhile, links E-cadherin to intracellular actin, and its expression has been shown to
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be significantly down-regulated in metastatic prostate cancer tissues, in comparison with 
primary tumours, suggesting that its loss of function plays a critical role early on in metastasis 
(Bryden et al., 1999).
1.2.2 Cell-matrix adhesion and ECM degradation
Integrins are critical in mediating cell-matrix binding, and over-expression of some of their 
isoforms has been linked to increased invasion, perhaps due to their involvement in cell motility 
pathways and basement membrane (BM) attachment (Cress et a l,  1995). In addition, they have 
been demonstrated to work alongside ECM and BM degrading enzymes at metastatic sites. The 
most important of these enzymes include matrix metalloproteinases (MMPs), capable of 
digesting the collagen, laminin, and fibronectin, that make up these structures (Nagle et al., 
1994). MMPs are regulated by tissue inhibitors of metalloproteinases (TIMPs), and 
discrepancies in the MMP:TIMP ratio have been shown to induce invasiveness in tumour cells 
(Lokeshwar et al., 1993). Urokinase-type plasminogen activator, an activator of the MMP 
cascade, is of particular importance in metastatic prostate cancer development (Hart et al., 
2002).
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Figure 1.6: The process o f metastasis is characterised by several basic steps; local invasion, 
intravasation, migration in the circulation, adhesion and extravasation, and finally colonisation 
o f a secondary site (Adapted from (Clarke et al., 2009)).
1.2.3 Cell migration and motility
In the prostate as well as other cancers, cell motility and migration depend on GTP-binding 
proteins such as Ras and Rho, which are involved in processes such as cytoskeletal 
construction, intracellular signalling, as well as whole cell, and cell membrane movement 
(Oxford and Theodorescu, 2003). Ras for example, regulates cell proliferation, gene 
transcription, apoptosis, and invasion, and is mutated in around 30% of solid tumours (Adjei, 
2001). Rho GTPases act downstream of Ras, and regulate actin dynamics to lead cell growth 
and movement, important during cell migration and prostate metastasis. Their importance was
Local invasion Intravasation and 
migration
31
proven when the use of inhibitors to the Rho-Ras pathway resulted in a reduction of the 
migratory and motile capacity of prostate cancer cells, suggesting that the pathway is activated 
during metastasis (Sequeira et al., 2008).
1.2.4 Intravasation and survival in the circulation
As a primary tumour grows, it requires more oxygen and nutrients in order to progress. In order 
to overcome this problem, it starts to develop new blood vessels through the secretion of 
angiogenic factors such as hypoxia-inducible factor-1 (HIF-1) and vascular endothelial growth 
factor (VEGF), allowing a greater flux of resources to build up, and the tumour to grow 
(Shweiki et al., 1992). In addition, these blood vessels offer a means of escape for the cancer 
cells to leave the primary tumour, penetrate into the vessel, and shed into the blood’s circulatory 
system through a process called intravasation. This process involves multiple adhesive 
interactions, and is facilitated by the loss of CD82, normally responsible for anchoring tumour 
cells to the endothelium (Bandyopadhyay et al., 2006).
Alternatively, some tumour cells might also enter the circulation through the lymphatic system. 
Cancer cells can invade the lymphatics in the primary site, where they are drained into the 
lymph nodes, and enter the blood circulation either via efferent lymphatic vessels that end up in 
the venous system, or by newly formed blood vessels serving the lymph node metastases 
(Paget, 1889). Tumour cells are then disseminated throughout the body, where the vast 
majority are destroyed during cellular clearance from the circulation, mainly due to their large 
size. The 0.1% that do survive, probably do so by aggregating with platelets in the blood, 
concealing them from immune surveillance through the production of chemokines, cytokines, 
and growth factors (Im et al., 2004). These cells need to survive long enough in order to 
colonise a distant site of preference.
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1.2.5 Extravasation and colonisation of distant site
The idea that cancer cells ‘home’ to specific organs was first recognised by Paget over a century 
ago with his ‘seed and soil’ hypothesis, which states that selected cancer cells (seeds) will only 
readily grow at specific sites (soil) (Paget, 1989). The majority of prostate and breast cancers 
for example, choose the bone as their preferred metastatic site. More recent research however, 
has established that this is probably due to the efficiency of a particular type of cancer cell to 
grow in the microenvironment and molecular background of a specific organ, so ‘the 
compatibility o f the ‘seed’ with the ‘soil’. Other factors that contribute to this homing 
phenomenon are the presence of chemokines and the availability of energy-rich sources (Fidler, 
2001).
Upon arrival at the distant site, the cancer cells arrest on the endothelial surface of the blood 
vessel and undergo transendothelial migration, a process involving numerous adhesive 
interactions initially involving selectins and stabilised by integrin binding (Orr et a l,  1995). 
The cells then penetrate the endothelial junctions by a process known as extravasation. 
Endothelial cells aid in transmigration, as they retract following cancer cell attachment by the 
alteration of the expression, and localisation of adhesion molecules such as N-cadherin, VE- 
cadherin, and PECAM-1 (Voura et a l,  1998).
Once within the secondary site, the new micro-environment surrounding the metastatic 
cells is initially hostile and the survival of the cells depends on their molecular features and the 
ability to successfully engage in cross-talk with their surrounding environment. The 
cytoskeletal protein ezrin appears to facilitate this process by aiding the cells in resisting stress 
and linking them to the cytoskeleton (Khanna et al., 2004). In addition, growth-factor receptor- 
ligand interactions between the cancer cells and host cells result in an interactive signalling 
loop, thereby up-regulating survival pathways and angiogenesis (Derynck et a l,  2001). These
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processes allow the cells to survive and establish themselves in their new environment, 
developing a secondary tumour.
1.3 Prostate cancer m etastasis
At the early stages of prostate cancer, the tumour remains confined within the prostatic capsule. 
However, once the cells acquire genetic changes to make them more aggressive, they begin to 
penetrate into surrounding tissues including; the erectile nerves, seminal vesicles, bladder, and 
rectum. Some cells meanwhile are disseminated around the body via either the lymphatic or 
vascular route. If via the former route, the prostate lymphatics drain into the periprostatic 
subcapsular network, with primary drainage occurring via the internal and external iliac, 
perivesical, obturator, and the presacral nodes, while secondary drainage transpires at the 
inguinal, common iliac, or para-aortic nodes (Cellini et al., 2003). Surviving prostate cancer 
cells can then metastasise to preferred sites which include; the bones, lungs, liver, or brain. 
However as mentioned above, the red bone marrow of the axial skeleton is the preferred site for 
prostate cancer metastasis, with around 90% of advanced prostate cancer patients developing 
skeletal metastases (Taichman et a l,  2002)
1.3.1 Why the bone?
The reason why prostate cancers have a predilection for the bone is as of yet, unclear. 
One possible reason however, may be the high vascularity of the bone marrow, whose 
capillaries (sinusoids) are perhaps more permissive to circulating tumour cells due to the 
fenestrated endothelial cells that line them (Paku et al., 2000). In addition, the prostate is 
surrounded by a rich venous plexus known as Batson’s Plexus, which connects the gland to the 
venous drainage system of the spine, explaining the frequent occurrence of lumbosacral spinal 
metastases seen in advanced prostate cancer patients (Batson, 1995).
34
Another perhaps more important reason is the bone micro-environment, and the bone-derived 
growth factors released by bone cells, which may have proliferative effects on the cancer cells 
(Mundy, 1997). The chemokine receptor CXCR4 for example, has been shown to be involved 
in the motility and invasion of prostate cancer cells during metastatic implantation in the bone 
marrow. In addition, its expression increases with prostatic malignancy, with the highest 
expression levels being seen in highly aggressive and bone metastatic prostate cancer samples 
(Taichman et al., 2002).
Another important stimulus appears to be the need of prostate cancer cells for a lipid source, 
which they require as a form of energy in order to carry out metabolism and tumour cell 
maintenance. This was demonstrated with PC-3 cells, which absorbed lipids and grew rapidly 
when lipids were present within the bone marrow (Brown et al., 2006). The main reason why 
prostate cancer cells are thought to metastasise to the bone however, appears to be due to the 
genetic makeup of the cancer cell itself, allowing it to respond to the osteotropic factors present 
in the microenvironment of the bone, as described below.
1.3.2 Cell biology of bone development
The most common complication in advanced prostate cancer patients is morbidity from bone 
metastasis, with symptoms such as; bone pain, anaemia, pathologic fractures, and spinal cord 
compression. The few treatments that exist are merely palliative, as no cure has yet been 
discovered. For this reason, intensive research has gone into investigating the molecular 
mechanisms behind bone metastasis, and for this a thorough understanding of the biology of the 
bone is required.
1.3.2.1 The bone
The bone is a specialised, highly dynamic connective tissue, hardened by mineralisation with 
calcium phosphate that constantly undergoes remodelling. Its functions are mechanic in nature, 
by acting to sustain and protect body structures, offering rigidity and shape, and aiding in
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locomotion. The vertebrate skeleton is made up of long bones and flat bones, of which there 
exist two major histological types of mature bone tissue. The compact or cortical bone is dense 
and organized in structure, and mostly found in long bone shafts and flat bone surfaces. It is 
composed of concentrically laid down bone, surrounding a network of blood vessels, 
lymphatics, nerves, and connective tissue (known as an osteon or Haversian system). 
Trabecular or cancellous bone meanwhile, is lighter, less dense, and irregular in structure, 
forming the edges of long bones and the inner segments of flat bones. It is made up of 
intersecting rods and plates (trabeculae) with interceding marrow, giving it a sponge-like 
structure. A typical bone is comprised of an outer layer of compact bone that is spread upon the 
surface of cancellous bone and the medullary cavity.
Compact bone makes up around 80% of the total skeleton, situated mainly in the peripheral 
bones, whereas cancellous bone is mainly found in the axial skeleton. However, despite 
making up the minority of the skeleton, due to the greater surface area of cancellous bone, it is 
the site where the majority of bone turnover occurs. This process involves four types of bone 
cells; the osteocytes which are rooted within the bone matrix, osteoblasts and osteoclasts, and 
finally, the bone lining cells which are located on the surface of bones (Datta et al., 2008).
1.3.2.2 Osteoblasts
Osteoblasts derive from mesenchymal cells under the regulation of BMPs, osteoblast- 
stimulating factor (OSF-1), and IGF-I, amongst others (Yang et a l,  2001). The cells secrete a 
collagen-proteoglycan bone matrix known as osteoid, capable of binding calcium salts which 
thereby induces its mineralisation, converting it to bone. This bone matrix deposition occurs in 
both intramembraneous and endochondral bone formation, and is regulated with spatiotemporal 
coordination by a variety of endocrine, paracrine, and autocrine factors (Ducy et al., 1999).
In addition, osteoblasts can regulate the differentiation of osteoclasts by the secretion of factors 
such as Macrophage colony-stimulating factor (M-CSF), Interleukins (IL-1,-6 and -11), tumour
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necrosis factor (TNF), parathyroid hormone, and vitamin D, amongst others, and can also 
regulate osteoclast localisation by altering expression levels of adhesion molecules involved in 
osteoclast:bone matrix binding, allowing osteoblasts to recruit osteoclasts to sites of resorption 
(Athanasou, 1996).
Following bone formation, osteoblasts have one of four fates; to become encased in the bone 
matrix to form osteocytes, undergo apoptosis, trans-differentiate into chondroid or chondroid 
bone depositing cells, or finally, transform into dormant osteoblasts to become bone lining cells 
that cover the bone surface. These cells act as a blood-bone barrier, since they regulate the 
passage of ions in and out of the bone extracellular fluid. In addition, if exposed to parathyroid 
hormone or mechanical forces, they are capable of re-differentiating back into osteoblasts 
(Franz-Odendaal et al., 2006).
1.3.2.3 Osteocytes
Osteocytes are terminally differentiated osteoblasts that have become enclosed within the bone 
matrix, and despite them being the most abundant cellular constituent in adult bone, making up 
95% of all bone cells, little is known about this transformation. However, osteocyte phenotype 
and formation has been linked to type-I collagen cleavage, and a variety of cytoskeletal and 
matrix proteins (Holmbeck et al., 2005).
What is known is that their bone forming capacity is much lower than that of the osteoblasts, 
but despite this they play a vital role in bone structure maintenance. Osteocytes interact with 
each other via a network of cellular processes which proceed inside lacuna-cannaliculi within 
the bone matrix. Recent data has shown that osteocytes act via these networks as 
mechanosensory cells, capable of sensing mechanical stress and strain and interacting with 
osteocytes in order to maintain bone structure and mass (Datta et al., 2008).
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1.3.2.4 Osteoclasts
Osteoclasts are multinucleated cells that originate from haematopoietic precursors of the 
monocyte lineage, similar to macrophages. Due to their lineage, osteoclasts have villous folded 
plasma membranes, resulting in their characteristic ruffled border that acts like a lysosome, 
allowing the cells to carry out phagocytosis, like their macrophage relatives (Ash et al., 1980).
Osteoclasts enter the bone through blood vessels, where they bind to bone surfaces via integrin- 
mediated binding and occupy small depressions in the bone exterior known as Howship 
lacunae, to carry out the process of bone resorption. The osteoclasts secrete enzymes such as 
acid phosphatise as well as hydrogen ions via H+-ATPase pumps into the surrounding tissue, 
resulting in acidification and breakdown of the protein and inorganic portions that make up the 
bone matrix. This leads to bone demineralisation and the hollowing out of bone material to 
form the bone marrow cavity (Baron et al., 1985).
In order to prevent any defects in bone resorption, the number and function of osteoclasts needs 
to be highly regulated, as, if their numbers are too high, too much bone dissolving will occur 
resulting in disorders like osteoporosis, and if too little bone resorption occurs the hollowing of 
the bones for the marrow does not occur, resulting in osteopetrosis (Tondravi et a l, 1997).
1.3.2.5 Bone Matrix
Bone is composed of 50-70% mineral mainly in the form of hydroxyapatite and small amounts 
of carbonate, magnesium, and acid phosphate, which provide the bone with mechanical rigidity 
and strength. The rest is made up of 20-40% organic matrix, 5-10% water, and 3% lipid. The 
bone matrix functions to provide elasticity and flexibility to bone, and is composed mainly of 
type-I collagen with trace amounts of types III and IV, as well as an inorganic fraction made up 
of crystalline mineral salts and hydroxyapatite (Brodsky and Persikov, 2005)
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As mentioned above, bone matrix is deposited by osteoblasts as osteoid, and undergoes 
mineralisation to form bone. Matrix maturation correlates with alkaline phosphatase 
expression, which is secreted by the osteoblasts following mineralisation, and acts to precipitate 
hydroxyapatite which then facilitates calcium and phosphorus sequestration. In addition to the 
presence of collagen in the matrix, there exist a variety of non-collagenous calcium- and 
phosphate- binding proteins such as osteocalcin, osteopontin, and bone sialoprotein, which aid 
in the regulation of mineral deposition by controlling hydroxyapatite crystal size as well as in 
bone turn over and activity. The most abundant non-collagenous proteins however, are 
fibronectin and osteonectin, which are essential in regulating osteoblast differentiation, 
proliferation, and survival. Osteopontin on the other hand, affects the osteoclasts and is 
necessary for bone resorption (Clarke, 2008).
1.3.2.6 Bone marrow
The bone marrow is a highly specialised soft and diffusive connective tissue, known as 
myeloid. It is the source of blood cell production located within medullary cavaties of long and 
spongy bone. There exist two types of bone marrow; red and yellow. Red marrow is the only 
present form in infants and is responsible for the production of red blood cells. As an individual 
ages, this red marrow is progressively substituted by the yellow marrow, where cells have 
become saturated with fat and are incapable of blood cell production.
There exist two types of stromal cells in the bone marrow; haematopoietic stem cells, which 
give rise to three classes of blood cells; leukocytes (white blood cells), erythrocytes (red blood 
cells), and thrombocytes (platelets), and mesenchymal stem cells located in the vicinity of the 
central sinus of the bone marrow. These pluripotent cells are the progenitors of osteoblasts, 
chondrocytes, and myocytes, amongst others. They are capable of self-maintenance throughout 
an individual’s life, whose progeny make up tissues including; bone, tendon, ligament, and 
marrow stroma (Manolagas and Jilka, 1995).
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1.3.3 Bone remodelling: bone formation and resorption
Bone is a dynamic tissue that constantly undergoes remodelling and is capable of enduring 
regeneration throughout life. In order to maintain bone mass, a tightly regulated balance exists 
between osteoblastic bone formation and osteoclastic bone resorption. Remodelling begins to 
occur before birth, and continues throughout a person’s life. It involves the renewal of bone so 
as to sustain bone strength and mineral homeostasis. The process entails the continuous 
removal and resorption of old bone in order to prevent accumulation of bone microdamage, and 
replacing it with newly produced bone matrix that mineralises to form new bone (Clarke, 2008).
The process of remodelling involves four main steps; activation, resorption, reversal, and bone 
formation. Activation entails the recruitment of pre-osteoclasts from the circulation into bone, 
as well as their vitamin-D induced differentiation into mature osteoclasts which bind to the bone 
matrix. The activated osteoclasts then dig out a tunnel and resorb through old bone, closely 
followed by the osteoblasts that enter behind them. Reversal then occurs as the osteoclasts 
undergo apoptosis, and bone resorption is taken over by bone formation carried out by the 
osteoblasts, which line the bone surface and start to deposit layers of matrix into the cavity. 
The signals that link the end of bone resorption with the start of bone formation are thought to 
be triggered by growth factors including; transforming growth factor-P (TGF-(3), bone 
morphogenetic proteins (BMPs), Insulin growth factors (IGFs), and fibroblast growth factors 
(FGFs), as all are induced during bone turnover (Sims and Gooi, 2008).
Bone formation is followed by matrix mineralisation to form new bone, a process regulated by 
the osteoblasts that release small vesicles to induce accumulation of calcium and phosphate as 
well as destroying mineralisation inhibitors such as pyrophosphate and proteoglycans. Some of 
the osteoblasts become enclosed by the newly formed bone to become osteocyte or bone lining 
cells, while the rest undergo apoptosis. The tunnel gradually becomes filled with concentric 
layers of new bone, leaving only a narrow central canal with a capillary that sprouts down the
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centre of it. This canal acts as a means of access for osteoclasts and osteoblasts, while the blood 
vessel transports and supplies the bone cells with nutrients which they require in order to 
survive (Jaworski et al., 1981).
This process is tightly regulated by a variety of hormones, and involves the combined efforts of 
osteoblasts, osteoclasts, osteocytes, and bone marrow stromal cells. The most established 
cellular interaction is between the osteoclasts and osteoblasts, the key players in bone 
remodelling. Osteoclast differentiation, activation, and resorption is dependent on receptor 
activator of nuclear factor-icB ligand (RANKL), osteoprotegrin (OPG), macrophage colony- 
stimulating factor (M-CSF), parathyroid hormone (PTH), and 1,25-dihydroxy vitamin D3.
RANKL and M-CSF are secreted by both osteoblasts and bone marrow stromal cells, and both 
are critical in regulating osteoclastogenesis. M-CSF is critical for osteoclast precursor 
proliferation, differentiation, survival, and cytoskeletal rearrangement, essential for bone 
resorption. RANKL meanwhile, is required for osteoclast activation by inducing receptor 
activator of nuclear factor-icB (RANK). In fact, with low levels of M-CSF, RANKL is essential 
and sufficient for the complete differentiation of osteoclast precursors into mature osteoclasts 
(Lacey et al., 1998).
As the reversal from bone resorption to formation is such a critical step during bone 
remodelling, it makes sense that the osteoblasts control osteoclast activity. Therefore, RANKL 
exists both in a membrane-bound form on the surface of osteoblastic and stromal cells, as well 
as in a soluble form, secreted by these cells. In order to initiate its effects, RANKL needs to 
bind to its receptor RANK, present on the surface of pre-osteoclastic cells. The same is true for 
M-CSF, which is also secreted by the osteoblasts and needs to bind to its own receptor c-fms, 
also expressed on osteoclast precursors. RANK activation by RANK-L binding results in its 
interaction with downstream TNF-receptor associated (TRAF) family members such as; NF-kB, 
c-fos, Jun N-terminal kinases (JNK), and Akt/PKB, inducing transcription of genes vital for
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osteoclast activation and differentiation (Khosla, 2001). These genes include the monocyte- 
chemokines MCP-1 and RANTES, which are critical in the fusion of RANK+ mononuclear 
precursors and hence formation of multi-nucleated osteoclastic cells (Kim et a l,  2006).
Osteoblasts also secrete osteoprotegrin (OPG), a soluble decoy receptor of the TRAF 
superfamily that binds to RANKL with high-affinity thereby inhibiting its effects on the RANK 
receptor (Cohen, 2006). On the other side of the spectrum, osteoblasts can also promote 
osteoclast survival by secreting IL-6, which activates NF-kB and induces osteoblast RANK-L 
expression. Other pro-resorptive cytokines include TNF-a and IL-1 which act mainly by 
promoting M-CSF production and increasing RANKL expression, whereas TGF-p released 
from the bone matrix, has the opposite effect, by up-regulating OPG expression (Takai et al.,
1998).
Systemic hormones also play a role in bone remodelling and include PTH, vitamin D3i and 
glucocorticoids, which are capable of increasing RANKL production or decreasing OPG 
secretion, whereas estrogen increases OPG production (Hofbauer et al., 1999; Lee and Lorenzo,
1999). Finally, a more physical means by which osteoblasts can promote bone resorption is by 
secreting collagenase and tissue plasminogen, which can digest the unmineralised organic 
matrix that covers bone surfaces, and it is under these circumstances that osteoclasts resorb 
most efficiently (Chambers et al., 1985).
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Figure 1.7: Regulation of osteoclastogenesis that occurs during bone remodelling. Adapted 
from (Khosla, 2001).
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1.3.4 Bone metastases
In order for a malignant cell to establish itself in a secondary site, it requires several 
genetic changes to allow it to adapt and take advantage of the nutrients in its novel micro­
environment. Metastasis to the bone occurs in a comparable fashion to the process described in 
section 1.2.6. However, in order to invade this secondary site, the tumour cells need to acquire 
the capacity to migrate through the sinusoidal wall, invade the marrow stroma, and induce 
angiogenesis. Once a prostate cancer cell develops into micro-metastases within the bone 
marrow space, it results in an interruption of the osteoblast-fibroblast microenvironment, 
inducing osteoclast-mediated bone resorption and the discharge of stimulatory cytokines from 
the bone surface.
This in turn sets off a cycle of resorption and tumour stimulation, which as the metastasis 
progresses results in an imbalance of bone resorption and formation, ensuing in a simultaneous 
acceleration of the two processes and hence growth of the bone metastases (Clarke et al., 2009). 
Depending on the balance of bone resorptive and bone formation factors, the tumour cells 
stimulate either osteoclast or osteoblast cell formation, which ultimately decides the type of 
metastatic lesion that arises.
1.3.4.1 Osteolytic metastases
Unlike the bone metastases seen in breast and lung cancers, the majority of the metastases that 
arise from prostate cancer are osteoblastic in nature. However, a crucial first step during 
prostate cancer cell initial migration is the activation of osteoclast-mediated bone resorption. 
This acts as a means of de-bulking the bone, thereby allowing the tumour cells to penetrate into 
the bone matrix and stimulate the release of survival and growth factors that promote tumour 
progression.
Tumour cells induce bone resorption by recruiting osteoclast precursors by the release of 
chemokines such as M-CSF, and induce their differentiation into mature osteoclasts by the
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production of soluble RANK-L and parathyroid hormone-related protein (PTHrP). Increased 
levels of PTHrP have been demonstrated in the PC-3 prostate cancer cell line that is derived 
from bone metastases lesions (Iwamura et al., 1994). Osteolysis carried out by the osteoclasts, 
results in the release of growth factors that act both as autocrine and paracrine effectors of 
tumour cell survival, and later on, cytokines that promote bone formation. The former includes 
TGF-P, which in breast cancer is capable of increasing PTHrP tumour cell expression, resulting 
in a vicious cycle whereby PTHrP increases bone resorption, inducing a greater release of 
growth factors capable of inducing its own production and thereby promoting tumour cell 
growth (Mundy, 2002).
Osteolysis also promotes production of interleukins-8 and -11 (IL-8, -11) secreted by 
osteoblasts and bone marrow cells, which are chemokines capable of inducing osteoclast 
differentiation (Bendre et al., 2005). Meanwhile, family members IL-11 and IL-6 act as 
important mediators of pathological bone loss, and hence can stimulate osteoclast formation and 
activity. In addition, IL-6 can regulate the expression of members of the T family including 
RANK and OPG (Yang et al., 2005).
1.3.4.2 Osteoblastic metastases
As mentioned above, prostate cancer bone metastasis mainly results in the formation of 
osteoblastic lesions. Symptoms arising from this include; anaemia, increased vulnerability to 
infection, bone pain, pathological fractures, and spinal-cord compression. In order for these 
osteoblastic metastases to develop, bone resorption needs to occur so as to allow the tumour 
cells to invade the bone matrix, and eventually tip the neighbouring cytokine environment in 
favour of bone formation. The interactions between tumour cells, bone cells, and the bone 
matrix, form a cycle of osteoblastic lesion development (Figure 1.8). The mature osteoblasts 
proliferate and deposit new matrix for bone formation, and this un-mineralised matrix supplies 
the tumour cells with a fertile environment full of growth factors and non-collagenous proteins,
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which aid in tumour cell survival and proliferation. The tumour cells then in turn activate more 
osteoblasts, resulting in a cycle of bone formation and tumour growth (Clark and Torti, 2003).
The switch between osteolysis and bone formation is thought to occur due to the secretion of 
OPG by the tumour cells. As mentioned previously, OPG is a decoy receptor that can inhibit 
RANK-L secreted by the tumour cells, and thereby inhibits osteoclastogenesis and bone 
resorption. In addition, OPG acts as a survival factor by binding to monocyte-induced Tumour- 
necrosis factor-related apoptosis-inducing ligand (TRAIL) thereby protecting it from TRAIL- 
induced apoptosis. Therefore, over-expression of OPG by prostate cancer cells may explain the 
osteoblastic phenotype of the resulting bone metastases (Holen et a l,  2002).
In addition, prostate cancer cells secrete a variety of osteogenic factors including endothelins 
(ETs), TGF-J31, BMPs, IGFs, FGFs, platelet-derived growth factors (PDGFs), urokinase-type 
plasminogen activator (uPA), and PSA, which by inducing bone formation provide a fertile 
environment for prostate cancer cells, allowing for their survival and proliferation. Endothelins 
for example, are important factors in the regulation of bone formation, synthesised in vascular 
endothelial cells. When applied exogenously to prostate cancer cells, ETs act via the 
Endothelin-A receptor (ETAR), to enhance cell proliferation and osteoblast over-stimulation, 
along with promotion of the mitogenic effects of other growth factors such as IGFs, making it 
an essential intermediary of osteoblastic metastasis (Guise et a l,  2003). Treatment with ETAR 
agonist Atrasentan, has demonstrated promising results, with patients displaying reduced 
skeletal morbidity as well as a prevention of osteoblastic lesions in mice (Carducci et a l,  2003).
Levels of IGFs (IGF-1 in particular), are locally increased within the bone micro­
environment, and mitogenically stimulate osteoblasts and decrease collagen degradation as well 
as supporting the survival and growth of prostate cancer cells. This local increase in IGF-1 
levels correlates with an increase in the concentration of uPA and IGF-binding proteins, 
resulting in a release of active IGF-1, and hence an enhancement in IGF-receptor mediated
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osteoblast and prostate cancer cell proliferation (Koutsilieris and Polychronakos, 1992). It 
therefore comes as no surprise that IGF-I levels have been demonstrated to be associated with 
increased risk of prostate cancer, with low levels of IGF binding protein 3 (IGFBP-3) being 
present in patients with bone metastasis (Chan et a l,  1998).
FGFs meanwhile, are vital in the regulation of processes such as migration, proliferation and 
differentiation, and in the bone both the FGF-1 and FGF-2 isoforms can induce proliferation of 
immature osteoblasts, while decreasing the proliferation of mature osteoblasts. In addition, 
FGF-2 can inhibit osteoclastogenesis, suggesting that both isoforms can induce multiple and 
complex effects on bone cells (Valta et a l,  2006). PDGF isoforms can act as potent osteotropic 
factors that can contribute to osteoblastic migration and proliferation (Yi et a l,  2002).
PSA is a highly secreted prostate cancer protein with kallikrein serine protease activity. It acts 
to cleave osteolytic PTHrP into osteoblastic fragments capable of inducing bone formation due 
to their homology to ET-1, and capability of activating ETAR. Like uPA, PSA is also capable 
of cleaving IGFBP3 to release IGF-1, which promotes osteoblast proliferation. In addition, it 
can activate osteoblastic growth factors, including TGF-p. This again helps explain the 
osteoblastic phenotype of prostate cancer metastases (Cohen et a l,  1994).
Finally, although several members of the TGF-P family promote osteoclastogenesis, TGF-p2 is 
expressed by prostate cancer cells and is capable of inducing osteoblastic metastases. 
Constituents of the BMP subfamily, including BMP-2, -6, and -7, have high expression levels 
in prostate cancers and induce a similar bone-inducing effect. BMP-2 for example, promotes 
bone formation and regulates mineralization by synergizing with the Wnt pathway. BMP-6 
meanwhile has the opposite effect as it can enhance PTH and vitamin-D induced osteocalcin 
expression, which is vital in the regulation of osteoclasts (Masuda et a l,  2003).
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Figure 1.8: Mechanisms of osteoblastic metastases in prostate cancer. Tumour cells and the 
bone microenvironment interact to constitute a vicious cycle that contributes to the predominant 
osteoblastic lesions that form in metastatic prostate cancers (Adapted from (Fili et al., 2009)).
It is believed that with thorough understanding of the many complex pathways that occur in the 
bone, that anti-survival factors capable of inhibiting the pathways that aid in the growth of the 
cancer cells in this microenvironment can be developed. This would therefore allow for the 
production of drugs that can prevent or inhibit the metastasis of prostate cancer. The family of 
growth factors that this project focuses on is the bone morphogenetic protein family whose role 
in prostate cancer remains elusive to this day.
1.4 T he T ransfo rm ing  G row th  Factor-P  (TG F-P) superfam ily
The Transforming Growth Factor-p (TGF-p) superfamily is one of the biggest and most 
influential, ubiquitous family of proteins. To date, more than 30 structurally related growth
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factors have been identified in the TGF-p superfamily, including: TGF-ps, Activins, Inhibins, 
Bone and Morphogenetic Proteins (BMPs), Growth and Differentiation Factors (GDFs), and 
Mullerian Inhibiting Substance (MIS) (Heldin et al., 1997). Members of this family are dimeric 
pleiotropic proteins that are ubiquitously expressed in a wide range of different cell types, 
tissues, and species. They play an important role during embryonic development and regulate 
a wide variety of cellular processes including; proliferation, growth, migration, differentiation, 
apoptosis, and extracellular matrix production (Schmierer and Hill, 2007).
1.4.1 The Bone Morphogenetic Protein (BMP) family
The BMP subfamily contains over 20 members, which were initially described as inducers of 
bone formation by Urist et al. in 1965 (Granjeiro et al., 2005). Table 2.1 summarises the 
BMPs identified to date, along with the receptors they bind to. Like other members of the TGF- 
P superfamily, BMPs are synthesised as large precursor proteins, which following dimerisation, 
are proteolytically cleaved by a furin peptidase at the consensus sequence Arg-X-X-Arg. This 
leads to the formation of biologically active mature dimers, 110 to 140 amino acids in length. 
BMPs form either homo- or hetero-dimers linked by disulphide bonds, which is necessary for 
their biological activity. The active domain of BMPs contains a conserved motif of seven 
cysteines, six of which form a structure known as a cysteine knot, and this is involved in 
dimerisation (Massague et al., 1994).
Active BMP and TGF-P ligands signal through two types of serine/threonine transmembrane 
receptors; seven type-I and five type-II TGF-P receptors. Activation of these receptors leads to 
downstream signalling via two independent pathways; the Smad-dependent and Smad- 
independent pathways. Smads are the downstream signalling molecules used by TGF-p family 
members to alter the expression of their responsive genes, leading to changes in cellular 
properties (Miyazawa et al., 2002).
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TGF-p ligands can also interact with coreceptors that can either promote or impede receptor 
kinase signalling. Endoglin and the proteoglycan betaglycan (TGF-pRIII) for example, are 
capable of regulating TGF-P signalling. More specifically, TGF-pRIII mediates both ligand 
dependent and independent signalling via smad and non-smad signalling pathways. Its ligands 
include; TGF-p 1, 2, and 3, inhibin, and BMP-2, -4, and -6. In most cases, presentation of these 
ligands by TGF-pRIII increases their binding to their type-I and type-II receptors, and thereby 
promotes smad signalling. As TGF-P signalling is often growth inhibitory, this synergisation 
may be one of the reasons why TGF-pRIII is often lost in cancers. However, when bound to 
inhibin, the type-III receptor can lead to inhibition of BMP and TGF-P signalling (Gatza et al., 
2010).
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BMP Alternative
names
Type-I
receptors
Type-II
receptors
Smads References
BMP-2 BMP-2a ALK 3/6 BMPRII
ActRIIA 1/5/8
(Koenig et al., 
1994),(Liu etal . ,  1995), 
(Yamaji et al., 1994)
BMP-3 Osteogenin ALK 4 ActRILA 2/3 (Daluiski et al., 2001)
BMP-3B GDF-10
BMP-4 BMP-2B ALK 3/6 BMPRII
ActRIIA
1/5/8 (ten Dijke etal . ,  1994; 
Regazzoni et al., 2001)
BMP-5 ALK 3 1/5/8 (Beck et al., 2001) 
(Mailhot et al., 2008)
BMP-6
Vrgl, Dvr6
ALK
1/2/3/6
ActRIIA
ActRIIB
BMPRII
1/5
(Ebisawa et al., 1999; 
Ahmed et al., 2001)
BMP-7 OP-1 ALK2/3/6 BMPRII
ActRIIA
1/5/8 (Liu et al., 1995; Aoki 
et al., 2001; Nakagawa 
et al., 2004)
BMP-8A OP-2 ALK 3/6 (Zhao et al., 2001)
BMP-8B OP-3
BMP-9
GDF-2 ALK 1
ActRIIA
ActRIIB
BMPRII
1/5
(Brown et al., 2005; 
Lopez-Coviella et al., 
2006)
BMP-10 ALK 3/6 BMPRII
ActRIIA
1/5/8 (Mazerbourg et al. , 
2005)
BMP-11 GDF-11 ALK 4 ActRIIA
ActRIIB
2/3 (Oh etal . ,  2002; 
Andersson et al., 2006)
51
BMP Alternative
names
Type-I
receptors
Type-II
receptors
Smads References
BMP-12 GDF-7,
CDMP-3
ALK 3/6 BMPRII
ActRIIA
(Zhao et a l,  2001)
BMP-13 GDF-6 ALK 3/6 BMPRII
ActRIIA
1/5/8 (Gordon and Blobe, 
2008)
(Zhao et a l,  2001)
BMP-14 GDF-5 ALK 3/6 BMPRII
ActRIIA
1/5/8 (Chen et al., 2006)
BMP-15 GDF-9B ALK 6 BMPRII 1/5/8 (Moore et a l,  2003)
GDF-1 - ALK 4 ActRIIB 2/3 (Cheng et a l, 2003)
GDF-3 ALK 4/7 ActRIIA
ActRIIB
2/3 (Andersson et a l,  2007; 
Andersson et a l,  2008)
GDF-8 ALK 4/5 ActRIIB 2/3 (Rebbapragada et a l , 
2003)
GDF-9 ALK 5 BMPRII 2/3 (Mazerbourg and 
Hsueh, 2006)
GDF-15
PDF, MIC-1, 
PLAB, 
NAG-1, 
PTGFB
TGF-PRII 2/3 (Xu et a l, 2006; Johnen 
et a l,  2007)
Table 1.3: All identified BMPs to date, and their corresponding type-I and type-II receptors as 
well as the R-Smads they activate. Empty boxes mean receptors/smads have not yet been 
identified.
1.4.2 Bone Morphogenetic receptors and their structure (BMPRs)
Members of the TGF-p superfamily bind to two diverse subfamilies of receptors in order to 
mediate their cellular activity. These receptors termed type-I and type-II, are transmembrane 
serine/threonine kinase receptors. Both receptor types are required for downstream signalling
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to occur; the type-I receptors are unable to bind their ligands without the presence of the type-II 
receptors, while the latter is incapable of signalling without their type-I counterparts (Wrana et 
al., 1994). Seven type-I TGF-p receptors have been described in humans (Table 1.3), known as 
Activin Like Kinase Receptors 1-7 (ALK), of which all bind BMPs except for ALK-7. In the 
case of type-II Receptors, five receptors have been identified of which only 3 bind BMPs; BMP 
Receptor type-II (BMPR-II), Activin A Receptor type IIB (ActRIIB) and ActRIIA. TGF-P 
receptors type-II and -III are the type-II receptors used by TGF-P ligands (Moustakas and 
Heldin, 2009).
Both types of receptors are conformationally conserved and are made up of an amino terminal 
extracellular ligand binding domain, a single transmembrane domain, and a large 
serine/threonine kinase domain at their carboxyl-terminal (Attisano et al., 1994). Figure 1.9 
shows a structural diagram of both the type-I and type-II receptors.
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Figure 1.9: Structural diagram of the type-I and type-II TGF-0 receptors which are very similar 
to the BMP receptors. The boxes represent the conserved domains of most of the receptors of 
this family and the horizontal lines in the ECD represent the extracellular conservedly spaced 
cysteines. Adapted from (Kingsley, 1994).
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1.4.2.1 Receptor extracellular ligand binding domain
The structure of the extracellular domain (ECD) of both receptor types resembles the three 
finger toxin fold seen in several snake venom neurotoxins. The central P-sheet of this structure 
has a common pattern of eight characteristically spaced conserved cysteines, held together by a 
cluster of disulphide bonds (Greenwald et al., 1999; Kirsch et al., 2000). The three finger fold 
of one of the main type-I BMP receptors ALK-3 (BMPR-IA), is made up of two P-sheets, one 
a-helix, and two disulphide bonds. The other main BMP receptor, ALK-6 (BMPR-IB) has 10 
cysteines in its motif and shows 42.1% amino acid homology to the extracellular domain of 
human BMPR-IA.
The spacing of the cysteine motif in the ECD is homologous in all type I receptors, and is 
independent of their ligand binding specificity. Two distinctive domains exist within this 
cysteine stretch; six characteristically spaced cysteines at the N-terminal, and a cysteine box 
motif at the C-terminal composed of three cysteines which is characteristic of all TGF-p 
receptors, including type-II receptors (Wrana et al., 1994). In addition to the conserved 
cysteine motif, the C-terminal of both type-I and type-II receptor ECDs have conserved clusters 
of hydrophobic residues, critical in ligand binding. The structure of this groove of residues is 
common in both types of receptors, but is less distinct in type-II receptors. In addition, all type- 
I receptors apart from ALK-1, have a large protruding hydrophobic residue on the core a-helix 
which fits into a hydrophobic pocket of the ligand. This process is known as the ‘knob into 
hole’ motif of type-I receptor ligand binding (Kirsch et al., 2000).
The ECD of ActRIIA, ActRIIB, and BMPR-II, on the other hand, does not include an a-helix, 
and is made up of three anti-parallel p-sheets held together by four disulphide bonds. The first 
finger of the type-II receptor three finger toxin fold is the least conserved and shows most 
variability suggesting that it may act as a docking site for ligands and determines binding 
specificity (Kirsch et al., 2000).
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1.4.2.2 Receptor kinase domain
The intracellular cytoplasmic region of both types of receptors consists of an enzymatic 
serine/threonine kinase domain critical in transducing the downstream signal of BMPs. The 
kinase domains of the type-I receptors are highly conserved, but only share 40% homology with 
the amino acid sequence of the type-II kinase domain (Kingsley, 1994). Type-I receptors have 
a highly preserved region of 30 amino acids rich in serine and glycine, juxtamembrane and near 
to the N-terminal of their kinase domain (Wrana et al., 1994). This SGSGS motif is known as 
the GS domain and functions as a substrate for phosphorylation by the type-II receptors. This 
transphosphorylation is critical as it is required for activation of the type-I receptor, and hence 
downstream signalling.
In addition, type-I receptors have a 9 amino acid segment in their kinase domains known as the 
L45 loop, that along with an L3 loop in the C-terminal of Smads, is responsible for establishing 
the specificity of receptor-Smad interactions (Chen et al., 1998). The type-II receptor kinase 
domain on the other hand, is constitutively active and hence does not require any activational 
phosphorylation event (Mace et al., 2006). In addition, type-II receptors have a short serine- 
threonine rich tail at the C-terminal of their kinase domains, not seen in type-I receptors 
(Attisano et al., 1994).
1.4.3 The BMP signalling pathway
1.4.3.1 Ligand binding
TGF-p and BMP receptor mediated signalling involves ligands binding and activating specific 
multi-subunit receptor complexes to trigger a cytosolic kinase cascade (Wrana et al., 1994). 
Each ligand subunit is responsible for recruiting one type-I and one type-II receptor to form a 
receptor complex composed of six polypeptide chains containing the two ligand subunits and 
two pairs of each receptor type. In order to compensate for the outnumbering of receptors by 
ligands, receptors are capable of binding multiple ligands. Binding affinity is dependent on the
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energetic stability of the hydrophobic and electrostatic interactions between ligands and the 
receptor ECD (Allendorph et al., 2006).
In the case of TGF-p, the ligand binds to the knuckles of the three finger toxin fold of the 
receptor, where a sequential binding model is apparent, with TGF-P initially binding to its high 
affinity type-II receptor as a pre-existing homodimer allowing for the recruitment of the type-I 
receptor. This induces a conformational change in either the ligand or the receptor, resulting in 
an increased cross-linking ability between the two. This leads to activation of the Smad 
pathway via Smads 2 and 3.
As opposed to other TGF-p members, BMPs bind to the concave surface of the curved fingers 
of the receptor and have higher affinity for the type-I rather than the type-II receptor. BMPs 
can activate two different pathways depending on the way they oligomerise to the same types of 
receptors. If BMPs bind to preformed heteromeric complexes (PFC) of type-I and type-II 
receptors simultaneously, the Smad-dependent pathway is activated. On the other hand, if 
BMPs initially bind to their high-affinity type-I receptor and then recruit the type-II receptor 
into a heteromeric complex known as the BMP-induced signalling complex (BISC), this leads 
to activition of the Smad-independent pathway (Nohe et al., 2002).
1.4.3.2 The Smads
Smads are the downstream cytoplasmic signalling molecules of type-I TGF-p and BMP 
receptors. They are homologues of the originally identified mothers against decapentaplegic 
(Mad) and Sma proteins, found in Drosophila and C. Elegans, respectively (Heldin et al., 
1997). To date, 8 Smads have been identified in mammals. Smads are grouped into three 
subfamilies based on their structure and function; the receptor-regulated Smads (R-Smads); 
Smads 1, 2, 3, 5, and 8, common-partner Smad 4 (Co-Smad), and inhibitory Smads (I-Smads); 
Smads 6 and 7 (Moustakas et al., 2001). Figure 1.10 is a structural diagram of the three Smad 
subtypes showing their conserved domains and functions. R-Smads are direct substrates of the
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type-I serine/threonine receptors and are phosphorylated at their C-terminal Ser-Ser-X-Ser 
(SSXS) motif by these receptors, resulting in R-Smad activiation. Of the R-Smads, Smads 2 
and 3 are known as TGF-(3/activin activated Smads, whereas Smads 1, 5, and 8 are the BMP 
activated Smads (Miyazawa et a l , 2002).
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Figure 1.10: Structural diagram of the three Smad subtypes showing areas of homology (filled 
boxes) as well as conserved areas of functionality. In the case of the R-Smads, Smad2 doesn’t 
have DNA binding activity while Smad3 has an extra nuclear localisation signal (KKLKK). 
The SSXS motif at the C-terminal of R-Smads is a substrate for phosphoiylation by type-I 
receptors. Smad4, unlike the R-Smads can’t bind to the receptors and lacks this motif and 
instead uses the MH2 domain to interact with the R-Smads.
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Smad2/3 has been shown to colocalise to the cell membrane via a FYVE domain Smad 
interacting protein known as Smad-anchor for receptor activiation (SARA). Phosphoinositide 3 
kinase (PI3K) phosphorylates membrane phosphoinositides (Ptdlns). PtdIns3P for example, is 
a Ptdlns that is specifically located on membranes associated with the endocytic pathway. The 
FYVE domain is a cysteine rich region that binds two zinc ions, and proteins containing this 
domain are recruited to Ptdlns3 rich membranes via a basic patch within the FYVE region 
(Gillooly et al., 2001). During induction of TGF-p signalling, SARA acts to recruit Smad2 to 
its type-I receptor, resulting in its phosphorylation and dissociation from SARA allowing it to 
complex with Co-Smad4. Endofin meanwhile, functions as a BMP-specific Smad anchor for 
receptor activiation (Tsukazaki et al., 1998). Smad4 acts to form a heteromeric complex with 
the R-Smads and translocates them to the nucleus in order for them to regulate transcription of 
their target genes.
The I-Smads are structurally divergent from the rest of the Smads. They act as negative 
regulators of TGF-p signalling by binding to type-I receptors, thereby preventing R-Smad 
activation and also compete with Smad4 for hetero-complex formation. Smad7 is responsible 
for inhibiting TGF-p/activin and BMP signalling, whereas Smad6 is specific for BMP 
signalling (Hayashi et al., 1997; Hata et al., 1998).
The R-Smads are around 400-500 amino acids in length and are all structurally similar. They 
are composed of three distinct and conserved domains; an N-terminal Mad homology (MHl) 
domain, a non-conserved proline rich linker region, and a C-terminal MH2 domain. The MHl 
domains of the R- and Co-Smads are around 130 amino acids in length, and are highly 
conserved. This domain forms a compact globular fold composed of six small p-strands, three 
a-helices, and five loops (Heldin et al., 1997). The MHl domain regulates transcription by 
interacting with other transcription factors and contains a highly conserved p-hairpin eleven 
residues in length, which can directly bind to DNA through the major groove. This hairpin is 
displaced in Smad2 making it incapable of binding DNA (Attisano and Lee-Hoeflich, 2001).
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In the case of the I-Smads, the MHl domain is very short, with highly distinct sequences and 
hence also can not bind DNA. Furthermore, the MHl domain of inactive Smads acts as a 
repressor of the MH2 domain, by preventing it from forming a complex with Smad4. 
Phosphorylation of the C-terminal by the type-I receptor appears to unfold the two domains and 
alleviates the inhibition by MHl (Heldin et al., 1997). In Smad3, basic helix 2 consists of a 
KKLKK sequence that acts as a nuclear localisation signal and hence is critical during Smad3 
nuclear translocation (Attisano and Lee-Hoeflich, 2001).
The MH2 domain is around 200 residues in length, and consists of a sandwiched core of anti­
parallel p-sheets, with three a-helices on one end, and a loop/helix region composed of three 
loops and an a-helix on the other end. This domain is multifunctional and provides the Smads 
with their specificity and selectivity as well as transcriptional activity. A 17 amino acid region 
protruding from the Smad MH2 domain, known as the L3 loop, is responsible for mediating 
specific receptor interaction. In addition, three sulphates within the L3 loop are critical in 
oligomer formation, and when activated, Smads can form homo-oligomeric complexes by 
interacting through their MH2 domains (Lo et al., 1998). The interface of this complex is 
formed by the helix bundle of one subunit, and the loop/helix end of the other subunit (Chen et 
al., 2002).
Finally, the MH2 domain is also responsible for specific interactions with type-I receptors. This 
is due to a pocket of basic residues that acts as a docking site for the phosphorylated GS 
domains of these receptors (Chen et al., 2002). Smad4 however, does not interact with the 
receptors as it has an insertion element preventing it from doing so and instead acts as a docking 
site for other R-Smads.
The linker region of Smads meanwhile, is variable in sequence and length and also contributes 
to the oligomerisation of Smads. In addition, phosphorylation of four PXS/TP motifs within the 
linker region by mitogen-activated protein kinase (MAPK), acts as a mechanism to prevent the
60
accumulation of Smads in the nucleus (Kretzschmar et al., 1999). Finally, a proline rich PPXY 
(PY) sequence allows for interaction with WW motif containing proteins involved in Smad 
degradation (Zhang et al., 2001).
1.4.3.3 The Smad dependent pathway
Unlike TGF-P receptors, 30-40% of type-I BMPRs are found at the cell surface in the form of 
preformed heteromeric complexes (PFCs) with BMPR-II, in the absence of ligand binding, 
increasing to 50-60% upon ligand binding. This is thought to be due to an intrinsic affinity that 
the receptors have for each other, that is enhanced by ligand binding. When a BMP ligand 
binds to the receptor complex, it causes a conformational change, resulting in complex 
activation.
This conformational change is thought to expose a common structural motif of type-I receptors 
required for signalling specificity, known as the L45 loop. This loop is slightly different when 
comparing TGF-p and BMP ligands, and is responsible for them binding different sets of R- 
Smads (Smads2 and 3 being TGF-P specific, while Smadsl, 5, and 8 are BMP specific). The 
conformational change that occurs when BMPs bind the PFC, is thought to be necessary in 
order to make the L45 loop accessible to Smads. In addition, it is thought that BMP ligand 
binding to the type-I receptor alone is insufficient to expose the loop, or that BMPR-II 
recruitment may conceal it, thereby preventing Smad binding. This additional form of receptor 
binding allows for a higher variability and flexibility in receptor responses to various ligands, 
compared to their TGF-p counterparts (Nohe et al., 2002).
Therefore, during the Smad dependent pathway, dimeric ligand binding induces receptor 
complex formation, resulting in the type-II receptor trans-phosphorylating, and thereby 
activating the type-I receptor at their GS domains. The activated type-I receptor is then 
responsible for phosphorylating and activating its corresponding R-Smads at their SSXS motif.
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These activated R-Smads are then rapidly released from the type-I receptors and interact with 
Smad4 to form a hetero-oligomeric complex which translocates from the cytoplasm to the 
nucleus, where they can then alter transcription of target genes (Miyazawa et al., 2002; Nohe et 
al., 2004). Figure 1.11 illustrates both the Smad dependent and Smad independent pathways.
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Figure 1.11: BMP signalling and its pathway. Modified from (Moustakas and Heldin, 2009). 
Active proteins are demonstrated by a star. The letter P in a circle refers to phosphorylation. A. 
Dimeric BMP ligand can bind to a homo-oligomeric type-I receptor and then recruits the type-II 
receptor into a BMP induced Signalling Complex (BISC), resulting in activation of the Smad 
independent P38 MAPK pathway. Alternatively, LIMK1 has been shown to bind to the tail 
region of BMPRII, thereby regulating depolymerisation factor cofilin and its associated effects 
on the actin cytoskeleton. Whether or not this interaction with BMPR-II activates or inhibits 
LIMK1 activity, remains undecided, with one study claiming LIMK1 activation (Lee-Hoeflich 
et al., 2004), and another claiming the opposite (Foletta et al., 2003). B. If the ligand binds to 
a preformed complex (PFC) of the type-I and type-II receptors, the Smad pathway is activated. 
The type-II receptor activates and trans-phosphoiylates the type-I receptor which in turn 
phosphorylates R-Smads 1, 5, and 8, causing a conformational change where the MHl domain 
no longer inhibits the MH2 domain. These R-Smads then form a complex with Smad4 which 
translocates to the nucleus and along with co-activators and co-repressors, alters the expression 
of BMP target genes.
1.4.3.4 Transcription of target genes by Smads
Following Smad-complex translocation into the nucleus, Smads interact with other proteins 
including transcriptional coactivators and repressors in order to bind to specific DNA sequences 
and regulate expression of TGF-p family target genes. TGF-p/activin and Smad2/3 in complex 
with Smad4, bind specifically via their M Hl domains to Smad binding elements (SBE) with 
AGAC/GTCT sequences found in target gene promoters and enhancers (Shi et al., 1998). BMP 
Smadl on the other hand, binds with low affinity to SBEs and preferentially binds to GC-rich 
boxes with sequence GCCGNCGC (Kusanagi et al., 2000).
Smad target genes include Inhibitor of differentiation-1 to 3 (Idl-3), Smad6/7, type-I collagen, 
JunB and Mix.2. The most important of these is Id-1 which negatively regulates cell 
differentiation, and has been shown to act as an oncogene due to its ability to promote cell 
growth, survival, invasion, angiogenesis, and metastasis in various cancers (Ling et a l,  2006). 
TGF-p growth inhibition results in upregulation of Cyclin dependant kinase inhibitors (CDKI) 
P21 and P15, and Smad3 repression of C-myc expression (Miyazawa et al., 2002). Finally, 
TGF-p potently enhances expression of plasminogen activator inhibitor-1 (PAI-1). This process 
involves a positive feedback loop and interaction with activator protein 1 (AP-1), SP-1, P15, 
and P21 (Keeton et al., 1991; Datto et al., 1995).
1.4.3.5 Smad interacting proteins
As Smads generally bind SBEs with low affinity, they need to interact with and be recruited by 
several other transcription factors. Most of the proteins identified refer to interaction with 
Smad3 as opposed to BMP Smads. This is due to the fact that the MH2 domain of Smad3 is 
richer in charged amino acids and acidic residues in its upper N-terminal region, resulting in 
more efficient interactions with other proteins (Nicholls et al., 1991). The first of these proteins 
to be identified was Forkhead box HI (FOXHI) which specifically recruits activated Smad2/4 to 
promoters (Germain et al., 2000). Others include P53 (Cordenonsi et al., 2007), Runx
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transcription factors (Miyazono et al., 2004), Smad interacting protein-1 (SIP-1) (Feng et al.,
2000), Activating transcription factor-2 (ATF-2) (Sano et al., 1999), and YYI transcription 
factors which repress expression of genes including PAI-1 and Id-1 (Kurisaki et al., 2003).
In addition, Smads also interact with transcriptional co-activators and repressors. P300/CBPs 
are histone acetyl transferase (HAT) proteins that interact with Smads to enhance transcription 
of their target genes by increasing the accessibility of the transcriptional machinery (Miyazono 
et al., 2000). The repressors include TGF-P interacting factor (TGIF), C-Sloan-Kettering 
retrovirus (C-Ski), and Ski related novel gene (SnoN) which bind with Smad3/4 to their SBEs 
and recruit histone deacetylases (HDACs) to repress target gene expression. Induction of TGF- 
p signalling, results in C-Ski and SnoN degradation, allowing Smad3/4 to induce transcription 
(Massague and Chen, 2000; Zhao et al., 2001)
1.4.3.6 Smad degradation
The concentration of available Smads in the intracellular pool is regulated by HECT type E3 
ligases known as Smad Ubiquitination Regulatory Factors (Smurf) 1 and 2. The WW motifs of 
Smurfs interact with the PY domain in the linker region of R-Smads, inducing their degradation 
by the proteosome, which results in inhibition of TGF-p family signalling.
In addition, Smurfs are responsible for the translocation of I-Smads from the nucleus into the 
cytoplasm, and enhance I-Smad interaction with the type-I receptors (Ebisawa et al., 2001). 
This also results in Smurf-dependent ubiquitin degradation of the type-I receptors, leading to a 
down-regulation of cell surface receptor expression. On the other side of the spectrum, TGF-p 
signalling is amplified by the Ring type E3 ligase Arkadia, which induces the ubiquitination of 
Smad7 but not type-I receptors (Koinuma et al., 2003).
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1.4.3.7 Smad independent pathway
The alternative route that BMP signalling can take is Smad-independent, and is known as the 
P38 Mitogen-activated protein kinase (MAPK) pathway. During this cascade, the X-linked 
inhibitor of apoptosis protein (XIAP) acts as a positive regulator of the downstream 
components, linking the type-I receptor and the TGF-P activated binding protein (TAB 1/2/3) 
(Shibuya et a l,  1996). This protein activates TGF-p activated tyrosine kinase-1 (TAK1), which 
is a member of the MAPKK family and is capable of activating kinases including; P38 MAPK, 
Jun N-terminal kinases (JNK), Nemo-like kinase (NLK) and Nuclear Factor-icB (NF-kB) 
(Yamaguchi et al., 1995; Shirakabe et a l,  1997; Ishitani et a l ,  1999; Lee et a l,  2002). TAK1 
normally induces apoptosis by activating JNK or P38 MAPK pathways. However, in Xenopus 
embryos, the BMP signal was shown to interact with XIAP to inhibit TAK1 associated 
apoptosis by impeding the action of caspases (Yamaguchi et a l,  1999).
Alternatively, LIM Kinase 1 (LIMK1), a key regulator of actin dynamics, has been shown to 
colocalise with the tail region of BMPR-II, independently of the Smads. LIMK1 is a 
downstream effector of Rho GTPases and is responsible for phosphorylating and inactivating 
cofilin, an actin depolymerising factor. Whether or not interaction with BMPR-II stimulates or 
inhibits LIMK1 has been debated. One study demonstrated that BMPR-II prevents LIMK1 
from inactivating cofilin, an effect that was alleviated by BMP-4 binding (Foletta et al., 2003), 
while another showed that LIMK1 interaction with BMPR-II synergises with Rho GTPases to 
activate LIMK1 catalytic activity and cofilin inactivation (Lee-Hoeflich et al., 2004).
1.4.4 Regulation of BMP pathway
Both negative and positive mechanisms are responsible for modulating BMP signal 
transduction at an extracellular and intracellular level. Extracellularly, the pathway is impeded 
by secreted proteins known as the BMP antagonists, and include; Noggin, Follistatin, Chordin, 
Gremlin, and Cerberus, amongst others. They mainly act by competing for receptor binding
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with the BMP ligands either by binding to the receptors or ligands themselves (Canalis et a l,
2003). BMP activin membrane bound inhibitor (BAMBI) acts as a pseudoreceptor and 
inhibits BMP signalling. It contains a similar ECD to type-I BMP receptors, but lacks a kinase 
domain and acts by competing for BMP binding. BAMBI and most of the aforementioned 
antagonists function on a negative feedback loop, with BMPs up-regulating their expression 
(Onichtchouk et al., 1999).
Intracellular mechanisms of regulation include the I-Smads, as well as C-Ski and Smurfs, which 
are responsible for Smad degradation, whose functions have been previously mentioned. As I- 
Smads are targets of BMP signalling, the expression of I-Smads functions as a negative 
feedback loop (Ebisawa et al., 2001). In addition, there exists an intracellular antagonist known 
as transducer of ErbB2 (Tob), which binds Smads 1, 4, 5, and 8 , and blocks transcription of 
their target genes (Yoshida et al., 2000).
1.4.4.1 Cross talk between BMP signalling and other pathways
Despite the extensive amount of knowledge on BMP signalling, the signalling itself doesn’t 
provide us with an explanation for the complex functions of BMPs, in the right perspective. 
Recently it has become clear that this has to do with cross talk between BMP signalling and 
several other important signalling pathways, as well as the proteins that BMPs recruit. Hox 
proteins for example, are downstream BMP pathway transcription factors that are involved in 
morphological development as well as cell differentiation.
Smads are responsible for regulating Hox transcriptional activities, with Smads 1, 4, and 6  
being shown to mainly repress Hox transcriptional activation (Zhou et al., 2008). Hox proteins 
control processes such as cell death, proliferation, adhesion, and cell specification, but the effect 
they have is greatly dependant on cell type. BMPs regulate Hox gene expression, and due to 
the huge variety of cell type dependant functions that Hox proteins carry out, partially explains 
the contradicting effects that BMPs play on cells (Foronda et al., 2009).
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Additionally, signals induced by BMP and TGF-p/activin act antagonistically to each other. 
For example, as both ligand types require Smad4 for their signalling, its limited availability in 
the cytoplasm suggests that these ligands may compete for Smad4 during complex formation. 
In addition, the I-Smads, irrespective of which ligand induced their expression inhibit both 
BMP and TGF-P signals (Candia et a l,  1997).
Furthermore, various MAPK pathways have been shown to interact with BMP signalling, 
including the p38 MAPK pathway, activated by BMPs themselves. Smads 6  and 7 not only 
inhibit BMP Smad signalling, but also p38 kinase. Smad6  has been shown to physically 
interact with and block TAK1, which in turn may interact with other transcription factors to 
alter TGF-p gene expression (Kimura et al., 2000). Extracellular regulated MAPK (ERK) is 
capable of phosphorylating the linker region of R-Smads, inhibiting nuclear accumulation of 
Smadl, and hence BMP signalling (Kretzschmar et al., 1997).
On the other hand, BMP-2 Smad signalling stimulates activation of Ras and ERK, which 
enhance Smadl transcriptional activity in osteoblastic cells (Suzawa et al., 2002; Nohe et al., 
2004). Other Smads phosphorylated by kinases at their linker region include Smad2/3 by JNK 
and Hepatocyte growth factor (HGF), and Smadl by FGF and IGF (Pera et al., 2003; Mori et 
al., 2004). JNK for example, has been shown to phosphorylate Smad3, aiding in its activation 
by receptor complexes and its nuclear translocation thereby enhancing Smad3 signalling. This 
cross talk between Smad3 and JNK has been shown to be interdependent, with Smad-dependent 
signalling being required for sustained JNK activity (Engel et al., 1999).
IFN-y acting through the JAK-STAT pathway induces Smad7 expression and hence inhibits 
BMP signalling (Ulloa et a l,  1999). Additionally, signal transducer and activator of 
transcription 3 (STAT3) has been reported to complex with Smadl, translocate into the nucleus 
and with P300, activate target gene expression (Nakashima et a l,  1999). Finally, other 
pathways shown to anatagonise or synergise BMP signalling include Calmodulin which binds
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Smad4, Notch and Wnt/p-catenin signalling, and most recently oestrogen, which has been 
reported to interfere with BMP-2, -6 , and -7 Smad transcriptional activity, and inhibit BMP 
gene expression in the breast (Zimmerman et a l,  1998; Nishita et a l, 2000; Itoh et a l,  2004; 
Helms et a l,  2005).
1.4.5 Aberrant BMP signalling in prostate cancer
Due to the complexity and importance of the BMP signalling pathway, alterations such as 
mutations or expressional changes can occur at any stage, and although heavily regulated, 
misregulations in the pathway have been implicated in many different diseases. These include 
developmental syndromes, cardiovascular diseases, and most commonly cancer. The role of 
TGF-p and BMP ligands in cancer has been extensively studied and reviewed, but the function 
that their receptors and downstream molecules have is less clear (Gordon and Blobe, 2008).
In terms of cancer, TGF-P has been shown to potently inhibit the growth of most cell types, 
especially breast cancer cells (Chang et a l, 2007). In the prostate, TGF-p plays a critical role in 
controlling androgen dependence, and has been shown to induce loss of sensitivity to hormone 
mediated growth inhibition, and hence has been implicated in prostate cancer progression. The 
role of BMP signalling in prostate cancer has been thoroughly researched and elucidated and is 
explained below.
1.4.5.1 BMP expression in prostate cancer
BMPs specifically, have been implicated in the pathogenesis of a number of cancers including: 
prostate, colorectal, osteosarcomas, myelomas, and breast cancer (Ye et a l,  2007). For 
example, over-expression of BMP-4 and -7 has been shown in breast cancer cells, with BMP-7 
promoting the motility and invasiveness of breast cancer cell lines (Alarmo et a l, 2007; Alarmo 
et a l,  2009). Contrastingly, in the normal prostate, expression of BMP-2 and -4 is 
predominant, but considerable amounts of BMP-5, -6 , and -7 are also present. When comparing 
to prostate cancer tissues, expression of BMP-2 and -4 is slightly reduced, but BMP-7
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expression is significantly lower than in normal prostate samples (Bobinac et al., 2005). 
Additionally, we have recently shown that expression of BMP-9 and -10 is decreased or absent 
in prostate cancer tissues, especially in those of a higher grade (Ye et al., 2008).
Growth and differentiation factors (GDFs) are members of the BMP family that have also been 
implicated in prostate cancer. GDF-15, for example, is also reduced in prostate cancer tissues 
and appears to be dependent on the presence of androgen, as it expression is higher in LNCaP, 
an androgen-dependent cell line, than the androgen insensitive PC-3 and DU-145 cell lines. 
This loss of expression of BMP-7 and GDF-15 seen in prostate cancer tissues may be due to the 
prostate cancer cells shifting from an androgen-dependent phenotype, to an independent one. 
However, both appear to be re-expressed in metastatic prostate cancer tissues suggesting that 
they may aid in the metastatic process (Kakehi et al., 2004). BMP- 6  meanwhile, is expressed 
at low levels in localized prostate cancers, but its expression is significantly increased in 
samples from metastatic prostate cancers and bone lesions, suggesting that like BMP-7 and 
GDF-15, it may play a role in prostate cancer progression and metastasis (Haudenschild et al.,
2004).
1.4.5.2 Expression of BMPRs and BMP signalling molecules in prostate cancer
In normal prostate tissue, the expression of BMPRs including BMPR-IA, BMPR-IB, and 
BMPR-II, has been shown to be localised to the epithelial compartment. In contrast, prostate 
cancer tissues often exhibit loss of BMPR expression, and their expression significantly 
correlates with tumour grade, tumour stage, and clinical stage. Expression of the BMPRs was 
lower in prostate cancer tissues with worsening Gleason scores and tumour grade in prostate 
cancer tissues with poor prognosis (Kim et al., 2000). In well differentiated tumours (Gleason 
score 4), loss of expression of BMPR-IA and BMPR-IB was seen in 17% of cases, while 
negative BMPR-II expression was detected in 33%. In poorly differentiated tumours (Gleason 
scores 8-10) however, expression of BMPRs was lost in around 80% of the tissues. However,
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only BMPR-II down-regulation was shown to significantly correlate with 5 year survival rates 
and a higher rate of reccurence (Kim et al., 2004).
In reference to prostate cancer cell lines, expression of the BMPRs is contradictory. The 
laboratory has recently shown expression of BMPR-IB and BMPR-II in prostate cancer cell 
lines; PC-3, DU-145, CAHPV10, and LNCaP, as well as in immortalalised prostate epithelial 
cell lines PZHPV7, PNTIA, and PNT2C2. BMPR-IB expression was high in all the mentioned 
cell lines but BMPR-II expression was lower in the prostate cancer cell lines compared to the 
epithelial cell lines. Furthermore, expression levels of both the receptors increased in response 
to HGF (Ye et a l,  2007). In contrast, a different study showed expression of all three BMPRs 
in LNCaP, DU-145, PC-3, and PC-3M (Kim et al., 2004), whereas another showed no BMPR- 
IA expression in LNCaP, DU-145, or PC-3, and BMPR-IB expression in only LNCaP 
(Brubaker et al., 2004).
In the case of the Smads, the laboratory has recently shown that there is no significant change in 
the expression of Smads 1, 2, 3, 5, 6 , and 8 , when comparing prostate cancer cell lines and 
prostate epithelial cell lines (cell lines mentioned above). However, expression of Smad4 and 7 
was barely detectable in the three highly metastatic prostate cancer cell lines PC-3, DU-145, 
and LNCaP, but showed higher expression levels in the less invasive CAHPV10 cell line and 
the prostate epithelial cell lines (Ye et al., 2008). Likewise, Smad4 expression was shown to be 
significantly down-regulated in high grade prostatic intraepithelial neoplasia and prostate cancer 
tissue, compared to tissue of benign prostate hyperplasia origin (Zeng et al., 2004).
However, in prostate cancer cells, BMP signalling events downstream of BMPRs are also 
dependent upon the type of BMPs initiating the process. For example, BMP-9 acts on PC-3 
cells via the Smad dependent pathway, whereas BMP-10 signals via the Smad independent 
pathway in the same cells (Ye et al., 2008; Ye et al., 2009). Cross talk between androgen 
receptor (AR) signalling and Smad mediated signalling within the prostate has been shown. In
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PC-3 and LNCaP cells, Smad3 treatment can induce activation of the AR, promoting tumour 
growth. In contrast, loss of Smad4 expression is needed to up-regulate AR activation, and when 
it is co-transfected with Smad3, AR activation is inhibited (Kang et al., 2002). Meanwhile, in 
the rat normal and malignant prostate, up-regulation of activated Smad2, as well as expression 
of Smads 3, 4, 6 , and 7, was observed following androgen deprivation after castration. This 
makes cells more responsive to TGF-|3, whose action and duration is regulated by the I-Smads 
which are also over-expressed. Expression of Smads 1 and 5 was barely detectable in both the 
normal and cancerous prostate, but pSmad2, Smad3, TGF-pRI and TGF-pRII expression, was 
up-regulated in the tumours in response to oestrogen stimulation, suggesting that oestrogen 
makes prostate cells more susceptible to BMP signalling (Brodin et a l , 1999).
1.4.5.3 Role of BMPs in prostate cancer
Due to the alterations in BMP expression in prostate cancers, substantial research has gone into 
elucidating the role that BMPs play during the development and progression of this disease. 
Indeed, several groups have shown that BMPs play a profound role on the biological properties 
of prostate cancer cells, especially during bone metastasis. Despite this, finding the precise 
mechanisms by which they exert their effects remains unclear. However, with the development 
of recombinant human BMPs as well as methods of altering their expression, it is now possible 
to investigate these mechanisms in vitro.
1.4.5.4 Role of BMPs on prostate cancer cell proliferation
TGF-p is well known for its growth inhibitory effects on a variety of cell types, including 
prostate cancer cells (Massague et al., 2000). The role of BMPs on cell proliferation however, 
remains unclear. Despite this, several BMPs have been shown to have an effect on the 
proliferation of prostate cancer cells. BMP- 6  and BMP-2 for example, were shown to inhibit 
the growth of prostate cancer cells including LNCaP and DU-145 (Brubaker et al., 2004). 
BMP-7 meanwhile, has been shown to inhibit the proliferation of androgen-independent PC-3
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and DU-145, inducing a G1 cell cycle arrest by up-regulating the expression of CDKI- 
P2 1 c'pi/wafi (Miyazaki et al., 2004).
However, the effect of BMPs on prostate cancer cell growth has been shown to be dependent on 
the concentration of fetal bovine serum (FBS) present, as BMP-7 failed to inhibit the growth of 
PC-3 cells in the presence of 10% FBS. In addition, BMP-7 mediated Smadl/5 
phosphorylation and Id-1 expression was reduced in cells grown in 10% FBS, in comparison to 
those grown in only 1%. This suggests that FBS may contain or induce expression of, BMP 
antagonists such as noggin or chordin, resulting in the inhibition of BMP-7 activity (Ide et al., 
1997).
In addition, the effect of BMPs is also dependent on the presence of androgen, as well as 
receptor type. When using the prostatic cell line LNCaP, signalling via BMPR-IA or -IB  was 
shown to have opposite effects on the growth rate of these cells. When LNCaP was cultured in 
the presence of rh-BMP-2 and androgen, it led to an increase in BMPR-IB expression and 
inhibited the growth rate of the cells. In contrast, when androgen was absent, the opposite was 
true and the cells showed increased growth via BMPR-IA. As BMP-2 can signal via BMPR-IA 
or -IB  in concordance with BMPR-II, it is feasible that when BMP-2 signals via BMPR-IA it 
leads to growth promotion of prostate cancer cells, while signalling via BMPR-IB leads to 
growth inhibition (Ide et al., 1997). Meanwhile, expression of a constitutively active form of 
BMPR-IB in PC-3 cells led to an inhibition of cell growth in vitro, and decreased the growth of 
prostate tumours in vivo when these cells were injected into nude mice (Miyazaki et al., 2004).
1.4.5.5 BMPs and apoptosis of prostate cancer cells
Cancer cells usually become resistant to apoptotic signals from the cell signalling pathways by 
altering the expression of pro-apoptotic and anti-apoptotic factors. Smad signalling regulates 
the expression of several genes involved in apoptosis. These include, growth arrest and DNA- 
damage-inducible 450 (GADD450), Bim, Death-associated protein kinase (DAPK), Src
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homology domain 2 (SH2)-containing 5’ inositol phosphatase (SHIP), and TGF-P inducible 
early gene-1 (TIEG-1) (Pardali and Moustakas, 2007). Smad3 for example, depending on its 
expression levels, can determine whether or not epithelial cells undergo apoptosis in response to 
TGF-p, by interacting with and blocking Akt/PKB (Conery et a l, 2004). In addition, in the 
normal and malignant prostate, there was an up-regulation in the expression of phosphorylated 
Smad2, as well as in non-phosphorylated Smad3, 4, 6 , and 7, after castration. Expression of 
these Smads was particularly present within apoptotic cells, suggesting that the TGF-p pathway 
is activated in the prostate after castration, resulting in the up-regulation of pro-apoptotic 
factors. The TGF-p pathway regulated apoptosis in vivo and hence may be deregulated during 
the progression of prostate cancers (Brodin et a l,  1999).
Several BMPs have been shown to induce apoptosis. The laboratory has recently shown that 
BMP-9 signals via BMPR-IB and BMPR-II to inhibit the growth of prostate cancer cells by 
inducing apoptosis via Smadl, 5, and 8  mediated up-regulation of pro-apoptotic factor Par-4 
(Ye et al., 2008). In addition, it also previously demonstrated that BMP-10, as well as 
decreasing in vitro cell growth, adhesion, invasion, and migration of prostate cancer cells, can 
also induce apoptosis by signalling via BMPR-IB in a Smad-independent manner leading to 
activation of XIAP and ERK, which are involved in the promotion of apoptosis (Ye et al., 
2009).
1.4.5.6 Role of BMPs in prostate cancer bone metastasis
Due to the role of BMPs as potent osteoinductive agents with a crucial role during skeletal 
development and fracture repair, the notion that they may also be involved in the development 
of osteoblastic lesions associated with prostate cancer metastasis, does not seem farfetched. 
One possible mechanism by which BMPs have been shown to induce this process, is by the 
activation of VEGF, which given its role in angiogenesis, osteoblastic differentiation, and 
chemotaxis, may be a key downstream player of BMP-mediated regulation of osteoblastic
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metastases. Indeed BMP-2, -4,-6, and -7 induced VEGF mRNA and protein expression in an 
osteoblastic cell line (Dai et a l,  2004). In contrast, BMP-9, when signalling via ALK-1 and 
BMPR-II in endothelial cells, activates Smad 1/5 downstream signalling to block VEGF 
mediated angiogenesis (Scharpfenecker et a l ,  2007).
Another mechanism by which BMPs can aid in prostate cancer metastasis is by promoting the 
motile and invasive capacity of tumour cells. BMP-7 and GDF-15 for example, were shown to 
be re-expressed in bone metastatic lesions, and BMP-2 alongside BMP-7, is capable of 
stimulating the migration and invasion of prostate cancer cells, an effect which was reversed 
when these cells were treated with the BMP antagonist, noggin. Furthermore, in vivo 
development of osteoblastic lesions associated with prostate cancer, was inhibited by the over­
expression of noggin, suggesting that BMPs do play a role during bone metastasis, and that the 
blocking of BMP activity may be a useful potential therapeutic treatment by acting to decrease 
the pain associated with metastatic lesions. Additionally, BMP-2, and to a lesser extent BMP-4, 
can also stimulate the migration of PC-3 cells in a dose dependent manner, an effect also 
inhibited by noggin (Feeley et a l,  2005). Finally, BMP-2 alongside BMP-6 , promotes the 
invasive capacity of prostate cancer cells in vitro, and when mice were treated with anti-BMP-6 , 
osteoblastic activity and bone production was reduced, implying that prostate cancer can 
encourage osteoblastic function through BMP- 6  (Dai et a l,  2005).
Despite the clear importance of BMP signalling in bone metastasis, other cross-talking 
pathways and cytokines present in the bone microenvironment have been shown to aid in the 
process. For example, both the osteoclastic PC-3 cell line which expresses osteoclast- 
associated cytokines including RANKL, IL-1, and TNF-a, and the osteoblastic LAPC-9 which 
expresses OPG, an inhibitor of osteoclastogenesis and minimal amounts of the aforementioned 
cytokines, secrete BMP-2, -4, and -6 , which are associated with bone formation (Lee et a l, 
2003). HGF, along with its receptor, meanwhile, are up-regulated in prostate cancer cells, and 
in androgen-independent prostate cancer cells, promotes their invasive capacity as well as
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formation of bone metastases. HGF was recently shown to up-regulate expression of BMPR-IB 
and BMPR-II in these cells, and as the bone has high levels of BMP, an up-regulation of its 
receptors would provide the prostate cancer cells with a growth and survival advantage within 
the bone microenvironment, aiding in osteoblastic metastasis. These results suggest that 
BMPR-IB and BMPR-II along with HGF play a role during the bone metastasis of prostate 
cancer cells (Ye et al., 2008).
1.5 G rowth and D ifferentiation Factor-9 (GDF-9); a m em ber o f the BM P family
Due to the obvious importance of BMPs in the development and progression of prostate cancer, 
a novel member of this family always sparks up interest. GDF-9 (or GDF-9a) is a member of 
the BMP family that has been identified as an oocyte growth factor which plays an important 
role in the regulation of folliculogenesis and ovulation (Su et a l,  2008). However, its role in 
cancer has scarcely been studied. Therefore, based on the obvious importance of BMPs in 
prostate cancer, and significant findings observed in previous projects carried out in the 
laboratory on BMPs in this disease (Ye et al., 2008; 2009), we are the first to investigate the 
role of GDF-9 in prostate cancer.
1.5.1 GDF-9 s tru c tu re  and  signalling
As previously mentioned, TGF-p and BMPs are produced as precursors made up of a longer N- 
terminal pro-region, signal peptide, and a shorter functionally active C-terminal mature 
polypeptide. Dimers of these precursor proteins are linked by disulphide bonds via conserved 
cysteine residues in the pro-region and mature peptide sequence. Once in the secretory 
pathway, the mature and pro-region are cleaved apart by furin proteases. The protein dimers 
are then secreted in order for them to bind their cell surface receptors. However, the TGF-p 
pro-region known as latency-associated peptide (LAP), remains non-covalently attached to the 
mature peptide, acting as a chaperone during complex exocytosis and preserving the ligand in 
an inactive state (Moustakas and Heldin, 2009). Additionally, LAP also mediates TGF-P
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deposition in the ECM by covalently linking to large secreted proteins and ECM proteins such 
as fibronectin (Rifkin, 2005). This LAP interaction of TGF-p ligands is conserved in the 
BMPs, but instead of acting as means of extracellular antagonism, restricts ligand availability 
by regulating mature ligand stability, processing, and degradation (Moustakas and Heldin, 
2009).
GDF-9 and BMP-15 (GDF-9B) are oocyte secreted factors that are processed in a similar 
fashion to their BMP relatives, being secreted as cleaved mature and proregion proteins. In 
addition, non-covalent interactions between the mature and proregion proteins were identified 
in both GDF-9 and BMP-15. Furthermore, the GDF-9 mature protein was also found to 
associate with the BMP-15 pro-region, which acted to regulate and immunoneutralise BMP- 
15/GDF-9 cooperativity (McIntosh et al., 2008). Before secretion however, their bioactivity is 
tightly regulated through phosphorylation by Golgi Casein Kinase (GCK) that occurs in the 
Golgi apparatus before secretion. This phosphorylation acts as a means of regulating protein 
bioactivity, with the dephosphorylated isoforms acting as antagonists of their phosphorylated 
counterparts (Tibaldi et al., 2010).
In addition, they also differ from other BMPs when it comes to post-translation. Members of 
the TGF-p family contain a characteristic conserved 7 cysteine knot within their mature region. 
The fourth cysteine is required for disulphide bond formation for covalent linking between 
monomers, to form dimers. GDF-9 and BMP-15 however, lack this fourth cysteine as it is 
replaced by a serine residue. Therefore, it is thought that these BMPs either form non-covalent 
bound dimers, or biologically active monomers (Liao et al., 2003).
Despite this difference in their structure, GDF-9 and BMP-15 still use BMP receptors in order 
to initiate their downstream signalling. GDF-9 has been shown to have highest affinity for 
TGF-pRI (ALK-5) and BMPR-II, thereby activating the TGF-p associated Smads, 2 and 3 
(Mazerbourg et al., 2004). BMP-15 meanwhile, also uses BMPR-II as a type II receptor, but
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BMPR-IB (ALK-6 ) as its type I receptor, and hence activates the BMP associated Smads, 1, 5, 
and 8  (Moore et al., 2003). This difference in receptors suggests that these related proteins may 
have different functions, with GDF-9 acting more like its TGF-p relatives, as opposed to the 
BMPs, like BMP-15. However, it has recently been shown that BMP-15 and GDF-9 act 
together to stimulate granulosa cell growth by signalling via BMPR-II (Edwards et al., 2008)
1.5.1.1 GDF-9 function
Expression of GDF-9 and BMP-15 has been described in oocytes of species including; rodents, 
ovine, and humans, and both have been shown to play a critical role in ovarian function. Mice 
lacking the GDF-9 gene demonstrated a block at an early stage of follicular development, 
making them infertile. This suggests that GDF-9 may play an important role in early follicular 
development. BMP-15 deficient mice on the other hand, exhibit only reduced fertility, whereas 
sheep with homozygous naturally occurring BMP-15 mutations (Inverdale sheep) are infertile. 
Both BMPs have been shown to co-operate during ovarian follicular development and ovulation 
rate and can promote cholesterol biosynthesis in cumulus cells (Su et al., 2008).
More specifically, GDF-9 is expressed throughout follicular development in the mammalian 
oocyte and can stimulate granulosa cell proliferation, pre-antral follicle growth, and cumulus 
cell expansion, partly by inhibiting FSH-induced cAMP production and steroidogenesis (Vitt et 
al., 2000). Meanwhile, treating human follicles with GDF-9 results in a greater percentage of 
viable cells in organ culture, suggesting it also plays a role in follicular survival. Furthermore, 
it has been demonstrated to act as an anti-apoptotic factor in pre-antral follicles, by preventing 
granulosa cells from undergoing apoptosis through activation of the PI3K/AKT pathway 
(Orisaka et al., 2006).
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1.6 A im s and objectives
From all the studies carried out on BMPs and their function in cancer, it is clear that they are 
important regulators during cancer progression and metastasis. In addition, due to the 
significant role they play in the bone, it can be implied that they may be vital in the process of 
bone metastasis, especially that of prostate cancer. Indeed, we have previously shown that 
BMP-9 and -10 have an inhibitory effect on the growth and motility of prostate cancer cells (Ye 
et al., 2008; 2009).
Despite the established importance of GDF-9 in female fertility, knowledge of its role in human 
cancer has been limited, and only recently have there been papers published on its expression in 
cancer. The laboratory has previously shown that GDF-9 inhibits the invasiveness of breast 
cancer cells, and that high expression of both GDF-9 and BMP-15 is present in tumour samples 
with good prognosis (Hanavadi et al., 2007). The only other study to suggest a role for GDF-9 
in cancer, demonstrated an up-regulation in its expression in an oral squamous carcinoma cell 
line, suggesting that in this type of cancer GDF-9 may aid in tumour progression and 
metastasis, opposite to its effects in breast cancer (Zhuang et al., 2010). However, a clear role 
for this protein in human cancer is still unclear.
Therefore, due to the importance of BMPs both in prostate cancer development and bone 
metastasis, as well as several studies indicating the potential of GDF-9 as a molecular marker in 
cancers, this study aims to be the first to characterise a role for GDF-9 in the development of 
prostate cancer. If clear mechanisms are established for the functionality of GDF-9 in prostate 
cancer, it may aid in the development of innovative treatments to either prevent the progression 
and metastasis of prostate cancer, or treat bone metastases of which to date there exist only 
palliative therapies.
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The specific aims of this study are:
1. To establish the expression profile of GDF-9 and its associated downstream molecules 
in a variety of prostate cancer cell lines.
2. By producing a plasmid construct of GDF-9, to force-express and knock-down its 
expression in prostate cancer cell lines, respectively. This would then allow for the 
effect that GDF-9 has on biological properties of cancer cells including adhesion, 
invasion, proliferation, motility, and migration, to be studied.
3. Generate recombinant human GDF-9 (rh-GDF-9) which can be used to treat the cells in 
order to support the effects seen with endogenous GDF-9, and determine its 
downstream signalling pathway.
4. Although the BMP receptors that GDF-9 activates to initiate its downstream signalling 
have been identified as ALK-5 and BMPR-II in the ovary, it is unclear as to whether 
this is the case in the prostate. Therefore, by carrying out phosphorylation studies, 
using a Smad3 inhibitor, and treating the cells with rh-GDF-9, it can be determined how 
GDF-9 downstream signalling allows it to exert its effects on prostate cancer cells. 
This includes determination of any downstream target genes and mechanisms involved 
in its functions.
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Chapter 2 
Materials and Methods
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2.1 General materials
2.1.1 Cell lines
This current study made use of seven prostatic cell lines; PC-3 acquired from the European 
Collection of Animal Cell Culture (ECACC, Salisbury, UK), DU-145, CA-HPV10, LNCaP, 
and PZHPV-7, which were all obtained from the American Type Culture Collection (ATCC, 
Rockville, Maryland, USA), and PNT-1A and PNT-2C2 which were generously given to us by 
Professor Norman Maitland (University of York, England, UK). Full details of these cell lines 
are supplied in Table 2.1. DMEM-F12 Media supplemented with 10% foetal bovine serum 
(FBS) and antibiotics was used to maintain the cells. The cells were kept for approximately 8 - 
10 passages in order to retain cellular integrity, before being discarded. Due to improper 
freezing of cell stocks, attempts to culture the prostatic epithelial cell lines PNT-1A, PNT-2C2, 
and PZ-HPV-7, were unsuccessful. However, this study did have access to RNA and protein 
samples procured from these cells.
2.1.2 Primers
All the primers used in this current study were designed with the use of the Beacon Design 
programme (Palo Alto, California, USA) and were synthesised by Invitrogen (Paisley, UK). 
The forward and reverse primers used for conventional RT-PCR and Quantitative PCR (Q- 
PCR) are provided in Table 2.2, those used for amplifying the GDF-9 coding sequence in Table 
2.3, and primers used for generating hammerhead ribozymes are detailed in Table 2.4.
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Cell line Origin Cell morphology Tissue type Metastatic site Features
PC-3 62 year old 
Caucasian male
Epithelial Adenocarcinoma 
(highly tumourogenic)
Bone Tumour stage: grade IV 
Isolation date: 1979 
Antigen expression: HLA A l, A9
Androgen receptor negative 
Adherent cells
DU-145 69 year old 
Caucasian male
Epithelial Carcinoma Brain Isolation date: 1978 
Antigen expression: Blood type 0; Rh+ 
Androgen receptor negative
LNCaP 50 year old 
Caucasian male
Epithelial Carcinoma left
supraclavicular 
lymph node
Isolation date: 1977 
Androgen and Estrogen receptor positive 
Cellular products: PSA, human prostatic acid phosphatase 
Adherent cells
CA-HPV-10 63 year old 
Caucasian male
Epithelial Non tumourogenic cell line 
derived from prostatic 
adenocarcinoma, transformed 
through HPV18 transfection
----
Isolation date: 1994 
Gleason grade: IV 
Adherent cells 
Cellular products: KLK3, PSA
PZHPV-7 70 year old 
Caucasian male
Epithelial Non tumourogenic epithelial cell 
line transformed through HPV18 
transfection ----
Derived from normal adult prostatic epithelial cells
PNT1A 35 year old 
Caucasian male
Epithelial Normal prostatic epithelial cell 
line, transfected and immortalised 
with SV40 DNA with a defective 
replication origin. ----
Derived from human prostate 
epithelium of the peripheral zone
PNT-2C2 33 year old 
Caucasian male
Epithelial Normal prostatic epithelial cell 
line, immortalised with SV40 
DNA ----
Table 2.1: Details of cell lines used in this study.
Table 2.2: Primers for conventional RT-PCR and Q-PCR (Primers were designed by Beacon 
Design programme (Palo Alto, California, USA) and were synthesised by Invitrogen (Paisley, 
UK)).
Gene Primer name Primer sequence (5’-3’) Annealingtemperature
Product 
size (bps)
GDF-9
GDF-9aF8 TGTTTTCCTATTAGCCTTGG
55°C 466
GDF-9aR8 ATTTGACAGCAGAGGAAAAA
GDF-9
GDF-9aF9 GCGCTTTTCAAAGTTCTATC
56 °C 432
GDF-9aR9 GGTCACATCAATCTGAATCC
GDF-9
GDF-9aFl GCAGAGGTCAGGAAACTGT
55°C 100
GDF-9aZRl ACTGAACCTGACCGTACAATGGAGCTCACACTCATTTTT
P-actin
BACTF ATGATATCGCCGCGCTCG
55°C 580BACTR CGCTCGGTGAGGATCTTCA
B-actin
BACTINZF GGACCTGACTGACTACCTCA
55°C 117BACT1NZR ACTGAACCTGACCGTACAAGCTTCTCCTTAATGTCACG
Rock-1
ROCK1F10 CATCTCGCATTCTACAAGTG
55°C 473
ROCK1R10 T AAAAACATGCCAGAGAGGT
FAK
FAKF1 AAC AGGTG AAG AGCG ATT AT
55°C 99
FAKZR1
ACTGAACCTGACCGTACACAGTAT
GATCGCCG1T1TC
Paxillin
PAXF1 CAATCCTTGACCCCTAGA
55°C 115
PAXZR1 ACTGAACCTGACCGTACATTGGAGACACTGGAAG'l'riT
SNAI1 SNAF ACTATGCCGCGCTCTTTCC
55°C 798
SNAR TCAGCGGGGACATCCTGAGC
RhoC
RHOCF8 GAGAAGTGGACCCCAGAG
55°C 117
RHOCZR
ACTGAACCTGACCGTACACTTCAT
CTTGGCCACGCTC
84
E-
Cadherin
ECADF8 CAGAAAGTTTTCCACCAAAG
55°C 106
ECADZR ACTGAACCTGACCGTACAAAATGTGAGCAATTCTGCTT
N-
Cadherin
NCADF1 ATTCTCAACCCCATCT
55°C 110
NCADZR1 ACTGAACCTGACCGTACATTCTCCACTTGATTTCCATT
Table 2.3: Primers for amplifying GDF-9 coding sequence.
Gene Primername
Primer sequence (5’-3’)
Annealing
temperature
Product
size (bps)
GDF-9a
GDF-9aExFl ATGGCACGTCCCAACAAAT
60-65°C 1362GDF-9aExRl ATTTGACAGCAGAGGAAAAA
GDF-9aExR2 TT AACG ACAGGTGCACTTTGTAGC
T7F TAATACGACTCACTATAGGG
BGHR TAGAAGGCAGTCGAGG
Table 2.4: Primers used for ribozyme synthesis.
Gene Primer name Primer sequence (5’-3’>
GDF-9
ribozyme-2
GDF-9aRIB2F
CTGCAGTAAGTGTTCAACGGTAGT
AATGCCTGATGAGTCCGTGAGG
GDF-9aRlB2R
ACTAGTGGAACTGCTATTTAACCT
GGATTTCGTCCTCACGGACT
GDF-9
ribozyme-3
GDF-9aRIB3F
CTGCAGCTGTGATAAGCCTGAGCA 
CTTGTGTC ATTC AAAT ATAACTG A 
TGAGTCCGTGAGGA
GDF-9aRIB3R
ACTAGTTTTAACATGACTCTGGTG
TCCCCCTCACTGATTTCGTCCTCAC
GGACT
T7F TAATACGACTCACTATAGGG
BGHR TAGAAGGCAGTCGAGG
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RBBMR TTCGTCCTCACGGACTCATCAG
RBTPF CTGATGAGTCCGTGAGGACGAA
2.1.3 Antibodies
2.1.3.1 Primary antibodies
Full details of the spectrum of primary antibodies used in this study are provided in Table 2.5.
2.1.3.2 Secondary antibodies
The secondary antibodies used for western blotting were horseradish peroxidise (HRP) 
conjugated anti-goat IgG, goat anti-rabbit IgG, and rabbit anti-mouse IgG antibodies, all 
supplied by Sigma (Poole, Dorset, UK). Those used for immunofluorescent studies are either 
goat anti-rabbit IgG TRITC conjugated secondary antibodies (Sigma, Poole, Dorset, UK), or 
FITC conjugated sheep anti-mouse, and rabbit anti-goat IgG, supplied by Santa-Cruz 
Biotechnology (Santa-Cruz, California, USA).
Table 2.5: Primary antibodies used during course of study
Antibody name Source
Molecular
weight
(kDa)
Supplier
Product
code
Anti-GDF-9
Goat
polyclonal
antibody
17.5/40/57/
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SANTA CRUZ BIOTECHNOLOGY, 
INC.
SC-12244
Anti-TGF-pRl
Goat
polyclonal
antibody
53
SANTA CRUZ BIOTECHNOLOGY, 
INC.
SC-33933
Anti-Smadl
Mouse
monoclonal
antibody
52/56
SANTA CRUZ BIOTECHNOLOGY, 
INC.
SC-7965
Anti-p-smadl
Goat
polyclonal
antibody
52/56
SANTA CRUZ BIOTECHNOLOGY, 
INC.
SC-12353
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Anti-Smad2
Goat
polyclonal
antibody
55-60 SANTA CRUZ BIOTECHNOLOGY, INC
SC-6200
Anti-Smad3
Mouse
monoclonal
antibody
54 SANTA CRUZ BIOTECHNOLOGY, 
INC
SC-110154
Anti-p-Smad3
Rabbit
polyclonal
antibody
54 SANTA CRUZ BIOTECHNOLOGY, 
INC
SC-130218
Anti-ROCK-1
Goat
polyclonal
antibody
160 SANTA CRUZ BIOTECHNOLOGY, INC
SC-6056
Anti-FAK
Mouse
monoclonal
antibody
125
BD Transduction Laboratories 610088
Anti-p-FAK
Rabbit
polyclonal
antibody
125
SANTA CRUZ BIOTECHNOLOGY, 
INC
SC-101680
Anti-Paxillin
Mouse
monoclonal
antibody
68
BD Transduction Laboratories 610051
Anti-p-Paxillin
Rabbit
polyclonal
antobody
68
SANTA CRUZ BIOTECHNOLOGY, 
INC
SC-101774
Anti-SNAll
Mouse
monoclonal
antibody
29 SANTA CRUZ BIOTECHNOLOGY, INC
SC-10433
Anti-RhoC
Goat
polyclonal
antibody
24 SANTA CRUZ BIOTECHNOLOGY, INC
SC-26481
Anti-E-cadherin
Goat
polyclonal
antibody
120/135
SANTA CRUZ BIOTECHNOLOGY, 
INC
SC-7870
Anti-JNK
Mouse
monoclonal
antibody
46/54
SANTA CRUZ BIOTECHNOLOGY, 
INC
SC-137018
Anti-ERKl/2
Mouse
monoclonal
antibody
42/44
SANTA CRUZ BIOTECHNOLOGY, 
INC
SC-135900
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Anti-Actin
Mouse
monoclonal
antibody
42
SANTA CRUZ BIOTECHNOLOGY, 
INC
SC-8432
Anti-His-Probe
Mouse
monoclonal
antibody
Dependent 
on protein
SANTA CRUZ BIOTECHNOLOGY, 
INC
SC-8036
Anti-Phosphoserine
/threonine
Rabbit
polyclonal
antibody
Dependent 
on protein
Abeam pic ab17464
Anti-GAPDH
Goat
polyclonal
antibody
37
SANTA CRUZ BIOTECHNOLOGY, 
INC
SC-20358
Anti-rabbit 
(whole molecule) IgG 
peroxidise conjugate
Goat
polyclonal
antibody
Dependent 
on primary
Sigma A-9169
Anti-goat 
(whole molecule) IgG 
peroxidise conjugate
Rabbit
polyclonal
antibody
Dependent 
on primary
Sigma A-5420
Anti-mouse 
(whole molecule) IgG 
peroxidise conjugate
Rabbit
polyclonal
antibody
Dependent 
on primary
Sigma A-9044
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2.2 Standard reagents and solutions
2.2.1 Solutions for use in cell culture
0.05MEDTA
lg  KC1 (Fisons Scientific Equipment, Loughborough, UK), 5.72g Na2H P0 4 (BDH Chemical 
Ltd., Poole, England, UK), lg  KH2 P 0 4  (BDH Chemical Ltd., Poole, England, UK), 40g NaCl 
(Sigma-Aldrich, Inc., Poole, Dorset, England, UK) and 1.4g EDTA (Duchefa Biochemie, 
Haarlem, The Netherlands) was dissolved in 5L distilled water, adjusted to a pH of 7.4, 
autoclaved, and stored until further use.
Trypsin (25mg/ml)
This solution was made up by dissolving 500mg trypsin in the 0.05M EDTA, before being 
mixed, and then filtered through a 0.2pm minisart filter (Sartorius, Epsom, UK). This solution 
was then aliquoted into samples of 250pl and stored at -20°C until further use. When required 
for cell culture work, one of these aliquots was further diluted in 10ml 0.05M EDTA and used 
to detach the cells.
Balanced Saline Solution (BSS)
79.5g NaCl, 2.1g KH2 P 0 4, 2.2g KC1 and l . lg  of Na2 H P04, was dissolved in 10L of distilled 
water, and the pH amended to 7.2, using 1M NaOH (Sigma-Aldrich, Inc., Poole, Dorset, 
England, UK).
lOOx Antibiotic cocktail mix
5g streptomycin, 3.3g penicillin and 12.5mg amphotericin B in DMSO, were dissolved in BSS 
and filtered. 5ml was then added to a 500ml bottle of DMEM media.
2.2.2 Solutions for use in molecular biology
Tris-Boric-Acid-EDTA (TBE)
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5xTBE solution (1.1M Tris; 900mM Borate; 25mM EDTA; pH 8.3) was made up by dissolving 
540g Tris-Cl (Melford Laboratories Ltd, Suffolk, UK), 275g Boric acid (Duchefa Biochemie, 
Haarlem, The Netherlands) and 46.5g of EDTA in 10L of distilled water. The pH was adjusted 
to 8.3 using NaOH, and then stored at room temperature until further needed for use in agarose 
gel electrophoresis, when it was further diluted in water to a IX concentrate.
DEPC water
Prior to being autoclaved, 250ml of Diethyl Pryoncarbonate (DEPC) (Sigma-Aldrich, Inc., 
Poole, Dorset, England, UK) was supplemented to 4.75ml of distilled water.
Loading buffer (used for DNA electrophoresis)
25mg of bromophenol blue (Sigma-Aldrich, Inc., Poole, Dorset, England, UK) and 4g sucrose 
(Fisons Scientific Equipment, Loughborough, UK) was dissolved in 10ml of distilled water and 
stored at 4°C in order to avoid mould growth.
Ethidium Bromide
A stock solution of lOmg/ml ethidium bromide was prepared by dissolving 200mg of ethidium 
bromide powder (Sigma-Aldrich, Inc., Poole, Dorset, England, UK) in 20ml distilled water. In 
order to protect the solution from sunlight, it was then placed in a tube and covered in 
aluminium foil before being safely stored.
2.2.3 Solutions for use in cloning
LB agar
LB agar was prepared by dissolving lOg tryptone (Duchefa Biochemie, Haarlem, The 
Netherlands), 5g yeast extract (Duchefa Biochemie, Haarlem, The Netherlands), 15g agar, and 
lOg NaCl, in 1L of distilled water, before adjusting the pH to 7.0, and autoclaving the solution. 
As soon as it was further needed, the solution was melted and left to cool, before adding 
antibiotics and pouring the solution into 10cm2 Petri dishes (Bibby Sterilin LTd., Staffs, UK). 
These were left to cool and harden before being inverted and stored at 4°C.
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LB broth
lOg tryptone, lOg NaCl and 5g yeast extract was dissolved in 1L of distilled water. The pH of 
the solution was then adjusted to 7.0, and after being autoclaved was left to cool. Antiobiotics 
were then added and the solution stored at room temperature.
2.2.4 Solutions for use in protein work
Lysis Buffer
This was made up by dissolving 2mM CaCU, 0.5% Triton X-100, lmg/ml aprotinin, lmg/ml 
leupeptin and lOmM Sodium Orthovanadate in 50ml distilled water. The solution was then 
stored at 4°C until further use.
10% Ammonium Persulphate (APS)
lg  APS was dissolved in 10ml distilled water before being aliquoted into fractions of 2.5ml. 
This was then stored at 4°C until further use.
Tris Buffered Saline (TBS)
24.228g Tris and 80.06g NaCl was dissolved in 1L of distilled water in order to make a lOx 
TBS (0.5M Tris, 1.38 M NaCl, pH 7.4) stock solution. The pH was then adjusted to 7.4 using 
HC1 and stored until further use.
lOx Running buffer (for SDS-PAGE)
lOx running buffer (0.25M Tris, 1.92M glycine, 1% SDS, pH8.3) was prepared by dissolving 
303g of Tris, 1.44kg of Glycine (Melford Laboratories Ltd., Suffolk, UK) and lOOg SDS 
(Melford LaboratoriesLtd., Suffolk, UK) in 10L of distilled water. Prior to use this solution 
was further diluted to a lx concentrate.
Transfer buffer
15.5g Tris and 72g glycine was dissolved in 4L distilled water before 1L of methanol (Fisher
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Scientific, Leicestershire, UK) was added to make a final volume of 5L.
Ponceau S stain 
Supplied directly by Sigma.
Coomasie blue stain
lOOg Coomassie Brilliant Blue (Sigma-Aldrich, Inc., Poole, Dorset, England, UK) was 
dissolved in 100ml acetic acid (Fisher Scientific, Leicestershire, UK) and 250ml ethanol (Fisher 
Scientific, Leicestershire, UK), which was then added to 650ml distilled water.
Coomasie blue destain
500ml of methanol was mixed with 100ml acetic acid (Fisher Scientific, Leicestershire, UK) 
and then added to distilled water to make up a final volume of 1L.
2.2.5 Solutions for purification of histidine-tagged recombinant protein
8x Phosphate buffer (PBS), pH 7.4
1.42g Na2 H P0 4 .2H20  (177.99g/mol), l . l l g  NaH2P 04. H20  (137.99g/mol), and 23.38g NaCl 
(58.44g/mol) was dissolved in 100ml distilled water, adjusted to the correct pH, and filtered 
through a 0.45pm filter.
2M imidazole, pH  7.4
13.62g imidazole was added to 100 ml distilled water, adjusted to the correct pH, and filtered. 
0.1M N iS04
2.63g N iS0 4 .6H20  was dissolved in 100ml distilled water and filtered.
Binding buffer
In order to make up 24ml binding buffer, 3ml 8 x PBS was mixed with 0.12ml 2M imidazole, 
and topped up to 24ml with distilled water.
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Elution buffer
To prepare 8 ml elution buffer, 1ml 8 x PBS was mixed with 2ml 2M imidazole and topped with 
distilled water to a volume of 8 ml. The pH was then adjusted to pH 7.4-7.6 , and the final 
solution filtered.
2.2.6 Solutions for use in immunocytochemical staining
Diaminobenzidine (DAB) chromagen
2 drops of wash buffer, 4 drops of DAB (Vector Laboratories, Inc., Burlingame, USA) and 2 
drops of H20 2 were added to 5ml of distilled water and shaken well before use.
ABC Complex
The ABC complex is prepared by using a kit provided by Vector Laboratories Inc. (Burlingame, 
USA). 4 drops of reagent A and B were added to 20ml of wash buffer before being mixed 
thoroughly and left at room temperature for 30 minutes before being used.
2.3 Cell culture, maintenance, and storage
2.3.1 Preparation of growth media and cell maintenance
• Dulbecco’s Modified Eagle’s medium (DMEM/ Ham’s F-12 with L-Glutamine; E15- 
813, PAA Laboratories, Somerset, UK), pH 7.3 containing 2mM L-glutamine and 
4.5mM NAHCO3 , supplemented with 10% heat inactivated Foetal Bovine Serum (PAA 
Laboratories, Somerset, UK) and an antibiotic cocktail, was used to routinely culture 
the cells used in this study.
• Cell lines transfected with the pEF6 /His plasmid were originally cultured in 5pg/ml 
blasticidin S (Melford laboratories ltd, Suffolk, UK) selection media until they were 
ready to be transferred into 0.5pg/ml blasticidin S maintenance media.
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• All the cell lines were cultured in 25cm2 and 75cm2 culture flasks (Greiner Bio-One 
Ltd, Gloucestershire, UK) with a loosely fitted cap in incubator at 37°C, 98% 
humidification, and 5% C 02.
• Cell confluency was visually assessed using a light microscope and approximating the 
percentage of cells covering the surface of the tissue culture flasks. If needed for 
experimental work, the cells were left to grow until they reached sub-confluency (2-3 
days). All handling of cells was carried out aseptically, using a Class II Laminar Flow 
Cabinet with autoclaved and sterile equipment. Cells were routinely sub-cultured when 
they had reached a confluency of 80-90% (5-7 days), as explained in section 2.3.2.
2.3.2 Adherent cell trypsinisation (detachment) and cell counting
• As mentioned above, once the cells had reached a confluency of approximately 80- 
90%, the medium was aspirated before being briefly rinsed with sterile EDTA in order 
to remove any remaining serum which has an inhibitory effect on the action of trypsin.
• Adherent cells were then detached from the tissue culture flask using l-2ml of 
Trypsin/EDTA (0.01% trypsin and 0.05% EDTA in BSS buffer) by incubating the cells 
at 37°C for approximately 5 minutes.
• Once detached, the cell suspension was then poured into 20ml universal containers 
(Greiner Bio-One Ltd, Gloucestershire, UK) before being centrifuged at l,600rpm for 5 
minutes in order to pellet the cells.
• The excess liquid was then aspirated and the cell pellet resuspended in an appropriate 
amount of medium, and the cells were either counted for use in immediate experimental 
procedures, or transferred into fresh tissue culture flasks for re-culturing.
• Cells were counted using a Neubauer haemocytometer counting chamber (Mod-Fuchs 
Rosenthal, Hawksley, UK) using an inverted microscope at a magnification of 10x10 
(Reichert, Austria). A haemocytometer allows for the calculation of the number of
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cells in a predetermined volume of fluid in order to obtain the quantity of cells per 
millilitre, and an accurate estimation of cell density for use in in vitro and in vivo cell 
function assays.
• The haemocytometer chamber is divided into 16 squares with dimensions of 1mm x 
1mm x 0.2mm. For consistency of cell density, two of these 16 squared areas were 
counted. This allowed for determination of cell number by using the following 
equation:
Cell number/ml= (number of cells in two 16 squares-^ 2) x (1 x 104)
2.3.3 Storing cells in liquid nitrogen and cell resuscitation
Cell stocks of low passage number that needed to be stored were done so in liquid nitrogen.
• Cells were trypsinised as described in section 2.3.2 and resuspended in medium with 
10% Dimethylsulphoxide (DMSO; Fisons, UK) at a cell density of lxlO6 cells/ml.
• This cell suspension was then divided into 1ml aliquots and transferred into pre­
labelled 1.8ml cryopreserve tubes (Nunc, Fisher Scientific, Leicestershire, UK) 
before being wrapped in protective tissue paper, stored overnight at -80°C, and then 
transferred to liquid nitrogen tanks for long term storage until required.
• In order to resuscitate the cells, they were removed from liquid nitrogen and left to 
rapidly thaw before being transferred into a universal container containing 10ml pre­
warmed medium, and incubated for 10 minutes at 37°C.
• This was followed by centrifugation at l,600rpm for 5 minutes to remove any excess 
DMSO, before re-suspending the pellet in 5ml media, transferring the suspension into a 
fresh 25cm2 tissue culture flask and maintaining it in an incubator.
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2.4 M ethods for RNA detection
2.4.1 Total RNA isolation
There are three main types of Ribonucleic acid (RNA) in the cytoplasm known as; ribosomal 
(rRNA), transfer (tRNA), and messenger RNA (mRNA). Despite its critical role of carrying the 
genetic information required for specific protein formation, cellular mRNA only constitutes 1- 
2% of the total cellular RNA. It is this type of RNA that is normally used in research, and 
indeed is used in this study.
• The protocol followed for RNA isolation was carried out using the ABgene Total RNA 
Isolation Reagent (TRIR) kit (ABgene, Surrey, UK).
• Cells were grown in a monolayer of 85-90% confluency before the medium was 
aspirated and replaced with RNA reagent (1ml per 5-10 x 106 cells), in order to induce 
cell lysis.
• This homogenate was passed through a transfer pipette, transferred into a 1.8ml 
eppendorf, and stored at 4°C for 5 minutes, to allow for complete nucleoprotein 
complex dissociation.
• This was followed by the addition of 0.2ml (per 1ml of RNA reagent) chloroform 
(Sigma-Aldrich, Inc., Poole, Dorset, England, UK), 15 seconds of vigorous shaking, 
and incubation at 4°C for 5 minutes.
• The resulting homogenate was then centrifuged at 12,000rpm for 15 minutes at 4°C 
(Boeco, Wolf laboratories, York, UK). Under these acidic conditions, the homogenate 
is separated into three phases; a lower organic phase containing protein, an interphase 
containing DNA, and finally an upper aqueous phase containing the RNA.
• This aqueous phase which should constitute around 40-50% of the total volume, was 
then carefully removed and transferred into a fresh eppendorf, before adding an equal 
volume (usually around 0.5ml) of isopropanol (Sigma-Aldrich, Inc., Poole, Dorset,
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England, UK), and incubating for 10 minutes at 4°C. After centrifuging the samples at 
12,000rpm for 10 minutes at 4°C, the RNA precipitate forms as a white pellet on the 
bottom of the eppendorf.
• The supernatant was then discarded, and the RNA pellet washed twice with 75% 
ethanol (3:1 ratio of pure ethanol and DEPC water). Each wash was carried out by 
adding 1ml 75% ethanol, vortexing, and subsequently centrifuging the samples at 
7,500rpm for 5 minutes at 4°C.
• After the final wash, the RNA pellet was briefly dried at 55°C for 5-10 minutes, in a 
Techne, Hybridiser HB-1D drying oven (Wolf laboratories, York, UK), so as to remove 
any remaining traces of ethanol.
• The final step was to dissolve the RNA pellet in 50-100pl (depending on pellet size) of 
DEPC water by vortexing for a short while. DEPC is used, as it is a histidine specific 
alkylating agent and inhibits the effect of RNAases, which require histidine active sites 
to carry out their function.
2.4.2 RNA Quantification
• Once RNA isolation was completed, the concentration and purity of the resulting RNA 
was measured with the use of a UV1101 Biotech Photometer (WPA, Cambridge, UK). 
This spectrophotometer had been previously set to detect ssRNA (pg/pl) at a dilution of 
1:10 by measuring the difference in absorbance between the RNA sample and DEPC 
water (used as a blank) at a wavelength of 260nm.
• By using a ratio of A260nm/A280nm an estimation of the purity of the RNA can be 
determined, with pure RNA reaching an optical density of 2.0, and RNA contaminated 
with ethanol or protein, reaching optical density values of less than 1.5.
• The samples were measured using Starna glass cuvettes (Optiglass limited, Essex, UK). 
The RNA samples were then either placed at -80°C for long term storage or used 
immediately for reverse transcription (RT).
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2.4.3 Reverse Transcription of RNA for production of cDNA
Reverse transcription (RT) is a simple and sensitive technique for mRNA analysis and acts as 
an enhanced and more rapid alternative to the more conventional methods of RNA examination.
• In this study RT is carried out by converting 0.25pg/pl of RNA into complementary
DNA (cDNA) using the iScript™ cDNA Synthesis Kit (Bio-Rad Laboratories,
California, USA). The protocol that was carried out is outlined below:
• Each reaction was set up in thin-walled 200pl PCR tubes (ABgene, Surrey, UK) as
follows:
Component Volume per reaction
5x iScript Reaction Mix 4pl
iScript Reverse Transcriptase lpl
Nuclease-free water xpl
RNA template (0.25pg/pl) xpl
Total Volume: 20p i
• The complete reaction was mixed and then incubated in a T-Cy Thermocycler (Creacon 
Technologies Ltd, The Netherlands) at the following temperatures:
5 minutes at 25°C
30 minutes at 42°C
5 minutes at 85°C
98
• Once the process was completed, the cDNA was diluted 1 in 3 with PCR water, and 
either used immediately as a template for conventional PCR, or stored at -20°C until 
further use.
2.4.4 Polymerase Chain Reaction (PCR)
Polymerase chain reaction (PCR) was initially devised in 1983 by Karey Mullis as a compelling 
method for detecting and amplifying a specific target sequence of nucleic acid.
• In this study, a particular gene of interest was amplified by PCR using the REDTaq™ 
ReadyMix PCR Reaction mix (Sigma, Dorset, UK). The reactions were set up in thin
walled PCR tubes in aliquots of 12pl as follows:
Component Volume
cDNA template lp l
Forward primer (working concentration of 1 pM) lp l
Reverse primer (working concentration of 1 pM) lp l
2xREDTaqTM ReadyMix 6pl
PCR H20  3pi
A negative control containing PCR water instead of the template (cDNA) was run 
alongside all the test samples to ensure there was no contamination.
• The PCR reactions were then briefly mixed before being placed in a T-Cy 
Thermocycler set to the following conditions;
Initial denaturation- 94°C for 5-10 minutes
Followed by 30-42 cycles of:
Denaturation -  94°C for 1 minute
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Annealment -  gene/primer specific temperature for 30-40 seconds 
Extension -  72°C for 1-1.5 minutes 
And finally:
Final extension -  72°C for 7-10 minutes
The cycling conditions are dependent, and vary, according to different sets of primers 
and the size of the PCR product.
• The primer binding sites along with the predicted product sizes were determined using 
the Primer3 (v.0.4.0) software available online (http://frodo.wi.mit.edu/T and the 
products were verified and visualised using agarose gel electrophoresis (as explained in 
section 2.4.5) and staining with ethidium bromide. In order to demonstrate a 
representative and reliable expression pattern, each RT-PCR was triplicated.
2.4.5 Agarose gel electrophoresis and DNA visualisation
Agarose gel electrophoresis is the most simple and common method of DNA separation and 
analysis. It works by using an electrical current to separate the amplified DNA according to 
charge and size. Depending on the product size, the samples were either run on a 0.8% agarose 
gel (used for large DNA fragments l-10kb in size) or a 2% gel (used for smaller fragments less 
than lkb in size).
• The agarose gels were prepared by adding the required amount of agarose (Melford
Chemicals, Suffolk, UK) to 400ml of TBE solution before being heated to completely
dissolve the agarose. An appropriate amount of this solution was then poured into 
electrophoresis cassettes (Scie-Plas Ltd., Cambridge, UK) containing well forming 
combs, before the gel was left to set at room temperature for 30-40 minutes.
• Once set, TBE buffer was poured over the gel until it reached to a level 5mm above the
gel surface. The comb was removed, and approximately 8pl of 1Kb DNA ladder (Cat
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No. 15615-016; Invitrogen, Paisley, Scotland), or 6-10pl of each PCR reaction, was 
loaded into the wells by placing the gel loading tip just over the well and dispensing the 
product into it.
• A power pack (Gibco BRL, Life Technologies Inc.) was then used to run the samples 
electrophoretically through the gel at a constant voltage of around 100V for 
approximately 30-50 minutes until the samples had migrated to around two thirds down 
the gel or as far as required for that particular product size.
• The DNA was then visualised by the addition of ethidium bromide which acts as a 
DNA intercalator and fluoresces, thereby absorbing invisible UV light and transmitting 
the energy into visible orange light. The gel was placed in ethidium bromide stain 
diluted in the TBE buffer and left for 15 minutes with constant agitation to ensure even 
staining, before being visualised under UV light using a UV illuminator (UVitech, 
Cambridge, UK).
• Images could then be captured with the use of a UV camera imaging system (UVitech, 
Cambridge, UK), and printed with a Mitsubishi thermoprinter (Mitsubishi UK, London, 
UK) or saved as a TIFF file. If insufficient staining was found, the gel was returned to 
the ethidum bromide stain for additional staining, or if destaining to remove any 
background staining was required, the gel was placed in water.
2.4.6 Gel extraction of DNA
PCR products of interest were extracted from the agarose gels using the GelElute™ Gel 
Extraction Kit (Sigma-Aldrich, Inc., Poole, Dorset, England, UK) the protocol of which was 
carried out as follows:
• Once the DNA electrophoresis had been completed, the required PCR products were 
excised from the gel using a sharp scalpel. The gel slice was then placed in an 
eppendorf and weighed, while the excess bits of gel were discarded.
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• This was followed by the addition of 300pl/100mg of Gel Solubulisation solution, and 
incubation at 55°C for 10 minutes or until the gel had dissolved entirely. The gel 
mixture was routinely vortexed in order to aid in the dissolving process. If the 
resulting solution was not yellow in colour, then an appropriate amount of 3M sodium 
acetate buffer (pH 5.2) was added until this colour had developed.
• While this was happening, the binding column was prepared by placing the GenElute 
Binding Column G into a 2ml collection tube as provided, and adding 500^1 of 
Column Preparation solution to the binding column. This was then centrifuged for 1 
minute, and the flow-through liquid discarded.
• The solution containing the dissolved gel was then placed into the binding column, 
centrifuged for 1 minute and the resulting flow-through discarded once more. This was 
followed by the addition of 700pl of wash solution before being briefly centrifuged, 
discarding the flow-through and re-centrifuging so as to dry and rid the column 
completely of wash buffer.
• The binding column was subsequently placed into a fresh collection tube, and the PCR 
products eluted using 50pl of elution solution or PCR water. The resulting product 
was then either used immediately or stored at -80°C.
2.4.7 Quantitative RT-PCR (Q-PCR)
Unlike conventional RT-PCR, which only allows for semi-quantification, Q-PCR is a method 
of detecting extremely small amounts of cDNA template within a sample while also 
determining an accurate and reliable value of the template copy number in each sample. This 
method works due to the use of a sequence specific DNA based fluorescent reporter probe 
which only quantifies the levels of DNA containing the probe sequence, thereby greatly 
increasing specificity.
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This current study uses the Ampliflour™ Uniprimer™ Universal system (Intergen company®, 
New York, USA) to quantify transcript copy number. The ampliflour probe consists o f a 3’ 
region specific to the Z-sequence (ACTGAACCTGACCGTACA) present on the target specific 
primers, and a 5’ hairpin structure labelled with a flourophore (FAM). When in this hairpin 
structure, the flourophore is linked to, and hence is in close proximity to, an acceptor moiety 
(DABSYL) which acts to quench the fluorescence emitted by the flourophore, preventing any 
signal from being detected.
During PCR however, the probe becomes incorporated and acts as a template for DNA 
polymerisation in which DNA polymerase uses its 5’-3* exonuclease activity to degrade and 
unfold the hairpin structure, thereby disrupting the energy transfer between flourophore and 
quencher, allowing sufficient fluorescence to be emitted and hence detected. The fluorescent 
signal emitted during each PCR cycle can then be directly correlated to the amount of DNA that 
has been amplified. This process is illustrated in Figure 2.1.
• Each reaction to be amplified was set up as follows:
Component Volume
Forward Z primer 0.3pl (lpmol/^il)
Reverse primer 0.3pl (lOpmol/pil)
Precision™ mastermix 5(xl
(Primer design Ltd., Southampton, UK)
Ampliflour probe 0.3|B (lOpmol/fil)
cDNA and PCR H20  4pl
• Each sample was then loaded into a 96 well plate (BioRad laboratories, Hemel
Hampstead, UK), alongside standards (ranging from copy numbers of lO'-lO8), covered
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with optically clear Microseal® (Biorad laboratories, California, USA) and this was 
placed in an iCycler10 thermal cycler and detection software (BioRad laboratories, Hemel 
Hampstead, UK) at the following conditions:
Initial denaturation- 94°C for 5 minutes
Followed by 80-90 cycles of:
Denaturation- 94°C for 10 seconds
Annealment- 55°C for 15 seconds
Extension -  72°C for 20 seconds
• The fluorescent signal is detected at the annealing stage by a camera where its geometric 
increase directly correlates with the exponential increase of product. This is then used to 
determine a threshold cycle (TC) for each reaction and the transcript copy number 
depends on when the fluorescence detection reaches this specific threshold.
• The degree of fluorescence emitted by a range of standards of a known transcript copy 
number is then used to compare to the amount emitted by each sample, allowing for the 
transcript copy number in each sample to be accurately calculated.
• Furthermore, the transcript copy number of each sample was then normalised against the 
detection of [3-actin or GAPDH copy numbers. The procedure was repeated at least 
three times, and representative date is demonstrated as expressional trends. Figure 2.2 
shows how transcript levels are quantified.
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Figure 2.1: Diagram showing function of the u-probe during DNA amplification using Q-PCR.
105
(A)
1300
1200
1100
H 1000
5  900
"8 800  
J  700  
3  600  
f  500  
|  400
“  300
tS? 200 
100 
0  
-100
0  2  4 6  8  10 12 14 16 18 2 0  2 2  24  2 6  2 8  3 0  32  34 36  38  4 0  4 2  44  46  4 8  SO 5 2  54  56
ten A k^ M k H W  v;  C y< l< : U K  - 5 « y d
(B)
Correlation Coefficient: 0,999 Slope:-3.737 intercept: 48.409 Y =-3.737 X + 48.409 
PCR Efficiency: 85.2%
o Unknowns
•  Standards
■S 40- 
u  35!
« 25 
£ 20
0 2 3 5 6 7 81 4
Log Starting Quantty, copy number
Figure 2.2: (A) Detection of transcript levels from a range of standard samples (108 to 102 
copy number) using the iCyclerIQ thermal cycler. (B) Subsequent generation of a standard 
curve from these samples.
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2.5 Methods for protein detection
2.5.1 Protein extraction and preparation of cell lysates
• Once cells had reached an adequate confluency, the cell monolayer was scraped off
using BSS and a cell scraper. The cell suspension was then transferred into a universal 
tube.
• This was followed by centrifugation at 2,000rpm for 5 minutes before the supernatant 
was poured off, and the cell pellet resuspended in 200-300pl (depending on pellet size) 
of lysis buffer.
• This was transferred into a 1.8ml eppendorf tube and placed for an hour at room 
temperature on a Labinco rotating wheel (Wolf laboratories, York, UK) to allow for 
cell lysis.
• The resulting suspension was then centrifuged at 13,000rpm for 15 minutes so as to
pellet any unwanted cell debris. The supernatant was transferred to a fresh eppendorf
tube, and the pellet discarded.
• The protein samples were then either quantified for SDS-PAGE as explained below, or 
stored at -20°C until further use.
2.5.2 Protein quantification and preparation of samples for SDS-PAGE
In order to standardise the protein sample concentration for western blotting, the amount of 
protein in each sample was quantified by following the protocol outlined in the Bio-Rad DC 
Protein Assay kit (Bio-Rad laboratories, Hemel Hampstead, UK).
• In a 96 well plate, lOmg/ml of bovine serum albumin (BSA) standard (Sigma, Dorset, 
UK) was serially diluted in lysis buffer to a concentration of 0.005mg/ml and used to 
set up a standard curve of protein concentration.
107
• 5(xl of either protein sample or standard was then pipetted into fresh wells, before 25 pi 
of ‘working reagent A’ (prepared by adding 20pl of reagent S per millilitre of reagent 
A), and 200pl of reagent B was added to each well.
• After mixing the samples, the plate was left at room temperature for 30-45 minutes in 
order to allow the colorimetric reaction to take place. Once this was complete, the 
absorbance of each of the wells was measured at 620nm using the ELx800 plate reading 
spectrophotometer (Bio-Tek, Wolf laboratories, York, UK).
• Using the absorbance of the standards, a standard curve was set up, and by comparing 
this to the absorbences of the samples, sample concentration was determined. The 
samples were then diluted in an appropriate amount of lysis buffer in order to normalise 
them to the required final concentration of 1.0-1.5mg/ml.
• This was then further diluted with 2x Lamelli sample buffer concentrate (Sigma- 
aldrich, St Louis, USA) in a ratio of 1:1 before the samples were denatured by boiling 
at 100°C for 5 minutes, and either loaded onto an SDS-PAGE gel or stored at -20°C 
until further use.
2.5.3 Preparing immunoprecipitates
Immunoprecipitation (IP) can be used for analysing intracellular phosphorylation that occurs in 
downstream signalling cascades. The process involves adding a specific antibody targeted 
against a protein of interest within a cell lysate. This is then mixed with sepharose or agarose 
bonded staphylococcal protein A, protein G, or both, in order to collect the ensuing protein- 
antibody complexes. These complexes are then centrifuged to induce precipitation, run on an 
SDS-PAGE gel, and evaluated using immunoprobing. The process was carried out as follows:
• Antibody targeted against a protein of interest was added to the cell lysate samples 
before being incubated at 4°C for 1 hour on a Labinco rotating wheel.
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• Following incubation, 50pl of conjugated A/G protein agarose beads (Santa Cruz 
Biotechnology, supplied by Insight Biotechnologies Inc, Surrey, England, UK) was 
added to each sample and placed back on the wheel for another hour in order to allow 
for the antibody-protein complexes to bind to the beads.
• Centrifuging at 8,000rpm for 5 minutes then acts as a way of removing any unbound 
protein or excess antibodies present in the supernatant. The protein pellet was 
subsequently washed twice with 300pl lysis buffer before being resuspended in 40- 
60pl of 2x sample buffer, and boiled for 5 minutes. The resulting samples were then 
run on SDS-PAGE gels as explained below.
2.5.4 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE)
• The system used to carry out SDS-PAGE in this study was the OmniPAGE VS 10 
vertical electrophoresis system. Resolving gels of a required percentage (depending on 
protein size) were prepared in 15ml aliquots (enough for 2 gels) by adding all the 
constituents at the amounts indicated below:
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Component 8% Resolving gel 
(50-100kDa 
proteins)
10% Resolving gel 
(20-90kDa proteins)
Distilled water 6.9ml 5.9ml
30% acrylamide mix (Sigma-Aldrich, St 4.0ml 5.0ml
Louis, USA)
1.5M Tris (pH 8.8) 3.8ml 3.8ml
10% SDS 0.15ml 0.15ml
10% Ammonia persulphate 0.15ml 0.15ml
TEMED (Sigma-Aldrich, St Louis, USA) 0.009ml 0.006ml
Table 2.6: Ingredients for resolving gel.
• The resulting mixture was then poured in between two glass plates held in place by a 
loading cassette, until a level 1cm below the top of the plate, and in order to prevent gel 
oxidation, the top of the resolving gel was covered with a 0.1% SDS solution.
• The gels were then left to polymerise at room temperature for approximately 30 
minutes, or until fully set. The excess SDS solution was then poured off before adding 
a sufficient amount of stacking gel in its place, prepared as shown below:
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Component Stacking gel
Distilled water 3.4ml
30% acrylamide mix (Sigma-Aldrich, 0.83ml
St Louis, USA)
1.0M Tris (pH 6.8) 0.63 ml
10% SDS 0.05ml
10% Ammonia persulphate 0.05ml
TEMED (Sigma-Aldrich, St Louis, 0.005ml
USA)
Table 2.7: Ingredients for stacking gel.
• Immediately after the addition of the stacking gel, a well forming Teflon comb is 
inserted before allowing the gel to polymerise at room temperature for around 20 
minutes.
• Once set, the loading cassette was transferred into an electrophoresis tank and covered
with IX running buffer before removing the well comb, and by use of a 50pl syringe
(Hamilton), loading 6-8pl of ColorPlus Prestained Protein Marker (New England 
BioLabs Ltd., Herts, UK), followed by 10-15jxl of the required protein samples.
• The gels were then run at 125V, 40mA, and 50W for a length of time appropriate for
the size of the protein of interest, in order to separate the proteins according to charge
and molecular weight.
2.5.5 Western blotting: transferring proteins from gel to nitrocellulose membrane
• Once SDS-PAGE was completed, the protein samples were transferred onto a 
nitrocellulose membrane by western blotting. The electrophoresis equipment was
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disassembled and the gel pried out from in between the two glass plates before 
discarding of the stacking gel. The resolving gel was then placed on the bottom 
graphite base electrode in a SD20 SemiDry Maxi System blotting unit (SemiDRY, 
Wolf Laboratories, York, UK) on top of 3 pieces of lx  transfer buffer pre-soaked filter 
paper (Whatman International Ltd., Maidstone, UK), and 1 sheet of Hybond 
nitrocellulose membrane (Amersham Biosciences UK Ltd., Bucks, UK).
• An additional 3 sheets of pre-soaked filter paper were placed on top of the gel to form a 
sandwich arrangement of paper: membrane: gel: paper, as shown in Figure 2.3. 
Electroblotting was then carried out at 15v, 500mA, and 8W for around 45 minutes to 
an hour. Once the proteins had been sufficiently transferred, the membranes were 
blocked over night at 4°C in 10% skimmed dry milk solution (10% milk powder and 
0.1% polyoxyethylene (20) sorbitan monolaurate (Tween 20) (Sigma-Aldrich, St Louis, 
USA) in 50ml TBS. This acts to block the proteins onto the membrane for subsequent 
antibody probing.
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SD20 Semi-Dry Blotting Unit
- electrode
------------------------------- J. 3 sheets of filter paper
Agarose gel
Nitrocellulose m em brane
 -----------  Z Z  j.3 sheets of filter paper
+ electrode
Power supply settings:
Voltage: 15v 
Current: 500mA 
Power: 5-8W 
Time: 45-60 minutes
Figure 2.3: Diagram depicting process of western blotting; the transferring of proteins onto a 
nitrocellulose membrane.
2.S.6 Protein staining
2.5.6.1 Staining membranes in Ponceau S
Ponceau S is a reversible and re-usable protein stain that does not interfere with any subsequent 
immuno-probing. Its main use is to confirm that protein transfer from the polyacrylamide gel to 
the nitrocellulose membrane has been successful, but can also be used to aid in membrane 
sectioning for multiple immune-probing. The protocol was carried out as follows:
• After the transfer was completed and before probing began, the membrane was 
immersed in Ponceau S solution for a few minutes at room temperature.
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• The solution was then washed off with distilled water until the bands become visible. If 
required, the membrane was then cut into several sections using a sharp and clean 
scalpel.
• Once the Ponceau was completely washed off it was placed in 10% milk solution.
2.5.6.2 Coomasie blue staining o f polyacrylamide gels
Coomasie blue is used to stain polyacrylamide gels following SDS-PAGE. This allows for 
visualisation of protein bands if no immuno-probing is required and can be used as a way of 
semi-quantifying the volume of the protein bands. The protocol was carried out as follows:
• The gel was immersed in Coomasie blue stain for approximately 30 minutes before 
being repeatedly washed in destain solution until the background staining had 
disappeared, and the protein appeared as blue bands. The gel can then be photographed 
or analysed.
2.5.7 Protein detection using specific Immuno-probing
• Once any staining was completed, the membrane was transferred into 50ml falcon tubes
(Nunc, Fisher-Scientific, Leicestershire, UK) ensuring that the membrane surface that 
had been in contact with the gel was facing upwards. 10% milk blocking solution was 
then added to the membranes and incubated for an hour at room temperature on a roller 
mixer (Stuart, Wolf-Laboratories, York, UK).
• Once this was done, the 10% milk solution was poured off and replaced with 10ml of 
3% milk solution (3% milk powder, 0.1% Tween 20 in TBS) for 15 minutes. This was
followed by incubation of the membranes for an hour at room temperature, with
primary antibody diluted 1:200 in 5mls of 3% milk solution.
• After pouring off the primary antibody solution, any remaining unbound antibody was 
washed off three times in 3% milk solution at 15 minute intervals.
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• Once washing was completed, the membranes were further incubated with 5ml of 
1:1000 HRP conjugated secondary antibody (of the same species) diluted in 3% milk. 
This was carried out for an hour at room temperature on a roller mixer.
• This was followed by two 15 minute washes in 10ml of 3% milk solution, and two 15 
minute washes with Tween TBS (0.1% Tween 20 in TBS), in order to wash off any 
unbound secondary antibody.
• A final two 15 minute washes with solely TBS was carried out so as to remove any 
residual detergent, before placing the membrane in weighing boats containing TBS 
solution, ready for chemiluminescent detection.
2.5.8 Chemiluminescent protein detection
Chemiluminescent protein detection was carried out using the Supersignal ™ West Dura system 
(Pierce Biotechnology, Inc., Rockford, IL, USA), which consists of a highly sensitive 
chemiluminescent substrate that detects the horseradish peroxidise (HRP) used during the 
western blot procedure. The protocol was carried out as follows:
• The two reagents provided were added in a 1:1 ratio (normally 4ml of each for a mini 
gel) into the weighing boat containing the membrane to be analysed. After 5 minutes 
incubation at room temperature with constant agitation, the membrane was carefully 
removed from the solution using forceps.
• Any excess solution on the membrane was then drained over a piece of tissue paper and 
transferred into a fresh weighing boat. The chemiluminescent signal was detected 
using an UVITech Imager (UVITech Inc., Cambridge, UK) which contains both an 
illuminator and a camera linked to a computer, which then captures and stores the 
image.
• Each membrane was subjected to varying exposure times until the protein bands were 
sufficiently visible. These images were then captured and further analysed with the
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UVIband software package (UVITEC, Cambridge, UK), which allows for protein band 
quantification.
• In this study, p-actin was used as a housekeeping gene and run alongside any other 
proteins to be detected, so as to allow for additional normalisation of the samples, and 
to compensate for any other negligible inaccuracies which may have occurred during 
the process. The cytokeletal protein p-actin is used due to its highly abundant and 
conserved nature within eukaryotic cells, and is one of the most widely employed and 
accepted internal controls in scientific research.
• In order to confirm reliability of the results, each western blot was carried out three 
times and the protein bands quantified and standardised separately, followed by 
calculation of mean values and graphical presentation of the results.
2.5.9 Immunohistochemical staining
This study uses a previously reported method of Immunohistochemical staining (Jiang et al.
2005) and was carried out as follows:
• 20,000 cells in 200pl DMEM media were seeded into chamber slides (Nalge, NUNC 
International, LAB-TEK®, USA) and left to incubate overnight at 37°C, with 5% C 0 2.
• The cells were then fixed in ice-cold pure ethanol for 30 minutes at 4°C, before being 
rehydrated with BSS for an hour at room temperature.
• This was followed by cell permeabilisation in 0.1% TritonXlOO in TBS for 5-10 
minutes at room temperature. This causes the cell membranes to rupture, releasing 
intracellular proteins.
• Permeabilisation was followed by blocking of the cells with horse serum (Vector 
Laboratories Inc., Burlingame, USA) in OptiMax Wash Buffer (BioGenex, San Ramon, 
USA) for 30 minutes at room temperature. 1-2 drops of horse serum per 5ml of wash 
buffer was diluted 1:20 in distilled water and used as the blocking solution.
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• After blocking, the cells were washed four times with wash buffer before being 
incubated for an hour at room temperature with primary antibody diluted 1:100 
(depends on antibody used) in blocking solution.
• Any unbound antibody was subsequently washed off with wash buffer. This was 
repeated 4 times before incubating the cells for a further 30 minutes at room 
temperature, with the corresponding secondary antibody diluted 1:1000 in blocking 
solution.
• After 4 washes with wash buffer, the cells were incubated with 200pl of working 
VECTASTAIN® Universal ABC complex (Vector Laboratories Inc., Burlingame, 
USA). The ABC complex was made up 30 minutes before use by mixing 4 drops of the 
supplied reagent A, with 4 drops of reagent B.
• The ABC solution was subsequently removed by washing four times with wash buffer 
before a few drops of DAB chromogen (Vector Laboratories Inc., Burlingame, USA) 
were added to the cells and left to incubate for 5 minutes in darkness. DAB was made 
up as follows; 2 drops of the provided buffer (pH 7.5), 4 drops of DAB, and 2 drops of 
hydrogen peroxide diluted in 5ml of distilled water.
• Following DAB addition, the solution should turn brown and once this had occurred, 
the DAB was washed off using distilled water before the cells were counterstained with 
Mayer’s haemotoxylin for approximately 1 minute.
2.5.10 Immunoflourescent staining
The method used in this study for fluorescent staining was carried out as previously reported 
(Jiang et al., 1999). 20,000 cells in 200pl DMEM media were seeded into chamber slides 
(Nalge, NUNC International, LAB-TEK®, USA) and left to incubate overnight at 37°C, with 
5% C 0 2.
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• After incubation cells can be treated with protein of interest if need be. The media was 
aspirated and the cells fixed with 200pl ice-cold pure ethanol for 20 minutes at 4°C.
• Following fixation, the cells were rehydrated with 200pl BSS for a minimum of 30 
minutes at room temperature.
• The cells were permeabilised with 0.1% TritonxlOO in TBS for 5-10 minutes at room 
temperature before being blocked with horse serum in OptiMax Wash Buffer 
(BioGenex, San Ramon, USA) for 30 minutes at room temperature as explained in 
section 2.5.9.
• Blocking was followed by four washes with wash buffer before the cells were 
incubated for an hour at room temperature with primary antibody diluted 1:100 
(depending on antibody used) in blocking solution.
• After a further four washes with wash buffer, the cells were incubated with the 
corresponding secondary antibody labelled with either FITC or TRITC diluted 1:100 in 
blocking serum.
• The secondary antibodies were subsequently washed off twice using wash buffer before 
the slides were mounted with Flouro-Save (CalBiochem, Nottingham, England) and 
viewed under a fluorescent microscope (Olympus). Photos were taken and analysis 
carried out using the Cell Analyser software (Olympus).
2.6 A lteration o f gene expression
2.6.1 Knocking down gene expression using Ribozyme Transgenes
In order to knockdown the expression of GDF-9, it was targeted at the mRNA level using 
hammerhead ribozyme transgenes that specifically target and cleave the GDF-9 mRNA 
transcript. The hammerhead ribozyme was first described by Forster and Symons in 1987 as a 
self-cleaving region in the RNA genome of various plant viroids and virusoids. The
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hammerhead motif was subsequently integrated into short synthetic oligonucleotides, 
transforming it into a turnover catalyst capable of cleaving various RNA targets (Uhlenbeck, 
1987; Haseloff and Gerlach, 1988).
Hammerhead motifs contain a conserved secondary structure that consists of three helical stems 
(I, II, and III) enclosing a junction known as the catalytic core, typified by various invariant 
nucleotides. The best codons demonstrated to be suitable for cleavage are AUC, GUC and 
UUC (Figure 2.4). In order to generate a ribozyme transgene specific to GDF-9, primers were 
designed using Zuker’s RNA mFold programme (Zuker, 2003) according to the secondary 
structure of the gene. Subsequently, an appropriate GUC ribozyme target site was chosen from 
within GDF-9’s secondary structure and the ribozyme created to specifically bind the sequence 
adjacent to this GUC codon. This made it possible for the hammerhead catalytic region of the 
ribozyme to bind to and specifically cleave the GUC sequence within the target mRNA 
transcript.
Following ribozyme design, the sequences were ordered from invitrogen as sense/antisense 
strands (as shown in Table 2.4) and joined to the transgene by carrying out touchdown PCR 
under the following conditions:
Initial denaturation- 94°C for 5 minutes
Followed by 8 cycles of each annealing temperature (total of 48 cycles):
Denaturation -  94°C for 10 seconds
Various annealment steps- 70°C for 15 seconds, 65°C for 15 seconds,
60oC for 15 seconds, 57°C for 15 seconds, 54°C for 15 seconds and 50°C for 15 
seconds.
Extension -  72°C for 20 seconds
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And finally:
Final extension -  72°C for 7 minutes
•  Subsequently, the transgenes were run on a 0.8% agarose gel in order to verify their 
presence as well as size before being cloned into the pEF6/His plasmid as described in 
section 2.7.
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Figure 2.4: Secondaiy structure of hammerhead ribozyme with bound substrate.
2.6.2 Gene over-expression
Primers capable o f amplifying the complete coding sequence o f GDF-9 with or without stop 
codon, were designed according to the GDF-9 mRNA sequence. High fidelity and accurate
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PCR (LA-PCR) was carried out using the DuraScript™ RT-PCR kit (Sigma-Aldrich, Inc., 
Poole, Dorset, England, UK) and cDNA from normal prostate tissue (previously shown to 
highly express GDF-9).
• The reaction was carried out at the following conditions:
Initial denaturation- 93°C for 2 minutes
Followed by 42 cycles of:
Denaturation -  93°C for 20 seconds
Annealment -  58°C (for SCD sequence) and 62°C (for NSCD sequence) for 20 seconds 
Extension -  68°C for 1.5 minutes 
And finally:
Final extension -  68°C for 10 minutes
• The resulting products were then run on a 2% agarose gel before being excised using 
the gel extraction kit (section 2.4.6) and then cloned into a pEF6/His plasmid as 
described in the following section.
2.7 TOPO TA gene cloning and generation o f stable transfectants
The TOPO TA expression system provides a highly efficient and simple one step cloning 
approach without the requirement of ligases, specific PCR primers, or any post PCR 
procedures. The process involves the direct insertion of Taq polymerase amplified PCR 
products into a plasmid vector suited for high level and constitutive expression in mammalian 
host cell lines, following transfection.
This current study uses the pEF6/V5-His-TOPO plasmid vector (Invitrogen Inc., Paisley, UK) 
which is provided linearised with a single 3’ Thymidine (T) overhangs for TA cloning, and a
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covalently bound Topoisomerase (Figure 2.5). Due to its template independent terminal 
transferase activity, Taq polymerase catalyses the addition of a single deoxyadenosine (A) to 
the ends of PCR products. This allows for efficient ligation of the PCR product into the 
plasmid vector due its 3’ T overhang mentioned above (the process of cloning is summarised in 
figure 2.6).
V5 epitope! 6xHis
pEF6/V5-His
TOPO®
5840 bp
Figure 2.5: Schematic of the pEF6 plasmid (taken from pEF6/V5-His TOPO TA Expression 
Kit protocol).
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2.7.1 TOPO cloning reaction
• The following reagents were placed in a pre-labelled eppendorf tube and mixed gently 
before being incubated for 5 minutes at room temperature.
4ul of PCR product
lul salt solution
lu l TOPO vector
2.7.2 Transformation of chemically competent E. coli
• 5pi of the cloning reaction set up in section 2.7.1 was mixed in a vial with chemically 
competent One Shot™ TOP 10 E.Coli (Invitrogen Inc., Paisley, UK) before being 
incubated on ice for 30 minutes
• This was followed by a heat-shock at 42°C for 30 seconds in a water bath, and 
immediate incubation back onto ice for 2 minutes.
• 250pl of SOC medium (warmed to room temperature) was then added to the cell 
suspension and left to shake horizontally at 200rpm on an orbital shaker (Bibby Stuart 
Scientific, UK) at 37°C for an hour.
• Following this incubation period, the E.coli mixture was spread onto pre-warmed 
selective LB-agar plates (with lOOpg/ml ampicillin) at high and low seeding densities, 
before being incubated at 37°C over night.
• As the pEF plasmid has antibiotic resistance genes to both ampicillin and blasticidin, 
only the cells that contain the plasmid are capable of growing on the agar. This is a 
way of selecting only the colonies positive for the plasmid containing your gene of 
interest. However, to confirm that the gene sequence has been inserted in the correct 
orientation, the colonies need further testing.
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2.7.3 Colony selection and analysis
• In order to ensure that a viable product will be produced, the colonies were analysed to 
verify that the gene expression sequence had been ligated into the vector in the correct 
orientation.
• This was done by carrying out PCR on around 10 colonies, with three different sets of 
primers. The first reaction uses a forward primer specific for the primer (T7F or 
BGHR) and a reverse primer specific for the sequence. T7F starts around 90bp before 
the beginning of the insert and so if the insert has been ligated in the correct orientation, 
the resulting product should be around lOObp bigger than the predicted product size. 
The second reaction contains T7F and a forward primer specific for the sequence. If a 
product is seen following amplification, then the insert is in the wrong orientation. If a 
band is seen for both reactions then the colonies contain a mixture of plasmids with 
both correctly and incorrectly inserted sequences. Finally, in order to verify that the 
full sequence has been inserted without degradation, a further reaction with T7F and 
BGHR is carried out on the colonies.
• Individual colonies were examined by lightly touching a labelled colony with a pipette 
tip, and mixing it into each PCR reaction before specific amplification of the desired 
sequence. The thermal cycler was set to the following conditions:
Initial denaturation- 94°C for 10 minutes 
Followed by 35 cycles of:
Denaturation -  94°C for 30 seconds 
Annealment -  56°C for 40 seconds 
Extension -  72°C for 1.5 minutes
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And finally:
Final extension -  72°C for 7 minutes
2.7.4 Plasmid purification and amplification
• Following colony analysis, the ones deemed to have the insert in the correct orientation 
were picked off the plate and inoculated in 10ml of LB broth with lOOpg/ml ampicillin, 
before being incubated at 37°C over night with constant agitation.
• The amplified E.coli were then pelleted by centrifugation at 4°C for 15 minutes at 
6,000rpm, and then used for plasmid extraction. This was carried out using the Sigma 
GenElute Plasmid MiniPrep Kit (Sigma-Aldrich, USA) according to the provided 
protocol, outlined below.
• The bacterial pellet was first resuspended in 200pl of resuspension fluid (containing 
RNase A) before being mixed thouroughly, and transferred into the provided 2ml 
collection tubes.
• This was followed by the addition of 200pl lysis solution and mixing by inverting the 
tubes 5-6 times. The resulting mixture was left at room temperature for 5 minutes 
before adding 350pl of neutralisation solution.
• The tubes were inverted several times again, and centrifuged at 12,000rpm for 10 
minutes. The resulting supernatant was then transferred into a fresh collection tube 
containing a Mini Spin Column, which binds the plasmid DNA after centrifugation at 
12,000rpm for 1 minute.
• The flow through was discarded before the column was washed with 700pl of wash 
solution (containing ethanol) and centrifuging at 12,000rpm for 1 minute. The flow 
through was discarded once more, before the column was dried by another minute of 
centrifugation.
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• The column was then transferred into a fresh collection tube for elution. This was 
carried out by adding 50-100pl of elution solution and centrifuging at 12,000rpm for 1 
minute. The resulting flow through containing the purified plasmid was collected, and 
around 4pl run on a 0.8% agarose gel in order to confirm the presence and purification 
of the plasmid.
2.7.5 Transfection of mammalian cells using electroporation
• Following plasmid extraction, the empty plasmid, and the plasmid containing the 
ribozyme transgene was used to transfect both the PC-3 and DU-145 prostate cancer 
cell lines respectively, while the plasmid with the GDF-9 coding sequence was 
tranfected into the PC-3 cells alone. As DU-145 cells already express such high 
endogenous levels of GDF-9, only GDF-9 knock-down was attempted in this cell line.
• The method of transfection used in this study was electroporation using an 
electroporator (Easyjet, Flowgene, Surrey, UK).
• Once the cells had reached confluency they were detached from their tissue culture 
flasks, counted, and approximately 2xl06 cells were resuspended in 1ml of media.
• 500pl of the cell suspension was then added into an electroporation cuvette 
(Eurgenetech, Southampton, UK), and following the addition of 3-5pi of plasmid, left 
at room temperature for 5 minutes.
• The cuvette was placed into the electroporator and subjected to an electrical pulse of 
310V before immediately being transferred into a fresh tissue culture flask containing 
media.
2.7.6 Establishment of a stable expression mammalian cell line
• Following transfection, in order to obtain a stable cell line expressing the gene of 
interest, the cultured cells needed to be selected so as to yield only the population of 
cells containing the required plasmid, and hence expressing the desired molecule.
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• As mentioned before, the pEF plasmid contains a resistance gene against blasticidin, 
and this is used as a form of mammalian cell selection. Therefore, the cells were 
cultured in selection media containing 5pg/ml blasticidin S for around 1-2 weeks so 
that those cells that did not contain the plasmid were killed off, allowing only the cells 
containing the plasmid to survive.
• Following selection, the cells were transferred into maintenance media containing 
0.5pg/ml blasticidin, in which they were cultured in, indefinitely. In order to verify that 
the cells were actually expressing the gene of interest, the cells were analysed by 
carrying out RT-PCR and western blotting.
• Once the cells had been verified to stably express the desired molecule, they were 
subjected to various in vitro assays in order to test the effect of altering the expression 
of that molecule on the biological properties of the cells. These assays are outlined in 
section 2.9.
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Figure 2.6: Flow chart summarising cloning and production of a stable expression mammalian 
cell line.
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2.8 Generating human recombinant protein (rh-GDF-9)
2.8.1 TOPO TA cloning
The process of cloning carried out for recombinant protein production was identical to the one 
previously mentioned in section 2.7, except that the primers used for plasmid design had a 
deleted stop codon (ATC), in order to allow for production of a histidine-tagged version of the 
protein of interest.
Once the ideal parameters for carrying out PCR were determined, the resulting PCR product 
was cloned into a pEF6/V5-His-TOPO vector using the exact method as previously described. 
This was followed by E.coli transformation, plasmid amplification, and finally plasmid 
purification using the GenElute™ Plasmid Miniprep Kit (Sigma-Aldrich,Inc.). The purified 
transgene and empty plasmid were then transfected into 3T3 cells (murine fibroblastic cell line, 
obtained from ATCC), respectively. After a few weeks of selection with 5pg/ml blasticidin, 
stable GDF-9 transfectents were established and used to produce rh-GDF-9.
2.8.2 Collection of condensed media containing recombinant protein
Following verification of the 3T3 cell line with the plasmid coding for histidine-tagged GDF-9, 
the cells were grown to large numbers, seeded into a 5L roller bottle, and left to grow at 37°C, 
while rotating on a wheaton bench top roller (Cole Parmer, Illinois, USA). Once the cells had 
adhered to the roller bottle, and reached sufficient confluency, the cells were left to grow in 
20ml serum free DMEM F12 media for 6-8 hours. This media was then collected and spun 
down for 5 mins at 6,000rpm, in order to remove any cell debris. The cells were then left to 
grow over-night in 10% DMEM F12 media containing 0.5pg/ml blasticidin, before being 
returned to serum free media as before. This process was continued until sufficient media was 
collected for protein purification, which was filtered before use. The cells were trypsinised off
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the roller bottle and spun down for 5 mins at 6,000rpm, to form a cell pellet, which was then 
lysed in SDS-free lysis buffer.
2.8.3 Condensing of rh-GDF-9 containing media
Before the conditioned media could be passed through a chelating column, it needed to be 
condensed down to 50ml. This was carried out using the Vivaflow 50 system (Sartorius 
Vivascience AG, Hannover, Germany), which is a modular tangential system that allows for 
fast concentration performance. Polyethersulfone membranes with various pore sizes retain 
90% of the molecules of that size or larger in the solution, thereby providing a molecular weight 
cut off point (MWCO). Several of these filters of varying MWCOs can be used in order to 
condense the media, and concentrate a protein of a desired size. The system is run by the use of 
a peristaltic pump (Masterflex pump™, Sartorious AG, Germany), that pumps the media 
through the connected filters, with the flow through ending up in two separate flasks, one 
containing the protein of the desired size, and the other containing proteins larger or smaller 
than the desired size.
• The components of the system were set up as shown in Figure 2.7 and rinsed, firstly 
with ethanol, and then distilled water, for 30 minutes each before use.
• The solution to be purified was then placed in the sample reservoir and the liquid was 
pumped through the system at a recirculation rate of 200-400ml/min, with the pressure 
indicator reading no higher than 2.5.
• When the desired volume was reached, the recirculation rate was reduced to 20- 
40ml/min, and the concentrated solution re-circulated through the system in order to 
maximise recovery.
• Once completed, the system was rinsed thoroughly with ethanol and distilled water 
before re-use.
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Figure 2.7: Diagram showing set-up of vivaflow 50 system.
2.8.4 Purification of rh-GDF-9 using the H iTrap chelating HP column
The rh-GDF-9 that should be present in the media collected above, carries a 6 residue histidine- 
tag at one end of the protein. This histidine-tag binds with high affinity to metals such as 
nickel, and this characteristic can be manipulated in order to purify the protein of interest. This 
current study uses a HiTrap™ purification kit (Amersham Bioscience UK Ltd., 
Buckinghamshire, UK). This kit comes with a ready-to-use HiTrap™ Chelating HP 1ml 
column, which when charged with Ni2+ ions, will selectively bind proteins with histidine 
residues exposed on their surface, by the process of immobilised metal affinity chromatography. 
This process allows for a quick one-step highly concentrated purification of the protein of 
interest.
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• Firstly, the twist off end was removed from the column, and a 5ml syringe filled with 
distilled water. In order to substitute manual syringing, the syringe was attached to a 
syringe pump (World precision instruments, Sarasota, Florida, USA) which can 
dispense liquid at a set rate and volume. This syringe was then in turn attached to the 
column with the provided adaptor, and the water left to run through the column at a rate 
of l-3ml per minute.
• Once the water had run through, the 5ml syringe was disconnected and replaced with 
a lm l syringe filled with 0.5ml of NiS04, which was then passed through the column, 
in order to charge the sepharose beads within the column. This was followed by 
another wash with 5ml distilled water.
• Next, 10ml binding buffer was passed through the column in order to equilibrate it in 
preparation for the conditioned media, which was then applied to the column in 10ml 
aliquots at a flow rate of l-3ml per minute. The flow through was collected as it may 
still contain some unbound protein.
• Once all the media had been passed through the column, it was washed with 10ml 
binding buffer, whose flow through was also kept as it contains imidazole and hence 
may have eluted some of the protein.
• The final step is elution and this was carried out with 5ml elution buffer. In order to 
prevent dilution of the eluate, this was done by collecting it in lml fractions with 
varying concentrations of imidazole (in this case 0, 1,5,10 and 20mM), allowing for 
varying binding affinities of the protein.
• The purification of each of the eluates was then run on an SDS-PAGE in order to see 
which aliquot contains the highest concentration of the recombinant protein, which in 
most cases would be the second or third eluate. This also acted as a means of assessing 
recombinant protein purification.
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• After the protein had finished eluting, the column was regenerated by being washed 
with start buffer making it ready for a new run of purification of the same protein, 
without the need to reload with nickel.
2.8.5 Desalting and buffer exchange
Before the recombinant protein could be used in any further experiments, any remaining 
imadazole needed to be removed as it may have an effect on the cells, once treated. This can be 
done in one of two ways; buffer exchange using dialysis, or centrifugal concentrators which 
was the method carried out and explained in this study.
This study uses Vivaspin centrifugal concentrators (Sartorious AG, Goettingen, Germany) 
which use ultrafiltration vertical membranes to combine protein filtration and recovery, 
avoiding any lengthy dialysis steps. The ultrafiltration membrane allows proteins to be retained 
while letting salts pass through freely, independently of protein concentration or molecular 
weight. The concentration of the protein of interest therefore remains unchanged and can be 
diluted back to the original volume with water or a salt-free buffer, such as PBS. However, it is 
also possible to dilute the protein with a new buffer, thereby completely exchanging the 
buffering substance. The process is carried out as follows:
• Firstly, the protein eluate was diluted 1 in 10 before a centrifugal concentrator of the 
appropriate molecular weight and volume was selected, and filled up to the maximum 
level with the diluted protein.
• The concentrator then underwent centrifugation for the recommended amount of time at 
an appropriate spin speed for the vivaspin model. In the case of the vivaspin 6 
(maximum of 6ml), 4000xg for 30 minutes.
• The flow through was then discarded and the concentrator refilled with an appropriate 
sample to the maximum level. This process was continued until the desired 
concentration of salt was reached.
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• Once this was achieved, the concentrated, desalted sample was retrieved from the bottom 
of the concentrate pocket, with a pipette.
Select device Spinning Discard filtrate. Spin to concentrate
with correct canses salts to Rf-fiD concentrate target protein and
MW and fill passthrough back np to original recover de-salted and
with sample membrane9 volume using fresh concentrated final
solution buffer. protein.
Salt is now diluted.
Figure 2.8: Figure depicting vivaspin centrifugal concentrator system (adapted from Sartorious 
GA manual).
2.8.6 Quantification of recom binant protein
Once the concentration of imidazole was reduced to a negligible amount, the resulting protein 
was run on another SDS-PAGE alongside a serial dilution of BSA standard starting at a 
concentration of 50pg. The volume of the recombinant protein band was then compared to a 
similar sized band of a known concentration of BSA, in order to determine the approximate 
concentration of the recombinant protein. This was carried out using the UVIband software 
package (UVITEC, Cambridge, UK) which allows for protein band quantification.
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2.9 In vitro cell function assays
These assays can be used to quantify cell density as they adhere to multi-well plates, with or 
without Matrigel (a basement membrane substitute). After a set amount of time, the cells are 
stained with crystal violet (0.2% mixed with 2% ethanol, and dissolved in distilled H20), which 
stains DNA. The cells can then either be counted, or the amount of crystal violet that the cells 
have absorbed can be quantified, by solubilising the dye, and measuring the absorbance at 
540nm using a spectrophotometer.
2.9.1 In vitro adhesion assay
• Wells in a 96 well plate were coated with lOOul of serum free media with 5pg (stock 
concentration 0.5mg/ml) Matrigel (BD Matrigel™ Matrix, Magrigel™ Basement 
Membrane Matrix, Biosciences). The Matrigel was then left to dry for 1 hour at 55°C.
• To rehydrate the Matrigel, lOOul of sterile water was added to each well and left for an 
hour at room temperature.
• The media was aspirated and 30,000 to 40,000 cells diluted in 200pl DMEM, were 
seeded into each well and left to adhere at 37°C, with 5% C 0 2 for 40 minutes.
• The media was discarded, and the wells washed with BSS to remove any unbound cells. 
The cells that had remained adhered after washing were fixed in 4% formalin for 10-20 
minutes, and then stained with 0.5% crystal violet for 10 minutes. The dye was washed 
off and the plates left to dry, before the stained cells were photographed and counted 
using a microscope. Due to the fluid dynamics within the small sized wells of a 96 well 
plate, matrigel sets unevenly, causing cell aggregation around the edges of the well. 
Therefore, in order to avoid these areas, only the cells which had adhered to the centre 
of the well were counted, making sure that the same area of the well was assessed for 
each sample.
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2.9.2 In vitro invasion assay
• 8 pm pore Transwell inserts (FALCON®, pore size 8.0pm, 24 well format, Greiner Bio 
one, Germany) were placed into wells of a 24 well plate (NUNC™, Greiner Bio one, 
Germany), using forceps in order to prevent contamination.
• Each insert was subsequently coated with lOOpl serum free media with 50pg Matrigel, 
and left to dry for several hours at 55°C.
• The Matrigel was then rehydrated with 200pl sterile water for an hour at room 
temperature.
• The water was discarded, and 30,000 cells aliquoted in 200pl DMEM were seeded into 
each insert. 600pl media was then added to each well, surrounding the inserts, and the 
cells were incubated for a maximum of 96 hours, with 5% C 0 2 at 37°C. This set up is 
shown in figure 2.9.
• After 96 hours incubation, the invasive cells migrate through the Matrigel, and the 
porous membrane to the other side of the insert. The Matrigel layer and the non- 
invasive cells were then removed from inside the insert using some tissue paper. If this 
step is not carried out, the Matrigel would also be stained with crystal violet, making it 
difficult to distinguish between the background and invading cells.
• The invasive cells were then fixed for 10-20 minutes with 4% formalin, and then 
stained with 0.5% crystal violet for 10 minutes. The crystal violet was washed off, the 
plates left to dry, and the stained cells photographed and counted under a microscope.
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Figure 2.9: Schematic diagram showing in vitro invasion assay.
2.9.3 In vitro cell growth assay
• The protocol by Jiang et al. was followed (Jiang et al., 2005). 200pl of media 
containing 3,000 cells was seeded into four 96 well plates and if required, were treated 
with a protein of interest in serum free media.
• These plates were then left to incubate at 37°C, with 5% CO2 , for a period of 24 hours, 
48 hours, 72 hours, and 120 hours, respectively.
• After incubation, the media was discarded, and the cells fixed with 4% formalin for 10- 
20 minutes, before being subsequently stained with 0.5% crystal violet for 10 minutes. 
The dye was washed off with water, and the plates left to dry.
• The dye was then solubilised using lOOpl acetic acid, and cell growth was assessed by 
measuring the absorbance at 540nm using a spectrophotometer (BIO-TEK, Elx800, 
UK). The growth rate was calculated as a percentage, using the absorbance taken at 24 
hours as a baseline.
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2.9.4 In vitro motility assay using Cytodex-2 beads
The motile capacity of the tumour cells was assessed using a cytodex-2 bead motility assay, 
following the procedure previously described by Jiang and Rosen (Jiang et al., 1995; Rosen et 
al., 1990). This procedure entails adhering cells to the surface of cytodex-2 beads and 
transferring them into a culture plate, where the cells will move from the beads onto the surface 
of the culture plate, and can then be counted and assessed.
• lxlO6 cells were incubated with lOOpl of cytodex-2 beads (GE Healthcare, Cardiff, 
UK) for 3.5 hours in 10ml of media in order to allow the cells to adhere to the surface 
of the beads.
• The beads were subsequently washed twice using 5ml of media so as to remove any 
non-adherent or dead cells.
• Following the second wash, the cells were resuspended in lm l of media, 200pl of 
which was then transferred in triplicates, into a 24 well plate containing a further 800pl 
of media, and left to incubate over night.
• The following day, the cells that had migrated from the cytodex-2 beads and adhered to 
the surface of the culture plate, were washed with BSS several times, in order to 
remove any remaining cytodex-2 beads.
• The cells were then fixed using 4% formaldehyde for 5 minutes, stained with 0.5% 
crystal violet for 10 minutes, and counted using a microscope at 40x magnification. At 
least 4 random fields were counted per well, and the procedure was carried out three 
independent times in order to obtain statistical relevance.
2.9.5 Electrical cellular impedance sensing (ECIS)
Electrical Cellular Impedance Sensing (ECIS) is a novel method used as an alternative to the 
conventional function assays mentioned above. It works using an array of 8 wells, each 
containing a gold electrode. These measure the current and voltage across this electrode,
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calculating the impedance and resistance. From the impedance changes, effects on cell 
attachment and motility can be examined.
• Using 8W10E arrays (ECIS™ cultureware, Applied Biophysics, Inc., NY, USA), each 
well was stabilised at room temperature for around 20 minutes using 200|xl electrode 
stabilising solution (ECIS™, Applied Biophysics, Inc., NY, USA).
• The solution was then aspirated and replaced with 200pl DMEM F I2 media containing 
Hepes buffer (Lonza, Verviers, Belgium) and left until further needed.
• The media was aspirated, and 400,000 cells diluted in 400(xl DMEM were seeded into 
each well, and treated with a protein of interest if required.
• The array was then placed into an ECIS™ C 0 2 incubator (RS biotech 9600, R galaxy 
R+) which is connected to the ECIS™ Model 9600 Controller (Applied Biophysics, 
Inc., NY, USA). The software was set up so that resistance to the current flow was 
measured at 400Hz. Data was normalised using resistance from the first time point.
2.9.6 Analysing apoptosis with flow cytometry
Phosphatidylserine (PS), a phospho-lipid component of the cell membrane is normally located 
on the cytoplasmic side of cell membranes in normal live cells. However, when the cells 
become apoptotic, PS translocates from the inner to the outer leaflet of the cell membrane, 
resulting in it being exposed to the external cellular surroundings. In leukocytes, this functions 
as a trigger for macrophages to phagocytose the apoptotic cells.
In order to detect apoptosing cells, this current study uses the Vybrant® Apoptosis Assay Kit 
(Invitrogen, Inc., Paisley, UK) to carry out an apoptosis assay. This kit works due to the fact 
that it contains recombinant Flourescein conjugated annexin V (FITC annexin V) and 
Propidium Iodide (PI) solution. The calcium dependent phospholipid-binding protein annexin 
V, binds to PS with a high affinity, and hence when labelled with a fluorophore or biotin, can be 
used to detect apoptotic cells by binding to the PS on the outer leaflet of the cell membrane.
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PI on the other hand, is a red-flourescent intercalating dye, capable of permeating only through 
cell membranes of non-viable cells, and binding to their nucleic acids. Therefore, any cells that 
have lost their membrane integrity will be stained red by the PI, whereas the apoptotic cells, 
which are impermeable to PI, will be stained green by the FITC annexin V. Any live cells 
present in the solution will show little or no fluorescence. This partial staining allows for easy 
identification with the Partec CyFlow® SL flow cytometer and the accompanying FloMax 
software package (Partec GmbH, Munster, Germany). The protocol was carried out as follows:
• Both the adherent cells and those floating in the culture medium, were harvested and 
washed in PBS. The cell solution was then centrifuged, before lxlO6 cells were 
resuspended in IX annexin-binding buffer, sufficient for lOOpl per assay.
• 5p of FITC annexin V and lp l of PI working solution (lOOpg/ml) was subsequently 
added to each lOOpl cell fraction, and the cells were left to incubate for 15 minutes.
• Following incubation, 400pl of IX annexin binding buffer was added and mixed 
gently, before being placed on ice.
• Immediately after, the stained cells were analysed using the flow cytometer and 
FlowMax software package, by measuring any fluorescence emission at 530nm (FL1) 
and >575nm (FL3).
2.9.7 Analysing the cell cycle using PI
• Following harvestation of both adherent and floating cells (including detached mitotic, 
apoptotic and dead cells), the cells were centrifuged before being washed twice with 
PBS, and counted.
• lxlO6 cells were subsequently resuspended in 500pl of PBS, and fixed with 4.5ml of 
70% ethanol for 2 hours at 4°C.
• Following fixation, the cells were washed with PBS, and subsequently stained with lml 
of PI in a solution including TritonxlOO, used to additionally permeabilise the cells, and
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RNase A used to digest any double stranded RNA which can also bind to PI, so as to 
increase the specificity of DNA binding.
• After an incubation period of 30 minutes at room temperature, any fluorescence 
emitted by PI was detected with the flow cytometer and cell cycle analysis carried out 
using the FlowMax software.
2.9.8 Hoechst DNA stain for detection of apoptosis
The cells were firstly incubated either with DMEM with 10% FCS, or serum free, for a period 
of 48 hours before both the adherent cells and those floating in the culture medium, were 
harvested and washed in PBS. The cells were counted, and 20,000 cells were spun down before 
the cell pellet was resuspended in 20ng/ml Hoechst 33342 solution, and incubated in darkness 
for 15 minutes. The cells were centrifuged again, and resuspended with BSS before being 
mounted onto a cover slip, and visualised using a microscope under flourescent light. Hoechst 
stains DNA, and can help identify apoptotic cells due to their condensed chromatin. 
Apoptotic cells were counted and using the total number of cells, a percentage for the amount of 
apoptotic cells was calculated.
2.9.9 The Smad3 inhibitor
The Smad3 inhibitor (566405 Calbiochem, EMD Chemicals Inc., Gibbstown, USA) was first 
characterised by Jinnin et al. in 2006 (Jinnin et al., 2006). It is a cell-permeable pyrrolopyridine 
compound (7-Dimethoxy-2-((2E)-3-(l-methyl-2-phenyl-lH-pyrrolo[2,3-b]pyridin-3-yl-prop-2- 
enoyl))-l,2,3,4-tetrahydroisoquinoline) that selectively inhibits TGF-pl-dependent Smad3 
phosphorylation and Smad3-mediated cellular signalling, without having any effect on Smad2, 
p38 MAPK, ERK, or PI3K signalling.
The cells were treated with 3ng/ml Smad3 inhibitor, which was previously found to be the 
minimum working concentration (Jinnin et al., 2006). Treatment was carried out for 4 days in 
the case of a growth assay, 40 minutes for an adhesion assay, and 2 hours for RNA and protein 
extraction.
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Chapter 3
Altering the expression of GDF-9 in 
prostate cancer cells
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3.1 Introduction
Growth and Differentiation Factor 9 (GDF-9) is a member of the TGF-p superfamily and BMP 
subfamily, identified in 1993 by Mcpherron and Lee (McPherron and Lee, 1993). GDF-9 
expression was initially found to be exclusive to the ovary but has recently been detected in a 
variety of tissues including the breast, prostate, and oral squamous carcinomas (Hanavadi et a l, 
2007; Zhuang et a l, 2010). It is now known to be an oocyte derived growth factor vital in 
follicular development, so much so that mice lacking the GDF-9 gene exhibit a block at an 
early stage of follicular development, thereby making them infertile (Su et a l,  2008).
BMPs have been implicated in the pathogenesis of a number of cancers, including; colorectal, 
osteosarcomas, myelomas, breast cancers, and most specifically, prostate cancer and associated 
osteoblastic lesions (Ye et a l,  2007). The expression profile of BMPs and their signalling 
counterparts has been shown to be variable in prostate cancer cells. In addition, BMPs have an 
effect on a range of biological properties of prostate cancer cells such as growth, apoptosis, 
angiogenesis, and migration.
Although most BMPs have been shown to inhibit the growth of prostate cancer cells, several 
studies have shown that the effect that BMPs have on in vitro cell growth depends on their 
choice of receptors, the presence of androgen, and foetal bovine serum. BMP-2 for example, 
when signalling via BMPR-IA, has been shown to promote prostate cancer cell growth, but 
inhibit growth when signalling through BMPR-IB (Ide et a l,  1997).
Similarly to its family members, apart from its oocyte specific functions, GDF-9 has more 
recently been shown to play a role in various human cancers. The laboratory has previously 
shown that GDF-9 can inhibit breast cancer cell invasiveness, with high levels of GDF-9 
expression correlating with good prognosis (Hanavadi et a l, 2007). Another study 
demonstrated up-regulation of GDF-9 expression in an oral squamous carcinoma cell line, 
suggesting that unlike in breast cancer, GDF-9 may promote tumour progression in this cancer
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type (Zhuang et al., 2010). A clear role for GDF-9 in the progression of human cancer 
however, remains to be established, but it is plausible that like many other BMPs, GDF-9 may 
also be a factor in prostate cancer.
TGF-p has been shown to play a complicated role in regulating the autonomous, local, and 
systemic cellular responses that together control the development, progression, and prognostic 
outcome of human cancers. In prostate cancer, the cellular phenotypes of the tumour cells are 
induced and maintained by complex cross-talking networks between intracellular signalling 
pathways of the prostatic epithelial cells and their adjacent stroma. This intimate 
communication between prostate cancer cells and their microenvironment drives mutual stromal 
reactions to the prostate tumour epithelium, resulting in a vicious cycle that involves the 
microenvironment and cancer epithelium, which additionally promote the tumour epithelium to 
develop malignant properties, and may be responsible for carcinogenesis and bone metastasis 
(Sung and Chung, 2002).
In addition, once established, tumour cells undergo genetic modifications which allow them to 
secrete soluble factors that act in an autocrine fashion to promote the vicious cycle 
independently of the surrounding stroma. One of these factors is TGF-P, which is released by 
tumour epithelial cells, which along with VEGF secreted by both the epithelial and stromal cells 
can drive tumour progression (Stover et al., 2007). BMPs have also been shown to be capable 
of autocrine signalling due to their regulated processing and secretion, as well as interactions 
with components of their microenvironment. BMP-2, -6, and -7 for example, have been shown 
to be involved in the cycle of osteoblastic lesion development in prostate cancer bone 
metastases (Clark and Torti, 2003).
No previous studies have investigated a possible role for GDF-9 in this vicous cycle of prostate 
cancer progression. Therefore, based on the established implications of their BMP relatives in 
carcinogenesis, as well as the success of previous projects carried out in the laboratory based on
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BMPS in prostate cancer, this study aims to establish a role for GDF-9, by altering its 
expression levels in two prostate cancer cell lines. As GDF-9 has been shown to be processed 
and secreted in the ovary in a similar fashion to BMPs, and the laboratory has previously shown 
GDF-9 expression in both normal and malignant prostate epithelial cells (unpublished data), it 
was proposed that prostate epithelial cells could secrete GDF-9. Therefore, by altering the 
endogenous expression levels of GDF-9 in prostate cancer cell lines, it was hypothesised that 
GDF-9 secretion by prostate cancer cells would be modified accordingly, allowing the effect 
this would have on the aggressiveness of the prostate cancer cells to be analysed in the form of 
functional assays based on the associated biological properties of these cells.
In this study, GDF-9 expression plasmids and ribozyme transgenes were generated in order to 
over-express and/or silence GDF-9 expression in PC-3 cells, respectively. GDF-9 expression 
was further down-regulated in another prostate cancer cell line, DU-145 which expresses high 
levels of GDF-9. Following transfection with the plasmids, GDF-9 expression was verified 
using both mRNA and protein based methods. The remaining chapters in this study then aim to 
investigate the effect of altering GDF-9 expression on the biological properties of prostate
cancer cells in order to elucidate the function of GDF-9 in this cancer.
3.2 M aterials and methods
3.2.1 Materials
Polyclonal goat anti-GDF-9 antibody (SC-12244) was obtained from Santa Cruz Biotechnology 
(Santa Cruz, California, USA). All the primers used were synthesised and provided by
Invitrogen (Paisley, UK). Primer sequences are located in Tables 2.2 to 2.4.
3.2.2 Cell lines
PC-3 and DU-145 were the cell lines used to investigate the effects of targeting GDF-9, and 
were cultured in DMEM-F12 medium as described in section 2.3.
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3.2.3 Amplification of GDF-9 coding sequence
Amplification of the GDF-9 coding sequence was carried out using high fidelity and accurate 
PCR (LA-PCR) with the DuraScript™ RT-PCR kit (Sigma-Aldrich, Inc., Poole, Dorset, 
England, UK). Primers capable of amplifying the complete coding sequence of GDF-9 with or 
without stop codon were designed according to the GDF-9 mRNA sequence (Table 2.3) and 
cDNA from normal prostate tissue (previously shown to highly express GDF-9) was used as a 
template. LA-PCR was then carried out at the following conditions; 93°C for 2 minutes, 
followed by 42 cycles of 93°C for 20 seconds, 58°C for 20 seconds, and 68°C for 1.5 minutes, 
ending with a final extension period of 10 minutes at 68°C. After running and visualising the 
PCR product on a 0.8% agarose gel, the corresponding bands were extracted as described in 
section 2.4.6.
3.2.4 Generation of GDF-9 ribozyme transgenes
Hammerhead ribozymes targeting GDF-9 were designed using Zuker’s RNA mFold programme 
(Zuker, 2003), based on the secondary structure of GDF-9 mRNA. Primers containing 
restriction sites were then generated (Table 2.4), and used for ribozyme synthesis by carrying 
out touch-down PCR at the following conditions; 94°C for 5 minutes, followed by 8 cycles at 
each annealing temperature (total of 48 cycles): 94°C for 10 seconds, 70°C, 65°C, 60°C, 57°C, 
54°C, and 50°C for 15 seconds, 72°C for 20 seconds, and a final extension of 7 minutes at 72°C. 
Subsequently, the transgenes were run on a 2% agarose gel in order to verify their presence as 
well as size, before being cloned into the pEF6/His plasmid.
3.2.5 TOPO TA cloning of GDF-9 fragments or transgenes into a pEF6/His TOPO 
plasmid vector
Following verification, either the GDF-9 transgene or coding sequence was cloned into a 
pEF6/V5-His-TOPO plasmid (Invitrogen Inc., Paisley, UK), followed by transformation of 
constructed plasmid into E.Coli. Colonies of transformed E.Coli. were analysed by carrying out
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RT-PCR, using the T7F primer coupled either with RbBMR and RbTPF primers in the case of 
the transgenes, or BGHR and a GDF-9 specific primer in the case of the coding sequence. The 
correct colonies were then amplified, and the plasmids extracted using the Sigma GenElute 
Plasmid MiniPrep Kit (Sigma-Aldrich, USA).
3.2.6 Prostate cancer cell transfection and generation of stable transfectants
Following plasmid verification using DNA electrophoresis, the plasmids were transfected into 
PC-3 and/or DU-145 cells by electroporation at 310V, and were put through selection with 
5pg/ml blasticidin for up to two weeks. Empty plasmid vectors were also used to transfect the 
same cells in order to act as controls. Following selection, the surviving cells were grown to 
large numbers and verified for either GDF-9 knock-down or force expression, using RT-PCR, 
western blotting, and ICC. Full details of the cloning process are given in section 2.7.
3.2.7 RNA isolation, cDNA synthesis, and RT-PCR
RNA was isolated from the cells using the ABgene Total RNA Isolation Reagent (TRIR) kit 
(ABgene, Surrey, UK), and converted into cDNA by reverse transcription using the iScript™ 
cDNA Synthesis Kit (Bio-Rad Laboratories, California, USA), as described in section 2.4. This 
was then used as a template for RT-PCR, which was carried out at the following conditions; 
94°C for 5 minutes, followed by 30 to 42 cycles of 94°C for 30 seconds, 56°C for 30 seconds, 
and 72°C for 1 minute, and a final extension of 7 minutes at 72°C. The products were run on an 
agarose gel and visualised using ethidium bromide.
3.2.8 Protein extraction, SDS-PAGE, and Western blot analysis
Protein was extracted following cell lysis, and was then quantified using the DC Protein Assay 
kit (BIO-RAD, USA). Following SDS-PAGE, the proteins were transferred onto nitrocellulose 
membranes which were blocked, and probed with the specific primary (anti-GDF-9 1:200) and 
the corresponding peroxidise-conjugated secondary antibodies (1:1000). All of the antibodies
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used in this study are listed in Table 2.5. The protein bands were eventually visualised using 
the Supersignal™ West Dura system (Pierce Biotechnology, USA).
3.2.9 Immunoprecipitation
Following cell lysis, the lysates were treated with GDF-9 specific antibody. The resulting 
immune complexes were then collected using protein A and G beads attached to sepharose, 
which bind these complexes. The complexes then underwent precipitation by centrifugation, 
and were separated using SDS-PAGE and visualised by immuno-probing.
3.2.10 Immunocytochemistry
Immunocytochemical staining of GDF-9 in prostate cancer cells was carried out using specific 
primary antibody for the protein, followed by secondary antibody. For detailed ICC procedure 
refer to Section 2.5.9.
3.3 Results
3.3.1 Amplifying the coding sequence of GDF-9
In order to assess the effects of over-expressing human GDF-9 in prostate cancer cells, a 
mammalian expression construct had to be generated. For this purpose, the entire coding 
sequence of GDF-9 containing a 3’ ATC stop codon was amplified using specially designed 
primers and the Extensor Long Range Durascript PCR master mix™, which contains a proof 
reading enzyme that ensures amplification of large products with minimum mistakes. Gradient 
PCR was then carried out in order to determine the optimal annealing temperature for each pair 
of primers. Finally, using prostate tissue cDNA as a template and an optimal annealing 
temperature of 58°C, a final PCR was carried out and the products were run on an agarose gel 
(Figure 3.1 A). Products of the right size (1365bp) corresponding to the GDF-9 coding 
sequence were excised from the gel and extracted using the GelElute™ Gel Extraction Kit 
(Sigma-Aldrich, Inc., Poole, Dorset, England, UK). In order to verify that the band was
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successfully extracted and that it indeed contained the GDF-9 sequence, it was run on an 
agarose gel alongside an RT-PCR product containing the excised band as a template with GDF- 
9 specific primers (Figure 3.IB).
3.3.2 TOPO TA cloning of GDF-9 into a pEF6 plasmid
Once the GDF-9 coding sequence was prepared, it was cloned into a pEF/His plasmid vector. 
After the newly constructed plasmid was transformed into TOPIO E.Coli, the colonies were 
analysed to ensure not only that they contained the GDF-9 plasmid, but that the plasmids had 
incorporated the fragment in the correct orientation.
This was done by carrying out several PCR reactions. The first pairs the plasmid specific T7F 
primer, and a reverse primer specific for GDF-9. As T7F is located about 90bp upstream of the 
GDF-9 insert, considering the insert is ligated in the correct orientation, the resulting product 
should be approximately 520bp in length. The following reaction pairs T7F with a forward 
primer specific for GDF-9 and hence if a product of around 300bp is detected for a colony 
following amplification, the insert is ligated in the wrong orientation and hence cannot be used. 
If a colony has products for both of the aforementioned reactions, then the colony contains a 
mixture of correctly and incorrectly aligned inserts. Finally, in order to determine whether the 
entire sequence of GDF-9 has been inserted without degradation, a concluding reaction 
containing both T7F and BGHR was carried out which generates a product size of around 
1700bp. Figure 3.2A shows the analysis of various colonies using these three reactions.
The positive colonies (colony 1) were then further amplified, before being pelleted and 
undergoing plasmid extraction. Figure 3.2B shows the three aforementioned PCR reactions 
carried out on the extracted plasmid in order to ensure the correct plasmid was extracted. 
Furthermore, so as to determine plasmid integrity, the purified plasmid was run on an agarose 
gel as well as used as a template in an RT-PCR using GDF-9 specific primers to ensure correct 
insert orientation (Figure 3.3). This plasmid was then sent off to Geneservice Ltd. (Source
149
Bioscience, Cambridge, UK) for sequencing, in order to ultimately verify that the insert within 
the plasmid was genuinely GDF-9. The results showed a match between the sequence cloned 
into plasmid vector and the human GDF-9 precursor sequence (Figure 3.4).
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Figure 3.1: A. LA-PCR products of GDF-9 coding sequence visualised on an agarose gel. L 
is the DNA ladder and the annealing temperatures for LA-PCR in lane 1, 2, 3 and 4 are; 58°C 
60°C, 62°C and 64°C, respectively. The correct size o f extracted product is 1365bp as 
indicated by the arrow. B. Left lane: In order to confirm that the gel extract from the 
previous gel contained the GDF-9 coding sequence, it was run on an agarose gel, showing up 
as a band of the correct size atl365bp. Right lane: This gel extract was further used as a 
template for a PCR using GDF-9 specific primers GDF-9 F9+R9, in order to ensure that the 
gel extract contained the correct GDF-9 seqence (product size 432bp).
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Figure 3.2: A. Agarose gel showing PCR of E.coli colony analysis. L is the ladder, P stands for
correct orientation o f GDF-9, where the product sized at 532bp is a result of a PCR carried out on
each colony using a specific GDF-9 forward primer (F9) coupled with a plasmid specific reverse
primer (BGHR). N stands for incorrect orientation where the product sized at around 300bp is a
result o f PCR reaction using a plasmid specific forward primer (T7F) and a GDF-9 specific
forward primer as a reverse primer (F9). T stands for the PCR reaction using T7F and BGHR
plasmid specific primers, which should amplify the entire MCS of the plasmid (1600bp). Colony
1 (C -l) is the only positive colony, the rest are mixed as they have the gene both in the correct (P)
and incorrect (N) orientation. B. Following plasmid purification from colony C -l, the same PCR
reactions were carried out as in 3.2A, but using the purified plasmid as the template, rather than
the bacterial colony. As there is a 532bp band for the P reaction, no band for the N reaction, and a
1600bp band for the T reaction, this suggests that the purified plasmid contains the GDF-9
transgene in the correct orientation within the MCS of the plasmid.
152
A
GDF-9 SCD 
plasmid
B
( p
432bp 466bp
Figure 3.3: A. Following plasmid extraction and verification from colony C-l, the purified 
GDF-9 SCD S-3 plasmid was run and visualised on an agarose gel in order to demonstrate 
plasmid integrity. B. The plasmid was further used as a template for two PCR reactions using 
two different sets of GDF-9 specific primers; GDF-9 F9+R9 (432bp product), and GDF-9 
F8+R8 (466bp product), in order to further confirm that the plasmid contained the correct 
sequence.
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INNNNNNNNNNNCTTGG 
NANAAATTCCTCCTTTGGTTTTGC 
AGCTCAGATTGCTGCCAGTGCTGA 
GAGCTGGCCTCCTTCCCGC 
GCTTTGCACTACATGAAGA 
CAACACTGTTCGGCTCTTC 
TGGAACTGCTATTTAACCT
ACCGAGCTCGGATCCNCTAGTCCAGTGTGGTGGAATTGCCCTTATGGCACGTNNN 
GCTTTGCCTGGCTGTGTTTTCCTATTAGCCTTGGTTCTCAGGCTTCTGGGGGAGA 
GTT GGAAT CT GGGGCTAT GCCTTGGTCCTT GCT GCAGCATAT AGAT GAGAGAGACA 
LGTTCTATCTGTTGGGCGAGGTGGGTCACCTAGGCTGCAGCCAGACTCCAGA 
kGACATATGCTACCAAGGAAGGGATTCCTAAATCCAATAGAAGTCACCTCTA 
kCCCGGCACAAGCAGACT CCTGGAGACCAGGTAACAGGAAT CCTT CCATCAG 
'ACTACCGTTGAACACTTACTCAA6TCAGTCTTGCTGTACAATATCAACAAC 
TCAGTTTCTTTTICCTCTGCTGNCAAATGTGTGTGCAATCTAATGATAAAGGAGCCAAAGTCTTCTAGCAGGACTCTCGG 
CAGAGCTCCATACNCATTTACCTTTAACTCACAGTTTGAATTTGGAAAGAAACACAAATGGATTCAGATTGATGTGACCA 
GCCTCCTTCAACCTTTAGTGGCCTCCAACAAGAGAAGTATTCACATGNCTATAAATTrrACTTGCATGAAAGACCANCTG 
GAGCATCCTTTCANCACANAATGGTTGTTAACArGACTCTGGTGTCCCCCTCACNGATCTTATATTTGAATGACACANTH 
GCTCANGCTTANTCACANCTGGNATTCCCTTCATTATAAANGATGNNNTNCCATGGTCNTGACCTCNANANANTtJNNKCT 
GNCNTATCCNGNTGNANAAA1IGCTGCTGANGANTGGAHATCTCTCNNTCTCTCGTCTCNCNCANANNNKANGNAACTGTT 
ANTTCGNATCTAATNHNNCCNNTNNGGNNCTACNNTTCtnTCNNTCTCrTANNTGAATKNNTTTCKACNATTTNNTNCTTC 
CCNCNNANTGATGTGAGTCTCCNNNNNNTTTNNNNNCTANCTTTtWNNNCNTNNNTHGNNNNNNTCNNNNNTtmNNNNN 
TCNCTNCANNGTTTNNNCCCNTNNNNNNNNNNNNNNNNNNHGHNNNliNNNNNNNtlHNNNNNNNNNNNHNNNIJNNTNNTNT 
NCNNNNTTNKNNNNNtRrrNNNNtlNTNTNNNlJJJNNNANNNNIOJN
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Figure 3.4: Figure showing sequencing of GDF-9 plasmid. Right side of the Figure shows the results obtained from the sequencing of the GDF-9
plasmid, while the left shows this sequence being compared to the BLAST database which shows a positive match for GDF-9. N stands for
undetermined base.
3.3.3 Generation of a GDF-9 ribozyme transgene
In order to silence the expression of GDF-9 in prostate cancer cells, ribozyme transgenes of 
GDF-9 were generated and cloned into a pEF6 /His plasmid to allow for mammalian cell 
transfection. This would allow for comparison between the effects of knocking down, and 
over-expressing GDF-9 in prostate cancer cells. Figure 3.5 depicts the series of PCR actions 
carried out to construct a plasmid containing a GDF-9 ribozyme transgene. Based on the 
secondary structure of GDF-9, an appropriate targeting site for the ribozyme was first 
ascertained.
This was followed by ribozyme synthesis through touchdown PCR, and cloning into a 
pEF6 /His plasmid. In order to verify correct orientation of the ribozyme transgene, primers 
RbTPF and RbBMR were paired with T7F, respectively. These primers were specific to the 
ribozyme transgenes.
If the transgene is correctly orientated, a PCR product of around 140bp (T7F promoter starts 
90bp before insert and ribozyme sequence is around 50bp) should arise for the T7F+RbBMR 
reaction. However, if it is incorrectly orientated, a product of a similar size should appear for 
the T7F+RbTPF reaction. Following colony analysis, all those found to be positive for the 
transgenes underwent further amplification and finally, plasmid extraction. Colonies 2-9 and 3- 
10 were shown to have the highest levels of correctly orientated ribozyme transgene. The 
plasmids were then verified using DNA electrophoresis, in order to demonstrate successful 
isolation of correctly sized plasmids (Figure 3.5D).
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Figure 3.5: Ribozyme transgene synthesis. A. The ribozymes were generated using touchdown 
PCR and run on an agarose gel. B. The transgenes were cloned into a pEF6/V5-His-TOPO 
plasmid for mammalian cell transfection. C. After transformation into E.coli cells, the 
colonies were analysed using PCR in order to verify correct orientation of the transgene. L 
stands for ladder, P for correct orientation (140bp). which refers to a PCR reaction that uses a 
plasmid specific forward primer (T7F) and a ribozyme specific reverse primer (RbBMR), and 
N stands for incorrect orientation (14Qbp), where a plasmid specific forward primer (T7F) is 
coupled with a ribozyme forward primer as a reverse primer (RbTPF), in a PCR reaction. All 
o f the colonies except for c-2.6 had the transgene in the correct orientation. D. The plasmids 
were extracted from the correct colonies and verified with DNA electrophoresis.
3.3.4 Expression of GDF-9 in prostate cell lines
The expression of GDF-9 was examined in seven prostate cell lines, including PC-3, DU-145, 
LNCaP, CAHPV-10, PZHPV7, PNT1A, and PNT2C2. The first four are prostate cancer cells. 
PC-3 is derived from bone metastatic lesions originating from prostate cancer, DU-145 from 
brain metastasis, LNCaP from lymphatic metastasis, and CAHPV-10 from a localised prostate 
carcinoma. The remaining three are immortalised prostatic epithelial cells. Figure 3.6A shows 
mRNA levels of GDF-9 in these seven prostate cell lines using RT-PCR. Relatively lower 
levels of GDF-9 were revealed in PC-3 cells compared to the other prostate cancer cells or 
epithelial cells. This was consistent with the protein expression of GDF-9 in these cells (Figure 
3.6B). This not only demonstrated expression of GDF-9 in prostate cancer and epithelial cells, 
but also provided useful information for choosing cell lines and establishing in vitro cell models 
for subsequent experimental study.
3.3.5 Verification of GDF-9 forced expression in PC-3 cells
Following plasmid extraction, transfection into mammalian cell lines was possible. GDF-9 
expression was found to be detectable in PC-3 cells, albeit at rather low levels (Figure 3.6). It 
was therefore chosen as the preferred cell line for GDF-9 over-expression. PC-3 cells were 
electroporated and hence transfected with the GDF-9 over-expression plasmid constructs (PC- 
G^DF-y exP.^ as wejj as empty piasmi(j control, respectively (PC-3pEF). The cells were transfected 
on two different occasions within a few hours of each other (PC-3G D F ' 9 exp 1 and 2), to ensure 
successful plasmid expression.
Following selection with blasticidin, RNA and protein were extracted from these cells as well 
as from P C ^ ^  cells. Successful forced expression of GDF-9 was confirmed using PCR (Figure 
3.7A), western blotting, and immunoprecipitation (Figure 3.7B). Both of these methods 
demonstrated considerably higher levels of GDF-9 expression in the PC-3G D F ' 9 exp cells, 
compared to both the WT and pEF controls. 0-actin and GAPDH were used as loading controls
157
by acting to exhibit standardized levels of cDNA within the samples. ICC was also carried out 
to further confirm GDF-9 forced expression at the protein level. Stronger staining of GDF-9 
was seen in the PC-3G D F ' 9 exp cells compared to both the WT and pEF controls (p=<0.01) (Figure 
3.7D).
3.3.6 Verification of GDF-9 suppression with ribozyme transgenes in PC-3 and DU-145 
cells
In order to obtain reliable results, ribozyme transgenes were used to silence the expression of 
GDF-9 in both PC-3 and DU-145 cells. As mentioned previously, PC-3 expresses GDF-9 at 
relatively low levels, but still sufficiently enough for its expression to be suppressed. DU-145 
meanwhile was demonstrated to express relatively high levels of GDF-9, making it a suitable 
candidate for GDF-9 knock-down (Figure 3.6). Therefore, similarly to GDF-9 over-expression, 
both PC-3 and DU-145 cells were transfected with three separate GDF-9 targeting ribozymes, 
alongside an empty plasmid control, respectively.
Using PCR, expression of GDF-9 mRNA was reduced in the case of ribozyme 2 (PC-3GDF'9nb2), 
and completely eliminated with ribozyme 3 (PC-3GDF'9nb3), compared to the controls ( P C ^ ^  
and PC-3pEF) (Figure 3.7A). Ribozyme 1 was unsuccessful in repressing GDF-9 expression and 
hence is not shown. In DU-145 meanwhile, both ribozymes managed to completely eliminate 
GDF-9 expression (DU-145GDF'9nb2, DU-145GDF9nb3) (Figure 3.7B). A similar reduction in 
GDF-9 protein levels was demonstrated in both PC-3 and DU-145 cells, when carrying out 
western blot analysis and ICC (Figure 3.8 and 3.9).
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Figure 3.6: Screen of different prostate cell lines for GDF-9 expression using A. specific GDF-9 
F9+R9 primers in a PCR to show mRNA levels and B. an anti-GDF-9 antibody in a western blot to 
show mature GDF-9 mature dimer protein levels (40kDa). Unfortunately, no protein for PZHPV-7 
was available in the laboratory’s stocks.
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Figure 3.7: Verification of GDF-9 over-expression in PC-3 cells. A. PCR demonstrating 
considerably higher expression levels of GDF-9 in the three transfected cell lines compared to the 
controls. B. Left; Western blot (WB) analysis showing increased protein GDF-9 protein levels in 
PC-3GDF'9exp cells compared to the controls. Right; Immunoprecipitation (IP) of GDF-9 (The IP 
results may be plausible due to the bands o f the IgG heavychain, below the band for GDF-9), with 
PC-3GDF'9exp cells demonstrating significantly higher GDF-9 protein levels compared to the 
controls. The same anti-GDF-9 antibody used in the WB was used in IP. C. 
Immunocytochemical (ICC) analysis (using DAB chromagen) uses the same anti-GDF-9 antibody 
as for WB and IP, and the nuclei were counterstained with Haemotoxylin, before analysis was 
carried out. The results are similar to WB analysis, with the PC-3GDF'9exp cells demonstrating 
significantly stronger staining for GDF-9 protein compared to the controls. The graph shows the 
quantification of the density of GDF-9 cytoplasmic staining in each sample.
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Figure 3.8: Verification of GDF-knockdown in PC-3 and DU-145 cells. A. PCR demonstrating 
considerably reduced expression levels of GDF-9 in the two transfected cell lines compared to the 
controls. B. PCR showing reduced GDF-9 levels in the two knock-down DU-145 cell lines 
compared to the controls. C. Western blot analysis demonstrating significantly reduced levels of 
mature GDF-9 protein in p£_3 G D F -9 n b 3 ceus compared to the controls. D. Western blot analysis 
demonstrating significantly reduced levels of GDF-9 protein in DU-145GDF‘9nb3 cells compared to the 
controls.
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Figure 3.9: Verification of GDF-knockdown protein levels using ICC with an anti-GDF-9 antibody. 
A. The p c- 3 G D F ' 9 rib 2 and PC-3G D F ' 9rib 3 cells demonstrated considerably less staining for GDF-9 
compared to the empty plasmid control. B. DU-145GDF‘9rib2 and DU-145GDF'9rib3 demonstrated 
considerably weaker staining for GDF-9 compared to the control.
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3.4 Discussion
GDF-9 is renowned for its role as an oocyte derived growth factor vital in follicular 
development and although its expression was initially thought to be exclusive to the ovaries, 
subsequent studies have shown a wider tissue distribution including breast cancer cells, and oral 
squamous carcinomas (Hanavadi et al., 2007; Zhuang et a l, 2010). No previous study 
however, has investigated the expression levels of GDF-9 in the normal or malignant prostate, 
even though significant roles have been demonstrated for many of its BMP relatives in prostate 
cancer. The apparent importance of BMPs in prostate cancer lies in their osteoinductive 
properties and regulatory roles during bone development and remodelling. Bone metastasis is a 
common complication of many cancers, including that of the prostate with 90% of patients with 
advanced prostate cancer developing skeletal metastasis (Bubendorf et al., 2000).
BMPs have been demonstrated to stimulate osteoblast differentiation, and if enriched in bone 
matrix can facilitate bone metastasis development. Prostate cancer cells that acquire genetic 
phenotypes that allow them to up-regulate expression of bone specific cytokines including 
BMPs, can then adapt to the bone microenvironment with more ease and establish bone 
metastases. Expression of BMP-6 , BMP-7, and GDF-15, for example is highly elevated in bone 
metastases originating from prostate cancer suggesting they aid in the metastatic process 
(Thomas et al., 1998; Dai et al., 2004). Although the osteogenic properties of GDF-9 have not 
been investigated, it is possible that like its relatives it may have some function in prostate 
cancer progression and metastasis.
In this current study, we firstly demonstrated the presence of GDF-9 expression in seven 
prostatic cell lines. The cell lines used here have extensively been used as models for in vitro 
studies on prostate cancer. PC-3, DU-145, and LNCaP are aggressive prostatic carcinomas 
derived from metastatic sites of the bone, brain, and lymph nodes, respectively. CA-HPV-10 
meanwhile represents a less aggressive prostatic adenocarcinoma cell line immortalised with
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HPV-18. PZ-HPV-7, PNT-1A, and PNT2-C2 meanwhile, are immortalised prostatic epithelial 
cell lines. According to the mRNA levels of GDF-9, its expression appears to be higher in the 
less aggressive prostatic carcinoma cell lines, along with those of the prostatic epithelium. DU- 
145 is the only exception, as it expresses relatively high levels of GDF-9. PC-3, the main cell 
line used in this study meanwhile, expresses relatively low levels of GDF-9. The protein levels 
show a similar trend. Unfortunately, due to inappropriate freezing down of cell stocks, it was 
not possible to culture the prostatic epithelial cell lines in order to determine whether altering 
the expression of GDF-9 would have an effect on these cells.
This screening process also aided in the determination of which cell lines to use for the 
remainder of the study. As previously mentioned, like other BMPs, GDF-9 is secreted from 
cells in order for it to bind to its receptors on the cell surface. Therefore, in order to investigate 
the effect of GDF-9 on the biological functions of prostate cancer cells, we altered GDF-9 
expression in PC-3 and DU-145 cells. Initially, a mammalian expression vector was 
constructed containing the entire GDF-9 coding region. This coding region contained a stop 
codon in order to allow for production and secretion of native GDF-9 protein, without any 
expression of plasmid by-products downstream from the insert.
As PC-3 cells express low levels of GDF-9, it was chosen as the cell line to transfect in order to 
determine the effects of GDF-9 over-expression in this cell line. GDF-9 over-expression was 
verified at both the mRNA and protein level using PCR and western blot analysis, amongst 
others. It was hypothesised that over-expression of GDF-9 would increase its secretion by PC-3 
cells and hence allow it to compete for receptor binding with other BMP ligands already present 
in the cells, thereby promoting GDF-9 downstream signalling and its associated effects. As 
endogenous expression levels of GDF-9 in DU-145 cells were already high, over-expression 
was not attempted as it was assumed that this would have no added effect.
164
In addition, we generated hammerhead ribozyme transgenes in order to silence GDF-9 
expression in both PC-3 and DU-145 cells which both express the protein, DU-145 at a high 
level. The ribozymes proved to be successful as they efficiently down-regulated expression of 
GDF-9 both at the mRNA and protein level. This would allow for determination of whether the 
effect over-expressing GDF-9 in PC-3 is genuinely due to its alteration, or whether other factors 
are having an influence. These tools of genetic manipulation aid in the generation of useful in 
vitro models allowing for the investigation of the impact a single molecule has in a cell line. 
Subsequent functional assays carried out in the rest of this study, are based on both the GDF-9 
knock-out and over-expressing cells.
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Chapter 4
Effects of targeting GDF-9 on the 
proliferative, adhesive, invasive, and 
motile capacity of prostate cancer
cells
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4.1 Introduction:
A cancer cell relies on varying vital biological processes with which to establish itself in its 
environment, and go on to further survive and progress. The most important of these include 
changes in cell growth, adhesive and invasive capacity, motility, and migration. Cancer cells 
can influence these processes in several ways, most significantly by altering the expression of 
molecules that play key roles in controlling these cellular traits. In the case of growth for 
example, a cancer cell might have reduced expression of cell cycle inhibitors, and up-regulated 
levels of growth promoters so as to allow it to continue through the cell cycle undeterred and at 
a greater capacity, despite having several mutations which would under normal circumstances 
induce growth arrest.
As previously mentioned, BMPs play an important role in the progression of prostate cancer 
and have been shown to influence all of these aforementioned cellular processes. Indeed, the 
majority of the BMPs appear to have reduced expression in prostate cancer cells, implying a 
tumour inhibitory role for these proteins. Expression of BMP-9 and -10 for example, is 
decreased or absent in prostate cancer tissues, especially in those of a higher grade. In addition, 
when BMP-9 and BMP-10 were force-expressed in these prostate cancer cells respectively, 
there was an inhibition of cell growth, adhesion, invasion, and migration, suggesting that both 
BMPs function as tumour suppressors in prostate cancer (Ye et al., 2008). Based on this and 
other studies, this laboratory has recently shown that expression of GDF-9, a family member of 
BMP-10, has reduced expression in breast cancer cells and when force-expressed in these cells, 
reduces their invasive capacity, suggesting that GDF-9 has an inhibitory effect on breast cancer 
progression (Hanavadi et al., 2007).
Chapter 3 describes how the expression of GDF-9 in prostate cancer cells was altered in two 
different ways; force-expression using a mammalian expression plasmid vector, and knock­
down using ribozyme transgenes. This following chapter now goes on to investigate the effect, 
if any, that these changes in GDF-9 expression have on these cells. The stable transfected cells,
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both the GDF-9 over-expressing and GDF-9 knock-down cells, were used in various in vitro 
cell function assays including; growth, adhesion, invasion, and motility. These assays are a 
well established and simple method of investigating the biological properties of cancer cells in 
vitro, providing a basic hypothesis with which to continue onwards in in vivo models. 
Following on from its supposed role in breast cancer, these function assays were carried out in 
order to determine what role, if any GDF-9 plays on these cellular processes, and in the 
progression of prostate cancer.
4.2 M aterials and methods
4.2.1 Cell lines
PC-3 and DU-145 prostate cancer cell lines were used in this current chapter, including the 
wild-type control, empty plasmid control and transfected cell lines. Cells were continuously 
maintained in DMEM media with 10% FBS and antibiotics. The stable transfected cells were 
maintained in the same media but with 0.5pg/ml blasticidin.
4.2.2 In  vitro growth assay
The cells were seeded into four 96 well plates, and incubated for 24 hours, 48 hours, 72 hours 
and 120 hours respectively, as described in section 2.9.3. Following incubation, the cells were 
stained with crystal violet before the absorbance was measured in order to determine cell 
number.
4.2.3 In vitro adhesion assay
The cells were seeded into a 96 well plate coated with matrigel as described in section 2.9.1. 
The cells were left to adhere for a period of 40 minutes, before being stained with crystal violet, 
and the cells counted.
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4.2.4 In vitro  invasion assay
The cells were seeded into transwell inserts with 8 pm pores coated with 50 pg matrigel, in a 24 
well plate and were incubated for a period of 4 days. Following incubation, the cells which had 
migrated through the matrigel to the other side of the insert were stained with crystal violet and 
counted.
4.2.5 In vitro motility assay
The protocol followed is described by Rosen and Jiang (Rosen et al., 1990; Jiang 
et al., 1995b). The cells were incubated with cytodex-2 beads and left over night, by which 
time the cells will have adhered to the surface of the beads. The beads carrying the cells were 
then transferred into a 24 well plate, where the cells move from the beads onto the surface of 
the culture plate. These cells were then stained with crystal violet, and counted.
4.2.6 ECIS
The cells were seeded into 8W10E electrical arrays and placed in an incubator with connection 
to ECIS™ machine (model 1600R) allowing the cells to adhere to the gold electrodes within the 
arrays, causing a change in resistance. The software was set up so that resistance to the current 
flow was measured at 400Hz.
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4.3 Results
4.3.1 Effect of altering GDF-9 expression on prostate cancer cell growth
The force-expressing and knock-down transfected prostate cancer cells were used in an in vitro 
growth assay alongside their wild-type and empty plasmid controls. Cell growth was 
significantly promoted in the GDF-9 over-expressing cells compared to the two controls (Figure
4.1 A). The cell growth at 120 hours was significantly greater in the pc_3 GDF-9exP 
(1922.9%±79.1%) compared to both P C ^  (958.6%±90.6%) and PC-3pEF (1297.5%±82.0%), 
p<0.001 versus both controls. Meanwhile, the opposite effect was seen in the GDF-9 knock­
down cells. A significant reduction in growth was seen at 120 hours in both pc_3 G D F -9 n b 2  
(631.1%±11.7%) and pc-3GDF9rib3 (435.7%±95.1%) cells compared to the P C ^  
(989.4%±35.4%) and PC-3pEF(929.3%±24.9%) controls, p<0.001 for both PC-3G D F 9 r ib 2  and PC- 
3 GDF-9nb3 ) compared to both controls (Figure 4. IB).
The same effect was demonstrated with the DU-145 GDF-9 knock-down cells where both DU- 
1 4 5 GDF-9rib2 (4 8 1 .5 %±2 6.7%) and DU-145GDF'9rib3 (380.4%±55.0%) had significantly reduced 
proliferative capacity compared to D U -M S^ (703.8%±40.1%) and DU-145pEF 
(641.5%±55.0%), p=0.001 for DU-145GDF'9rib2 versus DU-145pEF, and p<0.001 versus DU- 
145^ , whereas p<0.001 for DU-145GDF'9nb3 compared to both controls (Figure 4.2). In both the 
cell lines, GDF-9 ribozyme three seemed to have the most pronounced effect on growth, 
suggesting that it may have lower levels of GDF-9 expression as is demonstrated in chapter 3.
4.3.2 Effect of GDF-9 on prostate cancer cell adhesion
The cells were further analysed for their adhesive capacity in an in vitro matrigel adhesion 
assay. The GDF-9 over-expressing PC-3 cells had a significantly enhanced adhesive capacity 
compared to its controls. Significantly more pc_3 GDF-9exP ceps (70.5±12.1) had adhered to the 
matrigel compared to both the PC-3WT(46.0±10.9) and PC-3pEF(32.7±6.71) controls, p=0.004 in
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comparison with P C ^ 9^ , and p<0.001 compared to PC-3pEF (Figure 4.3A). In the case of the 
GDF-9 knock-down cells, the opposite effect was seen in that lower numbers of both PC-3GDF' 
9 n b 2  (28.7±3.01) and pc_3 G D F -9 r,b 3  (31.1±7.10) cells had adhered to the matrigel compared to PC- 
3WT(47.4±16.1)and PC-3pEF (60.3±9.85), p=0.001 for PC-3G D F ' 9 rib 3 versus PCO*7, and p<0.001 
versus PC-3pEF (Figure 4.3B). Meanwhile, p<0.001 for p£_3 G D F -9 n b 2  versus both controls.
This effect was less pronounced in DU-145 cells, where DU-145GDF'9nb2 (70.4±9.74) and DU- 
145GDF'9nb3 (64.3±8.70) cells demonstrated marginally reduced numbers of adherent cells 
compared to both 0 ^1 4 5 ^(8 8 .4 4 1 1 1 .0 ) and DU-145pEF (80.2±8.30), p=0.013 for DU-145gdf' 
9 rib 2 versus DU-145WT, and p=0.09 versus DU-145pEF, whereas p=0.009 for DU-145GDF'9rib3 
versus 0 0 -1 4 5 ^ , and p=0.0018 versus DU-145pEF (Figure 4.4).
4.3.3 Effect of GDF-9 on prostate cancer cell invasiveness
The cells were further analysed for their invasive capacity with the use of an in vitro invasion 
assay. The GDF-9 over-expressing PC-3 cells demonstrated a significant promotion in their 
invasiveness. A greater number of PC-3G D F "9 exp cells (58.3±9.69) had invaded through the 
matrigel to the other side of the insert compared to PC-3WT(21.2±4.36) and PC-3pEF(32.7±4.37), 
p<0.001 for pc_3 GDF-9exP compared to both controls (Figure 4.5A). However, knocking down 
GDF-9 in PC-3 cells; pC-3GDF‘9rib2 (30.0±4.36) and pc-3GDF'9rib3 (27.3±5.51), no change was 
seen on the invasive capacity of the cells compared to the PC-3WT (26.3±4.16) and PC-3pEF 
(28.713.51) controls, p=0.70 and p=0.74 for PC-3G D F ' 9 rib 2 and PC-3GDF 9 rib3 compared to PC-3pEF 
and p=0.35 and p=0.81 compared to PGG997, respectively (Figure 4.5B).
In the case of DU-145GDF’9nb2 (49.016.08) however, a marginal reduction in the invasive 
capacity of the cells was demonstrated compared to the DU-MS ' 9 7  (56.3l6.66) and DU145pEF 
(59.7ll.53) controls, p=0.23 compared to DU-145w and p=0.04 compared to DU-145pEF. DU- 
1 4 5 GDF 9 n b 3  (60.3l8.50) cells however showed no difference in invasiveness, p=0.56 compared 
to DU-145997 and p=0.90 compared to DU-145pEF (Figure 4.6).
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4.3.4 Effect of GDF-9 on prostate cancer cell motility
The cells were additionally evaluated for their motility using a cytodex-2 bead motility assay. 
Over-expression of GDF-9 demonstrated enhanced cell motility compared to the controls. A 
significantly larger proportion of p c -3 GDF'9exp cells (99.2±16.1) had migrated from the beads 
onto the surface of the culture plate in comparison with the P C -3 ^  (64.1±10.0) and PC-3pEF 
(76.6±2.22) controls, p=0.049 versus P C -S ^  and p=0.073 versus PC-3pEF (Figure 4.7A). 
Although the effect is only statistically significant when comparing to the WT control, the trend 
remains evident.
In contrast, the two GDF-9 knock-down cells demonstrated reduced cell motility compared to 
these two controls, with pc-3GDF 9 rib 2  (57.2±2.22) and pc-3GDF'9rib3 (29.7±2.00) both having 
smaller numbers of migrating cells compared to P C -S ^  and PC-3pEF, pcO.OOl for PC-3pEF 
versus both knock-down cells, and p=0.320 for P C O ^  versus pc_3 G D F -9 n b 2 5 and 0.028 versus 
PC-3G D F ' 9 rib 3 (Figure 4.7B). In the case of DU-145 cells however, although a slight reduction in 
the number of motile cells was observed in both the DU-145GDF'9rib2(30.7±5.98)and DU-145gdf’ 
9 rib 3 (29.3±5.73) cells compared to the DU-145WT (33.7±6.10) and DU-145pEF (35.8±4.88) 
controls, the data was not found to be significant, p=0.41 and p=0.13 for DU-145GDF'9nb2 and 
DU-145GDF9nb3 compared to D U -M S ^ and p=0.13 and p=0.06 compared to DU-145pEF, 
respectively (Figure 4.8).
These results suggest that GDF-9 over-expression has a more significant effect on the 
invasiveness of prostate cancer cells. This is plausible, as when a gene is over-expressed in a 
cell, it competes with other ligands for receptor binding, allowing it to dominate the resulting 
phenotype of that cell, whereas if a gene is knocked-down the cell compensates for this loss by 
allowing other genes to take over, making its loss unnoticeable, unless the gene is a main player 
in a certain trait.
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4.3.5 The effect of GDF-9 on the electrical resistance of prostate cancer cells
Electrical cellular impedance sending (ECIS) is an electrical method used to monitor cellular 
processes such as cell attachment, spreading, migration, and micromotion. The process entails 
a monolayer of cells being grown on a small gold film electrode deposited on the bottom of an 
electrical array. With the culture medium acting as an electrolyte, a current is applied to the 
system. As the cells begin to spread on the electrode, this current is impeded resulting in 
changes in both the impedance and resistance, which are measurable. The greater the resistance 
to the current flow, the more cells there are on the electrode, allowing for cell attachment to be 
quantifiably analysed.
PC-3GDF'9exp cells (1.19±0.035) demonstrated an increased resistance compared to both PC-3WT 
(1.03±0.033) and PC-3pEF(1.01±0.019), p=0.036 compared to PC -S^, and p=0.0051 compared 
to PC-3pEF. This increase in electrical resistance correlates with increased cellular attachment. 
This result follows on from that demonstrated in the conventional adhesion assay as described 
in section 4.3.2, suggesting that GDF-9 has a promotional effect on the adhesive capacity of 
PC-3 cells. In the case of DU-145 cells, there was no obvious reduction in the electrical 
resistance of DU-145GDF‘9rib2 (1.23±0.12) and DU-145GDF'9rib3 (1.35±0.067) compared to DU- 
1 4 5 ^  (1.37±0.23) and DU-145pEF (1.50±0.35), p=0.510 for DU-145GDF'9rib2 cells compared to 
DU-145pEF and p=0.606 compared to DU-145WT. For DU-145GDF‘9rib3p=0.943 versus DU-1 4 5 ^  
and p=0.53 versus DU-145pEF.
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Figure 4.1: Effect of GDF-9 on in vitro cell growth of PC-3 cells using the cell growth assay.
A. The cell growth of PC-3G D F ' 9 exp cells was significantly increased in comparison to the two 
controls, ** p<0.001 for GDF-9exp. cells compared to both controls. B. The cell growth of 
PC-3G D F ' 9 rib 2 and PC-3G D F ' 9 n b 3  was significantly reduced compared to both controls, **p=0.001 
for pc-S 0 0 ^ 3 versus PC -3^, and **p<0.001 versus PC-3pEF. Meanwhile, **p<0.001 for PC- 
3 GDF-9rib2 versus controls. Data shown is representative of at least 3 independent repeats. 
Error bars represent standard deviation. The 0 hour time point refers to an over night 
incubation before the cells were stained, and the absorbance used as a baseline in order to 
normalise the data.
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Figure 4.2: Effect of knocking down GDF-9 on in vitro cell growth of DU-145 cells using the 
cell growth assay. The cell growth of DU-145GDFJ9rib2 and DU-HS0 0 ^ 3 was significantly 
reduced compared to both controls, **p=0.001 for DU-145GDF'9rib2 versus DU-145pEF, and 
**p<0.001 versus DU-145^, whereas **p<0.001 for DU-145GDF'9rib3 compared to both the 
controls. Data shown is representative of at least 3 independent repeats. Error bars represent 
standard deviation. The 0 hour time point refers to an over night incubation before the cells 
were stained, and the absorbance used as a baseline in order to normalise the data. Due to the 
high endogenous levels of DU-145, no over-expression studies were attempted in this cell line, 
and hence only functional assays on DU-145 knock-down cells were carried out.
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Figure 4.3: Effect of GDF-9 on in vitro cell adhesion of PC-3 cells after 40 minute
incubation. A. The adhesive capacity of PC-3G D F ' 9  exp cells was significantly increased in 
comparison to the two controls, **p<0.001 for GDF-9exp. cells compared to both controls.
B. Adhesive capacity of PC-3G D F ' 9rib 2 and PC-3G D F "9rib3 was significantly reduced compared to 
both controls, **p=0.001 for pc-3GDF 9rib3 versus PC-3 ^ , and p<0.001 versus PC-3pEF. 
Meanwhile, **p<0.001 for PC-3G D F ' 9n b 2 versus both controls. Data shown is representative of 
at least 3 independent repeats. Error bars represent standard deviation.
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Figure 4.4: Effect of knocking down GDF-9 on in vitro cell adhesion of DU-145 cells using 
the matrigel adhesion assay, after 40 minute incubation. The adhesive capacity of DU-145gdf‘ 
’"h2 and DU-145GDF‘9rib3 was marginally reduced compared to both controls, *p=0.013 for DU- 
1 4 5 GDF'9rib2 versus D U-M S^, and p=0.09 versus DU-145pEF, whereas *p=0.009 for DU-145gdf' 
9rib3 versus DU- 145WT, and *p=0.0018 versus DU-145pEF. Data shown is representative of at 
least 3 independent repeats. Error bars represent standard deviation.
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Figure 4.5: Effect of GDF-9 on in vitro cell invasiveness of PC-3 cells using the in vitro 
transwell invasion assay, following 4 days incubation. A. The invasive capacity of PC-3GDF' 
9exp cells was significantly increased in comparison to the two controls, **p<0.001 for GDF- 
9exp cells compared to both controls. B. There was no significant difference in the invasive 
capacity of PC-3G D F ~9 n b 2  and PC-3G D F ' 9rib3 cells compared to the controls, p=0.70 and p=0.74 
for pc- 3 G D F ' 9 rib 2 and PC-3G D F ' 9 n b 3  cells compared to PC-3pEF, meanwhile p=0.35 and p=0.81 
compared to PC-3WT, respectively. Data shown is representative of at least 3 independent
repeats. Error bars represent standard deviation.
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Figure 4.6: Effect of GDF-9 on in vitro cell invasiveness of DU-145 cells using the transwell 
invasion assay, following 4 days incubation. There was a slight decrease in the invasive 
capacity of DU-145GDF'9rib2 compared to the controls, *p=0.04 compared to DU-145pEF and 
p=0.23 compared to DU- 145WT. In the case of DU-145GDF‘9rib3 however, no difference was 
seen in the invasive capacity compared to the controls, p=0.56 compared to DU-145WT and 
p=0.90 compared DU-145pEF. Data shown is representative of at least 3 independent repeats. 
Error bars represent standard deviation.
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Figure 4.7: Effect of GDF-9 on in vitro cell motility of PC-3 cells using the cytodex-2 bead 
motility assay. A. The motility of pc- 3 G D F ' 9 exp cells was significantly increased in 
comparison to the two controls, *p=0.049 versus PC-3WI and *p=0.073 versus PC-3pEF. B. 
Both GDF-9 knock-down cells showed reduced motility compared to the controls, 
**p<0.001 for PC-3pEF versus both knock-down cells, and p=0.320 for PC-3^ 1 versus PC- 
3 GDF-9nb2  ^ an(j *p=o.028 versus PC-3GDF'9rib3. Data shown is representative of at least 3 
independent repeats. Error bars represent standard deviation.
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Figure 4.8: Effect of GDF-9 on the cell motility of DU-145 cells using the cytodex-2 
bead motility assay. The motility of DU-145GDF'9rib2 and DU-145GDF*9rib3 cells was slightly 
decreased in comparison to the two controls, p=0.510 for DU-145GDF'9nb2 compared to 
DU-145pEF, and p=0.606 compared to DU-145^. For DU -145GDFJ9rib3, p=0.943 versus 
DU- 145WT and p=0.53 versus DU-145pEF. Data shown is representative of at least 3 
independent repeats. Error bars represent standard deviation.
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Figure 4.9: A. Effect of GDF-9 on electrical resistance of PC-3 cells using ECIS analysis, at 
a 2 hour time point. The electrical resistance of pc-3GDF'9 exp cells was significantly 
increased in comparison to the two controls, *p=0.036 for GDF-9exp. cells compared to PC- 
3 ^ ,  and p=0.0051 compared to PC-3pEF. Graph shown is representative of at least 3 
independent repeats. Table shows the means and standard error of means of the normalised 
resistance values obtained from these independent repeats.
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Figure 4.10: A. Effect of GDF-9 on electrical resistance of DU-145 using ECIS analysis, 
at 2 hour time point. The electrical resistance of DU-HS00^9"52 and DU-145GDF'9rib3 cells 
was marginally decreased in comparison to the two controls, p=0.510 for DU-145GDF‘9rib2 
cells compared to DU-145pEF, and p=0.606 compared to DU-145^. For DU-145GDF‘9nb3 
p=0.943 versus DU-145WT and p=0.53 versus DU-145pEF. Graph shown is representative 
of at least 3 independent repeats. Table shows the means and standard error of means of 
the normalised resistance values obtained from these independent repeats
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4.4 Discussion
GDF-9 is a well established follicular growth factor that has been shown to be vital during early 
follicular development. More specifically, GDF-9 is expressed throughout follicular 
development, and in the mammalian oocyte induces granulosa cell proliferation, pre-antral 
follicle growth, and cumulus cell expansion, partly by the inhibition of FSH-induced cAMP 
production and steroidogenesis. In addition, when human follicles are treated with GDF-9, it 
results in a greater percentage of viable cells in organ culture, suggesting it also plays a role in 
follicular survival (Vitt et al., 2000).
The role of GDF-9 in cancer however, remains more elusive. The laboratory has previously 
shown that GDF-9 has an inhibitory effect on the invasiveness of breast cancer cells (Hanavadi 
et al., 2007). A similar tumour suppressing role was observed in a human lung adenocarcinoma 
cell line with silenced mutant P53, where GDF-9 was upregulated (Ma et a l,  2006). In
contrast, another study demonstrated that GDF-9 expression is up-regulated in an oral 
squamous carcinoma cell line, suggesting that it may act as a pro-tumourogenic factor in oral 
cancers (Zhuang et al., 2010).
Much research has been carried out on BMPs and their function in cancer, which has made it 
clear that they play important roles during cancer progression and metastasis. In addition, due 
to their key role as regulators in the bone, it’s not a far stretch to suggest that they may be vital 
in bone metastasis, especially that of prostate cancer. This current study now shows that by 
altering the expression of endogenous GDF-9 in prostate cancer cells, that it is capable of 
promoting cell growth, adhesion, and motility, suggesting a pro-tumourogenic role for GDF-9 
in prostate cancer.
When GDF-9 was over-expressed in PC-3 cells, they demonstrated an increase in cell growth 
adhesion, motility, and invasion in vitro, compared to the two controls. This effect was inhibited 
when GDF-9 was knocked-down in these cells using ribozyme transgenes, which showed a
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reduction in all of the previously mentioned cellular properties. Although to a lesser extent, 
DU-145 cells transfected with GDF-9 ribozymes exhibited with a reduction in their proliferative 
and adhesive capacity, but no change in their motile and invasive capacity. The disparity seen 
between the DU-145 and PC-3 cell lines in response to GDF-9 may be due to variability in their 
expression profiles. For example, DU-145 has lower expression levels of BMPR-II, the type-II 
receptor for GDF-9, and lower levels of BMP antagonists Noggin and Follistatin, which may 
hinder GDF-9 signalling. Furthermore, unlike PC-3 cells that grow in a scattered fashion as 
independent cells, DU-145 cells grow in tight epithelial colonies, which may explain why GDF- 
9 was incapable of promoting their motility and invasion (Wells et al, 2005).
The promotion of cell growth in PC-3 and DU-145 cells by GDF-9 is in line with its role during 
folliculogenesis where it greatly promotes the proliferation and survival of granulosa cells (Vitt 
et al., 2000). In addition, GDF-9 was shown to up-regulate levels of cyclooxygenase-2 (COX- 
2), an enzyme that’s been implicated in carcinogenesis due to its association with VEGF (Elvin 
et al., 1999). This, along with its expression being shown to be up-regulated in an oral cancer 
cell line, GDF-9 may also act as a survival factor in oral squamous cell carcinomas (Zhuang et 
al., 2010).
In addition, the increase in the motile and invasive capacity of pc_3 GDF'9exP ce]is has also been 
demonstrated in keloids, a type of scar caused by excessive fibrous tissue, that unlike 
hypertrophic scars extends beyond the margins of the scar. GDF-9 expression was significantly 
higher in fibroblasts of the peripheral invasive area of the scar, compared to the central area. 
Furthermore, its expression was also higher in keloid rather than hypertrophic scars and normal 
skin, suggesting that GDF-9 aids in the invasive phenotype of this condition (Gao et al., 2010).
In the case of other BMPs in prostate cancer, their roles seem to greatly vary, and depend on a 
large range of different factors. For example, it has previously been shown that BMP-9 and -10 
can inhibit the growth, adhesion, invasion, and migration of prostate cancer cells (Ye et al.,
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2008; Ye et al., 2009). In contrast, BMP-2 and -7 have been demonstrated to promote the 
migration and invasion of osteoblastic prostate cancer cells LAPC-4 and LAPC-9, while both 
BMP-2 and -6 had a similar effect on the invasive capacity of C4-2B and LNCaP prostate 
cancer cell lines (Dai et al., 2005; Feeley et al., 2005).
However, it is often difficult to confirm the effects that BMPs have on cells as the same BMP 
can have contrasting effects in different cell types and environments due to factors including the 
supplement of FBS, presence or abscence of androgen, receptor type, and source of BMPs and 
their antagonists. BMP-2 for example, signals via BMPR-IA to promote the growth of LNCaP 
cells but can also signal via BMPR-IB to inhibit growth of these cells (Ide et al., 1997). 
Meanwhile, BMP-7 has been shown to induce epithelial-mesenchymal transition and thereby 
invasiveness of PC-3 cells, despite a different study claiming that BMP-7 had no effect on the 
migration and invasion of these cells (Yang et al., 2005; Feeley et al., 2006).
This study suggests that GDF-9 is an important regulator of the biological properties of prostate 
cancer cells, one which has a positive effect on the progression of prostate cancer. In order to 
further determine the role of GDF-9 in these processes, the following chapters analyse the effect 
of exogenous GDF-9 on these cells, and also investigate and highlight mechanisms to explain 
how GDF-9 goes about exerting its effects.
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Chapter 5
Generating recombinant human
GDF-9
187
5.1 Introduction:
In the previous chapter, the effects of altering the expression of GDF-9 on the biological 
properties of prostate cancer cells was investigated, and showed a pronounced effect on cell 
growth and adhesive capacity. These methods however, only act as a means of investigating 
the effects of endogenous GDF-9 in these cells, and in addition may inadvertently affect other 
genes within the cell. One other alternative therefore, is to treat the cells with exogenous 
protein, allowing it to bind to their cell surface receptors and induce downstream signalling. As 
this protein is made in the laboratory, its structure and quality are known, and as it is not 
incorporated into the genome of the cell, it theoretically should not have an effect on other 
genes. Therefore, in order to determine whether treating the cells with exogenous GDF-9 
protein would provide similar results to those seen when altering endogenous levels of GDF-9, 
a strategy for production of recombinant human GDF-9 (rh-GDF-9) protein was considered.
In recent years, the use of recombinant proteins in the laboratory has increased greatly, due to 
the simplicity and convenience of their use. Initially, the GDF-9 coding sequence was cloned 
into a pEF/V5-His-TOPO plasmid vector, similarly to GDF-9 forced-expression, except that in 
this case, the primers used to generate the coding sequence did not contain a stop codon. As the 
pEF/V5-His-TOPO plasmid vector has a six histidine tag downstream of the cloning site, this 
allowed for the recombinant protein to be expressed with a histidine tag on one end of it, which 
would eventually allow for easier and more effective protein purification. The plasmid was 
then transfected into 3T3 cells, a popular cell line for recombinant protein production, and 
grown to large numbers in order to allow for protein purification.
As recombinant GDF-9 was not commercially available and the downstream signalling pathway 
of the protein unclear, recombinant GDF-9 was produced in order to further elucidate its 
functions and signalling in prostate cancer cells. This chapter therefore focuses on the 
procedure of recombinant protein production, and its use in cell function assays and time course
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treatments, necessary for finally determining a possible role for GDF-9 in prostate cancer 
progression.
5.2 Materials and methods
5.2.1 Materials
The same antibodies as were used in chapter 3 were used to carry out studies in this current 
chapter. 3T3 cells were regularly maintained in DMEM-F12 medium supplemented with 10% 
foetal bovine serum, antibiotics, and 0.5pg/ml blasticidin for those in maintenance.
5.2.2 Amplifying GDF-9 coding sequence
Using primers which amplify the human GDF-9 coding sequence without a stop codon (Table 
2.3), a high-fidelity PCR was carried out following the same procedure as described in section 
3.2.3, before the corresponding band was excised from the gel following DNA electrophoresis, 
and purified.
5.2.3 Cloning of GDF-9 coding sequence into pEF/His TOPO plasmid vector
The GDF-9 coding sequence was cloned into the pEF/His TOPO plasmid vector in the same 
way as was described in sections 3.2.5 and 2.7, using the same primers for verification. The 
resulting plasmids were then purified as previously described.
5.2.4 Transfection
3T3 cells were then transfected with the GDF-9 and empty plasmid respectively, using 
electroporation at 290V. The electroporated cells were then put under blasticidin selection as 
described in section 2.7.
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5.2.5 Verification of GDF-9 over-expression in 3T3 cells using RT-PCR and western 
blotting
Both RNA and protein were extracted from the stable transfectant cells and were used in either 
western blot analysis or RT-PCR in order to confirm GDF-9 over-expression at both the mRNA 
and protein level. These methods were carried out as previously described in sections 2.4 and 
2.5.
5.2.6 Purifying recombinant human GDF-9 (rh-GDF-9)
Following verification, the transfected 3T3 cells were grown to large quantities and both 
conditioned media and cell lysate were used for recombinant protein purification using affinity 
chromatography as described in section 2.8.
5.2.7 Desaltification of purified rh-GDF-9
Following purification, the imidazole used during protein elution was removed using Vivaspin 
centrifugal concentrators as described in section 2.8.4.
5.2.8 Rh-GDF-9 quantification
The purified recombinant protein was run alongside a serial dilution of BSA standard on a 10% 
SDS-PAGE gel and stained using Coomasie blue. The bands were then photographed and the 
concentration of the recombinant protein quantified as described in section 2.8.5.
5.2.9 In vitro  cell growth assay
The cells were seeded into a single 96 well plate as described in section 2.9.3. Triplicates of 
each cell line were incubated with 10% FBS containing DMEM media either with or without 
20ng/ml of rh-GDF-9. Due to the high value and small volume of the rh-GDF-9 available, 
instead of analysing growth at days 1, 3, and 5, which would require multiple treatments with 
rh-GDF-9, growth was instead examined at day 4 alone. The cells were therefore fixed
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following 4 days incubation, and stained with crystal violet before the absorbance was 
measured in order to determine the effect of rh-GDF-9 on cell growth.
5.2.10 In vitro adhesion assay
The cells were seeded into a 96 well plate coated with matrigel as described in section 2.9.1. 
Triplicates of each cell line were incubated either with or without 20ng/ml of rh-GDF-9, for a 
period of 40 minutes, before being stained with crystal violet, and the cells counted.
5.2.11 In vitro  invasion assay
The cells were seeded into a 24 well plate containing transwell inserts with 8pm pores coated 
with 50 pg matrigel, and were incubated with or without 20ng/ml rh-GDF-9 in serum free 
media for a period of 4 days. Following incubation, the cells which had migrated through the 
matrigel to the other side of the insert were stained with crystal violet and counted.
5.2.12 In vitro  motility assay
The cells were incubated with cytodex-2 beads and left over night with or without 20ng/ml rh- 
GDF-9 in serum free media, by which time the cells will have adhered to the surface of the 
beads. The beads carrying the cells were then transferred into a 24 well plate, where the cells 
move from the beads onto the surface of the culture plate. These cells were then stained with 
crystal violet, and counted.
5.3 Results
5.3.1 Amplification of GDF-9 NSCD coding sequence
In contrast to the construction of a GDF-9 expression plasmid as was done in chapter 3, in order 
to generate rh-GDF-9, the primers used to amplify the GDF-9 coding sequence were designed 
to lack a stop codon (GDF-9 NSCD). Once cloned into the pEF/V5-His-TOPO plasmid, the
191
deleted stop codon enables the recombinant protein to be expressed with a histidine tag, which 
allows for more effective protein purification during affinity chromatography. The resulting 
products of the LA-PCR and the subsequently purified coding sequence are shown in Figure 
5.1.
5.3.2 Cloning GDF-9 NSCD into pEF/V5-His-TOPO plasmid vector
Following purification and verification of the GDF-9 coding sequence, it was cloned into a 
pEF/V5-His-TOPO plasmid vector and transformed into E.coli. The resulting colonies were 
then analysed for GDF-9 using PCR with T7F and BGHR primers, as described in section 3.3.2. 
Figure 5.2 shows colony analysis for GDF-9 using these primers. The colonies found to be 
positive for GDF-9 expression were then selected and used for plasmid extraction. The 
resulting purified plasmids were run on a gel, and then used as a template for an RT-PCR using 
GDF-9 specific primers (Figure 5.3A and B).
5.3.3 Verification of GDF-9 over-expression in 3T3 cells
The constructed GDF-9 plasmid vectors were then transfected into 3T3 cells alongside the 
empty plasmid control. Following several weeks of selection with blasticidin, the expression 
levels of GDF-9 both at the mRNA and protein level were assessed in the transfected cells. 
Figure 5.4A is a PCR demonstrating increased mRNA levels of GDF-9 in 3T3GDF-9exP cells 
compared to the S T S ^  and 3T3pEF controls. Figure 5.4B meanwhile, is a western blot 
demonstrating increased levels of the histidine protein (corresponding to recombinant GDF-9 
protein with the histidine tag) and GDF-9, in both 3T3GDF‘9N4exp and 3T3GDF'9N8 exp' compared to 
the empty plasmid control. These successfully confirmed GDF-9 over-expressing 3T3 cells 
were then used for further experiments.
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Figure 5.1: A. An LA-PCR was carried out in order to amplify the GDF-9 NSCD coding 
sequence, the products of which were run on an agarose gel. L is the DNA ladder, and the 
annealing temperatures used during the LA-PCR in lanes 1, 2, 3, and 4 are; 58°C, 60°C, 62°C, and 
64°C, respectively. The correct size of the GDF-9 NSCD product is 1362bp as indicated by the 
arrow. B. This 1362bp band was then excised from the gel above, and run in lane 1 of the 
agarose gel below it. Lane 2 shows a PCR carried out using this gel extract as a template with 
GDF-9 specific primers GDF-9 F9+R9 (432bp product), in order to ensure that excised band 
contained the GDF-9 sequence. 193
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Figure 5.4: Verification of GDF-9 over-expression in 3T3 transfected cells. A. RT-PCR 
showing elevated mRNA levels of GDF-9 in both 3T3GDF9N4exp and 3 X3 GDp-9N8exP cells, 
compared to both the 3T3wt and 3T3pEF controls. B. Western blot demonstrating increased 
levels of histidine and GDF-9 in both of the GDF-9 over-expressing 3T3 cells compared to 
empty plasmid control.
Figure 5.2: Agarose gel showing PCR of E.coli colony analysis. L is the ladder, P 
stands for correct orientation of GDF-9 (F9+BGHR-532bp), N for incorrect orientation 
(F9+T7F-300bp), and T for T7F+BGHR (1600bp). Colony 2 (C-2) is mixed and has the 
insert both in the incorrect, and correct orientation, whereas colonies C-4, C-6, and C-8 
have the correctly orientated insert, and were selected for plasmid extraction.
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Figure 5.3: A. The GDF-9 NSCD plasmids were extracted from the selected colonies, 
and run on an agarose gel in order to confirm integrity. B. A diluted sample of each 
plasmid was then used as a template for a PCR GDF-9 specific primers; GDF-9 F9+R9 
(432bp) in order to ensure they contained the GDF-9 NSCD sequence.
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Figure 5.4: Verification of GDF-9 over-expression in 3T3 transfected cells. A. RT-PCR 
showing elevated mRNA levels of GDF-9 in both 3T3GDF‘9N4exp and 3T3GDF'9N8exp cells, 
compared to both the 3T3wt and 3T3pEF controls. B. Western blot demonstrating increased 
levels of histidine and GDF-9 in both of the GDF-9 over-expressing 3T3 cells compared to 
empty plasmid control.
5.3.4 Purification of rh-GDF-9
Following verification of the transfectants for GDF-9, the 3T3GDF'9 N4 exp cells were grown to 
large quantities and both conditioned media and cell lysate were used to purify the recombinant 
protein through the use of metal (nickel) chelating affinity chromatography. The successfully 
purified rh-GDF-9 protein is demonstrated using western blot analysis with GDF-9 and anti­
histidine antibodies in order to verify that the protein purified was the required one (Figure 5.5). 
Following desaltification using Vivaspin centrifugal concentrators, the two eluates containing 
rh-GDF-9 were analysed once more for GDF-9 by western blotting analysis (Figure 5.6).
5.3.5 Quantification of rh-GDF-9
Following verification of rh-GDF-9, the recombinant protein was then quantified by running an 
SDS-PAGE with a serial dilution of known BSA concentrations (Figure 5.7). The gel was then 
stained in Coomasie blue, and photographed in order to allow the volume of the recombinant 
protein bands to be quantified by comparing it to the standard BSA curve. This then allowed 
for calculation of the concentration of the recombinant protein. Two of the eluates appeared to 
have the recombinant protein termed; Rh-GDF-9 1 and Rh-GDF-9 2, and were shown to have a 
concentration of 2.61pg/ml and 16.8pg/ml, respectively (Figure 5.8). The more concentrated 
recombinant protein was then used to carry out further experiments.
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Figure 5.5: Western blot analysis verifying purification of rh-GDF-9 from 3T3 transfectants 
using A. Anti-GDF-9 antibody; a, is the GDF-9 proprotein (70kDa), b, the precursor protein 
(57kDa), c, the mature ligand dimer (40kDa), and d, the mature monomer (18kDa). B. Anti- 
Histidine antibody, resulting in a product sized just over 70kDa, corresponding to the GDF-9 
proprotein and its histidine tag. M is the protein marker, lane 1 is 3T3pEF conditioned media, 
2 is 3T3GDF'9N4exp conditioned media, 3 is the media flow-through, 4 is the binding buffer 
flow-through, 5 is elution 1 (PBS), 6 is elution 2 (ImM imidazole), 7 is elution 3 (5mM 
imidazole), 8 is elution 4 (lOmM imidazole), 9 is elution 5 (20mM imidazole), 10 is 3T3gdf‘ 
9N4 ejcp cell lysate, 11 is cell lysate flow through, 12 is cell lysate binding buffer flow through,
and 13-18 are elutions 1-5 at same concentration as previous elutions.
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Figure 5.6: Western blot analysis using anti-GDF-9 antibody to verify the purification of rh- 
GDF-9 from 3T3 transfectants after desaltification; a, is the GDF-9 proprotein (70kDa), b, the 
precursor protein (57kDa), c, the mature ligand dimer (40kDa), and d, the mature monomer 
(18kDa). M is the protein marker; lane 1 is 3T3pEF conditioned media, 2 is 3 T3 gdf-9N4 exP 
conditioned media, 3 is 1 pm imidazole, 4 is rh-GDF-9 elution 1, and 5 is rh-GDF-9 elution 2.
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Figure 5.7: SDS-PAGE of rh-GDF-9 quantification. The molecular weight of BSA is 66.4kDa, 
while the two rh-GDF-9 proteins have a molecular weight of around 70kDa. M is the protein 
marker, whereas lanes 1-11 refer to a serial dilution of BSA standard ranging from lOOpg/ml 
down to a concentration of 0.049fig/ml. Lanes 12 and 13 contain the two recombinant protein 
eluates.
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Figure 5.8: Graph showing quantification of rh-GDF-9 using a standard curve of BSA
standards of a known concentration. The resulting equation of the line was then used to 
calculate the concentration of rh-GDF-9 compared to the BSA standards.
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5.3.6 Effect of rh-GDF-9 on the in vitro cell growth of prostate cancer cells
In order to determine whether treating prostate cancer cells with exogenous GDF-9 had similar 
effects on their biological properties as altering its endogenous expression, PC-3 WT cells were 
treated with 20ng/ml of rh-GDF-9 for a period of 4 days, and analysed for differences in cell 
growth, with the use of an in vitro cell growth assay. The PC-3 WT cells treated with rh-GDF- 
9 (1.35±0.28) had a significantly increased absorbance (and hence proliferation) compared to 
the untreated PC-3 cells (0.79±0.05), p=0.026 (Figure 5.9). This implies that rh-GDF-9 
promotes the growth of PC-3 cells. Six independent repeats were carried out, all showing the 
same trend.
A similar trend was seen in the DU-145 WT cells, in that the rh-GDF-9 treated cells 
(1.00±0.18) demonstrated an increased growth compared to the non-treated cells (0.85±0.02), 
p=0.292. Despite the clear trend however, the difference between treated and non-treated cell 
growth rate was not found to be statistically significant (Figure 5.10). The concentration of 
rh-GDF-9 (20ng/ml) was chosen, as it was the lowest concentration at which an effect on the 
growth of PC-3 cells was observed, and is the concentration commonly used for other rh-BMPs 
(See appendix, figure A l).
5.3.7 Effect of rh-GDF-9 on the in vitro adhesive capacity of PC-3 cells
In order to determine the effect of rh-GDF-9 on the in vitro adhesive capacity of PC-3 cells, PC- 
3 WT cells were treated with 20ng/ml of rh-GDF-9 for 40 minutes, before the cells were stained 
with crystal violet, and counted. The PC-3 WT cells treated with rh-GDF-9 (50.1 ±4.89) 
demonstrated a significant increase in adhesion in comparison to the untreated PC-3 WT cells 
(37.3±2.09), p=0.05 (Figure 5.11). At least three independent repeats were carried out for 
accuracy.
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5.3.8 The effect of rh-GDF-9 on the invasive and motile capacity of PC-3 cells
As shown in chapter 4, over-expression of GDF-9 in PC-3 cells led to an enhancement in both 
their invasive and motile capacity. In order to determine that this effect was due to GDF-9, the 
PC-3 cells were treated with 20ng/ml rh-GDF-9 and assessed for their motility and invasion. 
The rh-GDF-9 treated cells (36.3±5.13) demonstrated a slight increase in their invasive capacity 
compared to the untreated control (25.7±3.06), p=0.036 (Figure 5.12). In the case of motility 
meanwhile, rh-GDF-9 had a more significant enhancing effect on the motile capacity of the PC- 
3 cells (56.2±7.0), compared to the untreated control (30.0±5.6), p<0.01 (Figure 5.13). Three 
independent runs were carried out for accuracy.
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PC-3 WT+rh-GDF-9 PC-3 WT untreated
PC-3 WT+rh-GDF-9 
(n=3)
PC-3 WT untreated 
(n=3)
Mean 1.35 0.79
SD 0.28 0.05
Figure 5.9: Effect of rh-GDF-9 on in vitro cell growth of PC-3 cells after 4 days 
incubation. Due to the value and small volume of rh-GDF-9, growth was only 
examined on day 4, as opposed to days 0, 1,3, and 5, as demonstrated in chapter 4. 
After being stained with crystal violet, acetic acid was added in order to dissolve the 
stain allowing the absorbance to be measured. The absorbance and hence cell number 
of PC-3 cells was significantly increased when treated with 20ng/ml of rh-GDF-9 
compared to untreated PC-3WT, *p=0.026. Data shown is representative of 6 
independent repeats. Error bars represent standard deviation.
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Figure 5.10: Effect of rh-GDF-9 on in vitro cell growth of DU-145 cells, following 4 
days incubation as mentioned above. The cell growth of DU-145 cells was marginally 
increased when treated with 20ng/ml of rh-GDF-9, p=0.292. Data shown is representative 
of at least 3 independent repeats. Error bars represent standard deviation.
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PC-3 WT untreated
PC-3 WT+rh-GDF-9 
(n=3)
PC-3 WT untreated
(n=3)
Mean 50.1 37.3
SD 4.89 2.09
Figure 5.11: Effect of rh-GDF-9 on the in vitro adhesive capacity of PC-3 cells using the 
adhesion matrigel assay, following 40 minutes incubation. The adhesive capacity of PC-3 
cells was significantly increased when treated with 20ng/ml of rh-GDF-9, compared to the 
untreated PC-3WT cells, *p=0.05. Data shown is representative of at least 3 independent 
repeats. Error bars represent standard deviation.
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0 PC-3 WT untreated PC-3 WT +rh-GDF-9
PC-3 WT+rh-GDF-9 
(n=3)
PC-3 WT untreated
(n=3)
Mean 86.3 303
SD 14.2 8.14
Figure 5.12: Effect of rh-GDF-9 on the invasive capacity of PC-3 cells, following 4 
days incubation. The PC-3 cells treated with 20ng/ml rh-GDF-9 demonstrated a slightly 
increased invasive capacity compared to the untreated control cells, *p=0.036. Data 
shown is representative of at least 3 independent repeats. Error bars represent standard 
deviation.
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PC-3 WT untreated PC-3 WT+rh-GDF-9
PC-3 WT untreated
(n=6)
PC-3 WT+rh-GDF-9
(n=6)
Mean 30.0 56.2
SD 5.6 7.0
Figure 5.13: Effect of rh-GDF-9 on the in vitro motile capacity of PC-3 cell using the 
cytodex-2 bead motility assay. The PC-3 cells treated with 20ng/ml rh-GDF-9 
demonstrated a marked promotion in their motile capacity compared to the untreated 
control cells, **p<0.001. Data shown is representative of at least 3 independent repeats. 
Error bars represent standard deviation.
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5.4 Discussion
In the previous chapter, GDF-9 expression was both force-expressed and down-regulated in 
prostate cancer cells, in order to determine the effects that endogenous GDF-9 plays on these 
cells. These ensuing results demonstrated that when GDF-9 is over-expressed in PC-3 cells, 
that their in vitro growth, adhesive, invasive, and motile capacity was significantly promoted 
when compared to the two controls. The opposite was true for prostate cancer cell growth, 
adhesion, and motility when GDF-9 was down-regulated using ribozyme transgenes, suggesting 
that GDF-9 plays an important role in the cellular characteristics of prostate cancer cells.
In this current chapter, in order to further support these results and demonstrate that these 
effects are specific to GDF-9 itself, recombinant GDF-9 (rh-GDF-9) was produced as a source 
of exogenous GDF-9 protein with which to treat the cells. This was carried out using a 
mammalian expression factor to transfect 3T3 cells, a mouse fibroblast cell line, well 
established in the production of rh-proteins, with which previous rh-proteins had successfully 
been purified in the laboratory.
In order to simplify recombinant protein purification, the expression plasmid used adds a 
histidine tag to the C-terminal of the protein, thereby allowing for protein purification by metal 
chelating affinity chromatography. This is a very effective and reliable method in which to 
ensure purity of the resulting recombinant protein, with maximum exclusion of irrelevant 
molecules. This was verified with the use of western blot analysis with several antibodies to 
ensure that it was indeed GDF-9.
Once purified and quantified, rh-GDF-9 was then used in various in vitro assays to treat wild- 
type PC-3 and DU-145 prostate cancer cells in order to determine whether this would 
demonstrate with similar results to those seen in the previous chapter, and prove that these 
functional changes were specific to GDF-9. Indeed, when the PC-3 cells were treated with rh- 
GDF-9, an increase in the cell growth, adhesive, invasive, and motile capacity of these cells was
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evident when comparing to the untreated cells. In rh-GDF-9 treated DU-145 cells however, the 
increase in cell growth was found to be statistically insignificant. As DU-145 expresses high 
endogenous levels of GDF-9, it is possible that further addition of exogenous rh-GDF-9 would 
have little effect compared to that seen in the PC-3 cells, which express low levels of the 
protein. For this reason, no more functional assays were carried out on DU-145 cells.
These experiments along with those in the previous chapter, further imply that GDF-9 has an 
important role in the proliferative, adhesive, and motile capacity of prostate cancer cells, and 
that the use of recombinant protein is a simple and effective method which can be utilised in 
further experiments, including investigation of a protein’s signal transduction pathway.
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Chapter 6
GDF-9 promotes growth of prostate 
cancer cells by protecting them from
apoptosis
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6.1 Introduction
The previous chapters have shown that GDF-9 can promote the growth rate of prostate cancer 
cells, in both its endogenous and exogenous form. An increase in cell growth is vital for the 
progression of cancer cells as it allows for tumours to grow and establish themselves quicker. 
Most oncogenic factors can affect cell proliferation in two different ways; by disrupting the cell 
cycle, and/or by inhibiting the process of apoptosis.
TGF-p is known for its growth-inhibitory effects in a variety of cell types. Additionally, BMP- 
6 and BMP-2 have been shown to inhibit the growth of prostate cancer cells including LNCaP 
and DU-145 (Brubaker et al., 2004). The laboratory has recently shown that BMP-9 and -10 
can inhibit the growth, adhesion, invasion, and migration of prostate cancer cells by inducing 
apoptosis via Smad 1, 5, and 8 mediated up-regulation of pro-apoptotic factor Par-4, and the 
Smad independent pathway, respectively (Ye et al., 2008; Ye et a l,  2009).
GDF-9 meanwhile, has been shown to promote the proliferation and survival of granulosa cells 
(Vitt et al., 2000). In addition, its expression is up-regulated in an oral cancer cell line less 
apoptotic in nature, suggesting that GDF-9 acts as a survival factor in this cell type (Zhuang et 
al., 2010). The previous chapters have now shown that it has the same effect in prostate cancer 
cells. Therefore, in order to determine the mechanism behind this growth induction, the cells 
underwent apoptosis and cell cycle analysis using flow cytometry in order to investigate the 
effects of GDF-9 on prostate cancer cell growth in more depth.
6.2 M aterials and methods
6.2.1 M aterials
The antibodies used in this chapter are shown in Table 2.1 and include anti-caspase 3, P38, 
JNK, ERK, ALK-5, pSmadl, Smad3, pSmad3, and phospho-serine/threonine.
212
6.2.2 Investigating expression of apoptotic and cell cycle molecules using PCR and western 
blotting
Both RNA and protein were extracted from the stable transfectant cells treated with or without 
rh-GDF-9, and were used in either western blot analysis or RT-PCR, in order to investigate 
expression levels of apoptotic and cell cycle molecules at both the mRNA and protein level. 
These methods were carried out as previously described in sections 2.4 and 2.5.
6.2.3 Immunoprecipitation of serine/threonine phosphorylated ERK, JNK, and ALK-5
Protein extracted from PC-3 WT cells treated either with nothing, 3ng/ml Smad3 inhibitor 
alone, or 20ng/ml rh-GDF-9 alone, or in conjunction with 3ng/ml Smad3 inhibitor, was 
immuno-precipitated with anti-phosphorylated serine/threonine antibody in order to be able to 
detect levels of phosphorylated proteins. These immuno-precipitated protein samples were then 
run on an SDS-PAGE and blotted with anti-ERK, anti-JNK, and anti-ALK-5 antibody. Refer to 
section 2.5.3 for further details on immunoprecipitation method.
6.2.4 Immuno-flourescent staining of pSmad3 and pSmadl in GDF-9 transfected cells
The cells were lysed before being incubated with primary anti-pSmad3 or pSmadl antibody for 
an hour. The primary antibody was then washed off and replaced with the corresponding FITC 
labelled secondary antibody, before the cells were viewed using a fluorescent microscope.
6.2.5 In vitro  cell growth assay
The cells were seeded into a 96 well plate as described in sections 2.9.3. Triplicates of each cell 
line were incubated with 10% FBS containing DMEM media either with or without 20ng/ml of 
rh-GDF-9, and/or 3ng/ml Smad3 inhibitor. The cells were fixed following 4 days incubation 
and stained with crystal violet, before the absorbance was measured in order to determine cell 
number.
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6.2.6 Hoechst staining for apoptosis
The cells were incubated either with DMEM with 10% FBS or serum free, for a period of 48 
hours, before both the adherent cells and those floating in the culture medium were harvested 
and washed in PBS. The cells were then stained with Hoechst 33342 DNA stain for 20 
minutes, before the apoptotic cells were counted, and using the total number of cells, a 
percentage for the amount of apoptotic cells was calculated.
6.2.7 Apoptosis and cell cycle analysis using flow cytometry
Both the transfected PC-3 cells and PC-3WTcells treated with either 20ng/ml rh-GDF-9 alone or 
in conjunction with 3ng/ml Smad3 inhibitor, or 3ng/ml Smad3 inhibitor alone, underwent 
serum starvation for 48 hours before undergoing apoptosis analysis by flow cytometry. In order 
to detect apoptotic cells, this current study uses the Vybrant® Apoptosis Assay Kit (Invitrogen, 
Inc., Paisley, UK) which contains recombinant flourescein conjugated annexin V (FITC 
annexin V) and propidium iodide (PI) solution. The cells were stained with both FITC annexin 
V and PI solution, before the stained cells were analysed using the flow cytometer and 
FlowMax software package, by measuring any fluorescence emission at 530nm (FL1) and 
>575nm (FL3).
For cell cycle analysis, following harvestation of both the adherent and floating cells, the cells 
were centrifuged and counted. lxlO 6 cells were then fixed with ethanol, and subsequently 
stained with PI solution including TritonXlOO for cell permeabilisation and RNAase A to digest 
any dsRNA. After an incubation period of 30 minutes, the fluorescence emitted by PI was 
detected using cell cycle analysis with the FlowMax software.
6.3 Results
6.3.1 Analysing role of GDF-9 on the cell cycle using flow cytometry
As demonstrated in the previous chapters, GDF-9 can promote the growth of prostate cancer 
cell lines PC-3 and DU-145. In order to determine the mechanism by which GDF-9 promotes 
cell growth, the effect of GDF-9 on the cell cycle was analysed. This demonstrated that PC-
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^GDF Qexp. a }ower percentage of cells in the G1 phase (44.6%±2.57) and higher
percentage in the G2/M phase (43.2%±9.77), compared to the PC-3pEF control which had the 
majority of its cells in the G1 phase (59.8%±7.77) as opposed to the G2/M phase (30.2%±5.02), 
p=0.03 when comparing the G1 phase and p=0.10 for the G2/M phase. Furthermore, the PC- 
3GDF'9nb3 cells like the control, had the majority of its cells in the G1 phase (56.6±4.13) 
compared to the G2/M phase (26.9±4.56), p=0.71 for G1 phase and p=0.34 for G2/M phase 
compared to PC-3pEF (Figure 6.1).
6.3.2 The role of Cyclin D1 in GDF-9 associated growth promotion
The cyclins are responsible for regulating the Cyclin Dependant Kinases (CDKs) and for 
committing cells to the cell cycle. Cyclin D1 in particular, is responsible for regulating 
transition from G1 to S phase and thereby allowing cells to pass through the G1 check point and 
prepare for cell division (Harbour and Dean, 2000). As GDF-9 was shown to promote the 
progression of cells through the cell cycle, the expression of Cyclin D1 in response to GDF-9 
was analysed. An up-regulation in the expression of Cyclin D1 was demonstrated after 2 hours 
of treatment with rh-GDF-9 at both the mRNA and protein level (Figure 6.2).
6.3.2 Analysing the role of GDF-9 in apoptosis using flow cytometry
However, as the effect on the cell cycle was insufficient to explain the marked effect that GDF- 
9 had on the growth of prostate cancer cells, the effect of GDF-9 on the proportion of apoptotic 
cells was analysed using flow cytometry. GDF-9 appeared to reduce the level of apoptosis in 
PC-3 cells under starvation from serum. As shown in figure 6.3, there was a smaller proportion 
of apoptotic cells (both early and late) in pc-3GDF'9exp cells (7.46%±1.54) compared to the PC- 
3pEF(12.9%±2.86) control, p=0.04. In addition, pc-3GDF'9nb3 cells had a far greater proportion of 
apoptotic cells (27.0%±8.12) compared to the control, p=0.046. Meanwhile, PC-3 WT cells 
treated with rh-GDF-9 for 48 hours under serum starvation, also demonstrated a significant
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reduction in the number of apoptotic cells (3.69%±1.33) compared to the untreated control 
(13.2%±1.34), pcO.OOl (Figure 6.4).
6.3.4 Analysing role of GDF-9 in apoptosis using Hoechst DNA stain
In order to further determine whether GDF-9 has an effect on apoptosis, another method of 
analysing apoptosis was carried out. The cells were stained with Hoechst 33342 DNA stain, 
which when viewed under fluorescent light can help distinguish apoptotic cells with condensed 
chromatin, a hallmark of apoptosis. Figure 6C shows that p c - 3 GDF'9exp (6.06%±0.61) cells have 
a significantly lower percentage of apoptotic cells compared to PC-3pEF(12.9%±1.57), p=0.004. 
In addition, the pc_ 3 GDF-9nb3 (29.7%±4.66) cells demonstrated a significantly higher percentage 
of apoptotic cells compared to the control, p=0.006 (Figure 6.5).
6.3.5 Analysing expression of apoptosis effector molecules
Caspase 3, an executioner caspase is indicative of end-stage apoptosis. Therefore, in order to 
further determine whether GDF-9 has an effect on prostate cancer cell apoptosis, levels of 
caspase 3 were examined in the transfected PC-3 cells using western blot analysis. Caspase-3 is 
expressed as an inactive precursor, which is cleaved into p l l  and p l7  mature caspase-3 
subunits during apoptosis. The caspase-3 precursor is first cleaved to form a p20 peptide and 
the p l l  subunit, and then the p20 peptide is further cleaved to form the mature p l7  subunit. 
PC-3GDF 9exp demonstrated significantly lower expression levels of caspase-3 mature subunits, 
compared to both the controls and the PC-3GDF 9nb3cells, shown with the use of western blotting 
(Figure 6.6A). In addition, down-regulation in caspase-3 protein levels was also seen in PC-3 
WT cells exposed to 20ng/ml of rh-GDF-9 over a time period of up to 24 hours (Figure 6.6B). 
The levels of caspase-3 expression begin to show down-regulation after around 4 hours, and at 
24 hours its expression is only marginally visible.
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Figure 6.1: Analysis of cell cycle in PC-3 cells using flow cytometry. pc_3GDF-9exP cells had 
similar numbers of cells in both the G1 and G2/M phases, compared to the PC-3pEF control and 
PC-3GDF'9rib3 cells, which had the majority of their cells in the G1 phase as opposed to the G2/M 
phase, *p=0.03 when comparing the G1 phase, and p=0.10 for the G2/M phase of PC-3GDF'9cxp 
cells compared to PC-3pEF, p=0.71 for the G1 phase and p=0.34 for G2/M phase of PC-3GDF'9nb3 
compared to PC-3pEF.
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Figure 6.2: The effect o f GDF-9 on Cyclin D1 expression was analysed by treating PC-3 cells 
with 20ng/ml rh-GDF-9 for varying amounts o f time at the A. mRNA level using PCR with 
Cyclin D1 specific primers, demonstrating an up-regulation in Cyclin D1 expression and at B. 
the protein level using western blotting with an anti-Cyclin D1 antibody, which showed a 
similar effect.
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Figure 6.3: The apoptotic population in PC-3 cells was analysed using flow cytometry following serum hunger for
48 hours, in order to induce apoptosis. The positive control indicated PC-3 cells treated with H20 2 to show
induction of apoptosis. The percentage of apoptotic cells in the PC-3GDF'9exp cells was significantly reduced
compared to the control, *p=0.045. In addition there was a significant increase in the numbers of apoptotic cells in
PC-3GDF 9nb3 cells compared to the control, *p=0.046. A. Data shown demonstrates representative data of three
independent repeats. Segment Q1 of the quadrants refers to necrotic cells stained with high levels of PI, Q2 to late
apoptotic cells with high staining of both annexinV and PI, Q3 to healthy live cells with low staining of both PI and
annexinV, and Q4 to early apoptotic cells with high annexinV but low PI staining. B. Bar graph demonstrates the
mean apoptotic percentage of three independent repeats. Error bars represent standard error of mean. Apoptotic
index refers to total apoptotic population including both late apoptotic cells (Q2) and early apoptotic cells (Q4).
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Figure 6.4: PC-3 cells were treated with serum free media with or without 20ng/ml rh-GDF-9 for 48 
hours, and analysed for apoptosis using flow cytometry. The percentage of apoptotic cells in the PC-3 
cells treated with rh-GDF-9 was significantly reduced compared to the untreated control, **p<0.001. 
A. Data shown demonstrates representative data of three independent repeats. B. Bar graph 
demonstrates the mean apoptotic percentage of three independent repeats. Error bars represent 
standard error of mean. Apoptotic index refers to total apoptotic population including both early 
apoptotic cells (Q4) and late apoptotic cells (Q2).
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6.3.5 Investigating the downstream signalling pathway of GDF-9
In order to investigate the downstream signalling pathway of GDF-9 in prostate cancer cells, the 
effect of GDF-9 on the expression of pSmad3 (activated Smad3) protein levels, and 
phosphorylation of ALK-5, was investigated. Firstly, a time course was carried out where PC-3 
cells were treated with 20ng/ml rh-GDF-9 for different periods of time, after which protein 
levels of pSmad3 and Smad3 were analysed by western blot analysis (Figure 6.1 A). Expression 
of pSmad3 protein was up-regulated by rh-GDF-9 after only one hour of treatment while levels 
of non-phosphorylated Smad3 remained unchanged. Furthermore, IFC was carried out on the 
transfected PC-3 cells in order to determine whether endogenous GDF-9 also signals via 
Smad3. Indeed, pc_3GDF-9exP cells demonstrated significantly stronger nuclear staining of GDF- 
9 compared to the controls. The pc_3GDF-9nb3 cells meanwhile, had similar levels of pSmad3 as 
the controls. Meanwhile, no nuclear staining of pSmadl was found in the pc_3 GDF-9exP ceus or 
the controls, suggesting that GDF-9 does not signal via Smadl to exert its effects (Figure 6.7B).
The Smad3 inhibitor (Calbiochem, Gibbstown, USA) prevents phosphorylation and hence 
activation of Smad3, and so is an effective way of investigating its involvement. In order to 
demonstrate the actions of the Smad3 inhibitor, PC-3 cells were treated either with 20ng/ml rh- 
GDF-9, 3ng/ml Smad3 inhibitor alone, or 20ng/ml rh-GDF-9 along with 3ng/ml Smad3 
inhibitor. The cells treated with rh-GDF-9 alone demonstrated an up-regulation of pSmad3 
expression, whereas this was inhibited when the cells were treated with the Smad3 inhibitor, 
further suggesting that GDF-9 signals via this Smad (Figure 6.7C).
Furthermore, treatment with rh-GDF-9 alone or in conjunction with Smad3 inhibitor, resulted in 
an upregulation in levels of phosphorylated ALK-5 implying that GDF-9 signals via this 
receptor as has been previously reported. The addition of Smad3 inhibitor alone resulted in a 
reduction of p-ALK-5 levels. Although the reason for this remains unclear, the literature 
suggests that Smads may be involved in receptor up-regulation via a positive feedback loop 
(Figure 6.7D) (Miyazono, 2000).
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6.3.6 GDF-9 and Smad-independent signalling
Apart from the Smad-dependent pathway, BMPs are known to signal independently of the 
Smads via the mitogen-activated protein kinase (MAPK) pathway, a major signalling pathway 
involved in cellular proliferation affecting both apoptosis and the cell cycle (Nohe et a l, 2002). 
As GDF-9 has been shown to affect both of these processes, its effect on the expression of two 
key players of the MAPK pathway, ERK and JNK in PC-3 cells was analysed in response to rh- 
GDF-9. The cells treated with rh-GDF-9 demonstrated an up-regulation in the levels of both 
ERK and JNK. However, while this up-regulation in JNK levels was inhibited when treating 
the cells with Smad3 inhibitor, apparently being Smad3 dependent, in the case of JNK, treating 
cells with the Smad3 inhibitor either alone or alongside rh-GDF-9 did not affect the levels of 
ERK.
Furthermore, carrying out immunoprecipitation with a serine threonine phosphorylated 
antibody, and carrying out a western blot using ERK and JNK antibodies, levels of 
phosphorylated and thereby active ERK and JNK could be analysed. This demonstrated that rh- 
GDF-9 treatment could lead to an increase in the levels of active p-ERK and p-JNK both of 
which were shown to be Smad3 independent, suggesting that while JNK itself may be a target 
gene of GDF-9, that GDF-9 may signal Smad independently via both ERK and JNK (Figure 
6 .8).
6.3.7 The role of Smad3 in GDF-9 associated growth promotion
As previously shown, rh-GDF-9 can promote the growth of PC-3 cells. In order to determine 
whether this effect is due to GDF-9 signalling via Smad3, the PC-3 cells were treated with 
Smad3 inhibitor and a growth assay was carried out. The PC-3 cells treated with rh-GDF-9 
alone (0.93±0.03) showed the usual increase in growth compared to the untreated (0.72±0.07) 
control, p=0.042. Meanwhile, those treated with the Smad3 inhibitor alone (0.78±0.005) and 
along with rh-GDF-9 (0.72±0.05), showed similar growth rates to the untreated controls 
suggesting that the Smad3 inhibitor results in an inhibition of GDF-9 growth promotion, p<0.05 
for both the Smad3 inhibitor treated cells compared to the rh-GDF-9 treated cells (Figure 6.9).
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However, when these cells were analysed for apoptosis using flow cytometry, the addition of 
Smad3 inhibitor alongside GDF-9 did not inhibit its anti-apoptotic effect suggesting that GDF-9 
doesn’t signal through Smad3 to induce its anti-apoptotic effects. The PC-3 cells treated with 
Smad3 inhibitor alone (10.8%±1.99) exhibited similar apoptotic levels to the untreated cells 
(11.5%±2.54), whereas those treated with Smad3 inhibitor and rh-GDF-9 (4.72%±1.06) had 
reduced apoptotic levels, similar to those seen in cells treated with rh-GDF-9 alone 
(3.53%±1.00), p=0.722 for untreated cells compared to Smad3 inhibitor treated cells, and 
p=0.05 compared to Smad3 inhibitor and rh-GDF-9 treated cells (Figure 6.10). This suggests 
that GDF-9 may signal via Smad3 to affect the cell cycle and thereby promote cell growth.
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Figure 6.7: Downstream signalling of GDF-9. A. PC-3 cells treated with rh-GDF-9 
demonstrated increased pSmad3 protein levels compared to untreated control. Levels of 
total Smad3 remained unchanged. B. IFC staining demonstrating increased levels of 
nuclear pSmad3 staining in the PC-3GDF"9exp cells compared to controls and knock-down 
cells. Levels of pSmadl meanwhile, remained unchanged in the pc_3GDF-9exP cells 
compared to the controls. C. Western blot analysis showing that treatment of PC-3 with 
Smad3 inhibitor resulted in an inhibition of GDF-9 associated pSmad3 up-regulation. D. 
Treating PC-3 cells with 20ng/ml rh-GDF-9 for a period of 2 hours, resulted in increased 
phosphorylation of type I receptor ALK-5 compared to control, an effect that was 
downregulated by the Smad3 inhibitor.
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Figure 6.8: GDF-9 signalling via MAPK pathway in PC-3 cells. A. Levels of both 
unactivated ERK 1/2 (particularly ERK1) and activated p-ERK were increased in response to 
2 hour treatment with 20ng/ml rh-GDF-9. This was not affected by 2 hours treatment with 
3ng/ml Smad3 inhibitor. B. Both JNK and p-JNK levels were increased in response to rh- 
GDF-9, and while the increase in expression of p-JNK was not affected by 3ng/ml Smad3 
inhibitor, levels of JNK expression were inhibited when treated with this inhibitor.
227
A
bs
or
ba
nc
e
1.2
1.0
0.8
0.6
0.4
0.2
* —
PC-3 WT untreated PC-3 WT +rh-GDF-9 PC-3 WT PC-3 WT +rh-GDF-9
+Smad3 inhibitor +Smad3 inhibitor
PC-3 WT 
untreated
(n=3)
PC-3 +rh-GDF-9 
(n=3)
PC-3 +Smad3 
inhibitor
(n—3)
PC-3+rh-GDF-9 
+Smad3 inhibitor 
(n=3)
Mean 0.72 0.93 0.78 0.69
SD 0.07 0.03 0.005 0.04
Figure 6.9: Growth assay showing that treatment of PC-3 cells with 3ng/ml Smad3 inhibitor 
alone, or in conjunction with 20ng/ml rh-GDF-9, results in an inhibition of the GDF-9 
associated increased growth rate, *p<0.05 for both the Smad3 inhibitor treated cells, 
compared to the rh-GDF-9 treated cells. Data is representative of three indepenant repeats. 
Error bars represent standard deviation.
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Figure 6.10: Role of Smad3 in GDF-9 associated apoptosis. The cells treated with both 
3ng/ml Smad3 inhibitor and 20ng/ml rh-GDF-9 demonstrated similar apoptotic levels to those 
cells treated with rh-GDF-9 alone suggesting that the anti-apoptotic effect of GDF-9 is Smad3 
independent, p=0.722 for untreated cells compared to Smad3 inhibitor treated cells, and 
*p=0.005 compared to Smad3 inhibitor and rh-GDF-9 treated cells. Meanwhile, *p=0.01 for 
Smad3 inhibitor treated cells compared to the dual treated cells and *p=0.037 for untreated cells 
compared to rh-GDF-9 treatment alone. A. Data shown demonstrates representative data of 
three independent repeats. B. Bar graph demonstrates the mean apoptotic percentage of three 
independent repeats. Error bars represent standard error of mean. Apoptotic index refers to 
total apoptotic population including both early apoptotic cells (Q4) and late apoptotic cells (Q2).
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6.4 Discussion
The BMPs have been shown to have varying effects on prostate cancer cell growth. In the case 
of GDF-9, the previous chapters have shown that it is capable o f promoting the growth o f  
prostate cancer cells both endogenously through alteration of its expression, and exogenously 
with the use o f recombinant GDF-9 protein. This current chapter further investigates the 
mechanisms behind this growth induction.
Generally speaking, growth can be promoted in one of two ways; cell cycle progression or 
apoptosis inhibition. The cells were therefore used for apoptosis and cell cycle analysis by 
flow cytometry. This demonstrated that GDF-9 had a marginal effect on the cell cycle by 
acting to aid in the progression o f the PC-3GDF‘9exp cells from the G1 phase to the G2/M phase. 
More importantly, GDF-9 was shown to have a significant effect on prostate cancer cell 
apoptosis under serum deprivation by acting as an anti-apoptotic factor, with PC-3GDF'9exp cells 
showing a reduction in the proportion of apoptotic cells compared to the controls, and PC-3GDF' 
9rib3 cells demonstrating significantly greater levels o f apoptosis.
A hallmark o f cancer is that cells acquire the ability to proliferate uncontrollably and thereby 
typically lose the function o f genes associated with inhibiting the cell cycle. In order for cells to 
progress from the G1 phase and commit to the G2/M phase, they rely on the actions of cyclins 
which act as sensors to growth factor signals and lead to Rb phosphorylation and hence cell 
cycle progression (Sherr, 1996). As GDF-9 was demonstrated to have an effect on the 
progression into the G2/M phase, the expression o f Cyclin D1 in response to GDF-9 was 
analysed. Carrying out a time course o f rh-GDF-9 treatment on PC-3 cells led to an up- 
regulation o f Cyclin D1 expression, both at the mRNA and protein level. However, the effect 
of GDF-9 on the cell cycle was only found to be marginal, insufficient to explain the significant 
effect that GDF-9 has on prostate cancer cell growth.
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Apoptosis meanwhile, is orchestrated by a variety of molecules, including a family of cysteine 
proteases known as the caspases. Caspase 3 is known as an executioner caspase essential for 
Cytochrome C action and DNA fragmentation (Slee et a l,  2001). Levels of mature caspase-3 
protein subunits were shown to be reduced in the pc-3 GDF'9exp cells compared to the controls. In 
addition, protein levels of caspase-3 were gradually reduced over time when treated with rh- 
GDF-9, further showing a reduction in the levels of apoptosis in cells over-expressing GDF-9. 
This effect on apoptosis was further demonstrated using Hoechst 33342 DNA stain, where the 
PC-3GDF'9exp cells demonstrated significantly lower percentages of apoptotic cells compared to 
the control, and knock-down cells which had a much higher percentage of apoptotic cells.
In the ovary, GDF-9 has been shown to signal via ALK-5 and BMPR-II to activate Smads2 and 
3 and trigger expression of its target genes (Mazerbourg et al., 2004). In order to establish if 
this was also the case in prostate cancer cells, PC-3 cells were treated with rh-GDF-9 and 
analysed for pSmad3 and p-ALK-5 expression levels using both immunoprecipitation and 
western blot analysis. The results demonstrated an increase in the phosphorylation of both 
Smad3 and ALK-5 suggesting that GDF-9 uses a similar pathway in prostate cancer cells as it 
does in the ovary. Furthermore, p-ALK-5 levels were shown to be downregulated in response 
to the Smad3 inhibitor, suggesting that perhaps ALK-5 activation is dependent on Smad3. This 
positive form of regulation has been previously shown in TGF-0 signalling (Miyazono, 2000). 
Unfortunately due to the lack of specificity of the anti-BMPR-II antibody, the type-II receptor 
for GDF-9 was not able to be determined in this study.
Apart from Smad-dependent signalling, BMPs are known to signal via a Smad-independent 
MAPK pathway. GDF-9 was found to be no exception as cells treated with rh-GDF-9 
demonstrated increased levels of un-phosphorylated ERK and JNK, as well as p-ERK and p- 
JNK. Whereas JNK up-regulation was found to possibly be Smad3 dependent (needs further 
investigation), ERK, p-ERK, and p-JNK were not affected by the Smad3 inhibitor suggesting 
that while JNK and ERK may be GDF-9 target genes one Smad dependent and the other not,
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GDF-9 may also signal via these molecules in a Smad independent manner. Other studies have 
previously shown that cross talk between the JNK and the Smad dependent pathway is 
interdependent. For example, primary rapid activation of JNK by TGF-01 was demonstrated to 
be Smad independent, but the secondary more sustained JNK response was Smad dependent. 
Both of these pathways were shown to require Rho GTPase (Engel et a l, 1999). This suggests 
that it is possible for Smad3 to up-regulate levels of JNK, as shown in this study.
Furthermore, treating PC-3 WT cells with Smad3 inhibitor not only prevented pSmad3 up- 
regulation, it also led to an inhibition of GDF-9 associated promoted cell growth suggesting that 
GDF-9 signals via Smad3 to induce cell growth of prostate cancer cells. However, when the 
cells were analysed for apoptosis using flow cytometry, the Smad3 inhibitor had no effect 
suggesting that GDF-9 protects cells from apoptosis in a Smad3 independent manner, but that it 
may signal via Smad3 to promote the cell cycle via Cyclin D1 up-regulation. All in all, these 
results suggest that GDF-9 may act as an anti-apoptotic factor to promote the growth and 
survival of prostate cancer via the ERK and JNK pathway in a Smad-independent pathway, 
while acting to promote the proliferation through regulation of cell cycle via Cyclin D1 in a 
Smad-dependent manner.
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Chapter 7
GDF-9 promotes cell-matrix 
adhesion, invasion, and motility of 
prostate cancer cells by regulating 
adhesion and EMT molecules
233
7.1 Introduction
As previously demonstrated in chapter 4, GDF-9 can promote the adhesive, invasive, and motile 
capacity of prostate cancer cells. These cellular properties are all vital for tumour growth and 
aid in their progression and metastasis. As cells become more invasive, the tumour cells lose 
cell-cell adhesiveness while gaining mobility, allowing them to leave the primary tumour site 
and invade into adjacent tissues.
Following intravasation and survival in the blood stream, the cells extravasate at distant sites, 
leaving the blood stream. Here they undergo a process known as epithelial-mesenchymal 
transition (EMT), an important mechanism in the early stages of metastasis where epithelial 
cells become more fibroblastic in nature and exhibit reduced intercellular adhesion and 
increased motility (Thiery, 2002).
Several BMPs, including BMP-2 and BMP-7 have been shown to control motility and 
invasiveness of prostate cancer cells (Ye et al., 2007; Lai et al., 2008). BMP-4 meanwhile has 
been reported to induce EMT and hence motility of ovarian cancer cells (Theriault et al., 2007). 
There are several molecules that have been implicated in the control of these processes 
including known BMP target genes which may help explain their effects on these processes. 
This chapter therefore focuses on the mechanisms behind the capability of GDF-9 to promote 
prostate cancer cell motility and invasiveness by investigating expression levels of genes 
associated with both motility and EMT. These results will help clarify the role of GDF-9 in 
prostate cancer progression and motility.
7.2 M aterials and m ethods
7.2.1 Analysing expression levels of target molecules using RT and Q-PCR
PC-3 WT cells were treated with 20ng/ml rh-GDF-9 for varying amounts of time, alone or 
along with 3ng/ml Smad3 inhibitor, for 0, 30 minutes, and 1, 2, and 24 hours, respectively. 
RNA was isolated from both of these cells and the stable transfectants, before being used as a
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template for both Q-PCR and RT-PCR using specific primers for FAK, paxillin, RhoC, SNAI1, 
N-cadherin, E-cadherin, and ROCK-1. Refer to section 2.4 for further details.
7.2.2 Analysing protein levels of focal adhesion and EMT associated molecules using 
western blotting
PC-3 WT cells were treated with a time course of 20ng/ml rh-GDF-9 for 0, 1, 2, 4, and 24 
hours, respectively, before protein was extracted. In addition, protein was extracted from PC-3 
WT cells treated with 20ng/ml rh-GDF-9 alone or in conjunction with 3ng/ml Smad3 inhibitor 
for a period of 2 hours. Equal concentrations of the protein samples were then run on an SDS- 
PAGE and blotted using anti-FAK, anti-Paxillin, anti-p-FAK, anti-p-paxillin, anti-E-Cadherin, 
anti-SNAIl, and anti-RhoC antibodies.
7.2.3 Immuno-cytochemical staining of FAK and paxillin
Immuno-cytochemical staining of FAK and paxillin in PC-3 cells was carried out using specific 
primary antibody for the proteins, followed by HRP conjugated secondary antibody, ABC 
complex, and DAB. The cells were counterstained with Haematoxylin. For detailed ICC 
procedure refer to section 2.5.9.
7.2.4 Immuno-flourescent staining for RhoC and SNAI1 in GDF-9 transfected cells
The cells were incubated for an hour with anti-RhoC and anti-SNAIlprimary antibody, before 
the primary antibody was washed off and replaced with FITC labelled secondary antibody. The 
cells were then viewed using a fluorescent microscope. Refer to section 2.5.10 for further 
details.
7.2.5 Adhesion assay using Smad3 inhibitor and rh-GDF-9
PC-3 WT cells were treated with 20ng/ml rh-GDF-9 either alone, or in conjunction with 3ng/ml 
Smad3 inhibitor for 40 minutes, while allowing them to adhere to matrigel before they were 
stained with crystal violet, and counted.
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7.3 Results
7.3.1 The effect of endogenous GDF-9 on FAK and paxillin expression
As shown in the previous chapters, GDF-9 can promote the adhesive, motile, and invasive 
capacity of prostate cancer cells. Therefore, with the intention of determining a mechanism by 
which GDF-9 can exert these effects, the expression levels of well-established adhesion 
molecules FAK and paxillin were analysed at both the mRNA and protein level. pc_3 GDF-9exP 
cells demonstrated increased expression of FAK and paxillin compared to the two controls, both 
at the mRNA level using PCR, and at the protein level where enhanced staining for both FAK 
and paxillin was demonstrated using ICC staining (Figure 7.1 and 7.2). In addition, PC-3GDF" 
9r,b3 cells had similar mRNA levels of both molecules to the controls, suggesting that GDF-9 is 
capable of up-regulating expression of these molecules. Furthermore, DU-145GDF'9r,b3 cells 
demonstrated decreased expression of FAK and paxillin compared to the controls (Figure 7. IB 
and D). Due to the large amount of molecules that were screened, only DU-145GDF'9nb3 and PC- 
3GDF-9rib3 were usecj as tjiey were found to express the lowest levels of GDF-9.
7.3.2 Effect of rh-GDF-9 on expression of FAK and paxillin
To further confirm this hypothesis, PC-3 WT cells were treated with rh-GDF-9 for varying 
amounts of time to see if exogenous GDF-9 would have a similar effect on FAK and paxillin 
expression. Protein and mRNA was extracted from these cells, and using PCR and western blot 
analysis, expression levels of FAK and paxillin were analysed. Levels of FAK and paxillin 
mRNA were increased after only half an hour of treatment with rh-GDF-9 compared to the 
untreated controls (Figure 7.3A). This was further confirmed using Q-PCR where the mRNA 
levels of both molecules were quantified. The transcript levels of FAK were increased after 24 
hours (2.60xl0n ±1.09xl0n ) of treatment with rh-GDF-9 compared to the untreated control 
(1.38xl010±2.76xlOn ), p=0.07. The same effect was seen on paxillin mRNA levels where
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the levels at 24 hours (5.30xl0n ±2.10xl0n ) were higher compared to the untreated control 
(9.51xlOn ±2.82xlOn ), p=0.26.
In the case of protein levels, expression of paxillin was only increased after 4 hours treatment, 
and that of FAK only after 24 hours (Figure 7.3B). Furthermore, protein levels of 
phosphorylated and hence activated FAK and paxillin (p-FAK and p-paxillin), were analysed in 
order to determine whether GDF-9 not only up-regulates but also activates these molecules. 
Indeed, levels of p-FAK and p-paxillin were up-regulated at earlier time points than their non- 
phosphorylated counterparts, compared to the untreated controls.
7.3.3 Smad3 and its role in GDF-9 associated adhesion
As' the previous results demonstrate, GDF-9 downstream signalling involves the Smad- 
dependent pathway via Smad3, which it uses in order to exert its effects. The Smad3 inhibitor 
used in the previous chapter was used to treat PC-3 WT cells that were to be used in an 
adhesion assay, in order to determine whether GDF-9 signals via Smad3 to induce cell 
adhesion. The cells treated with Smad3 inhibitor along with rh-GDF-9 (33.1±7.18) resulted in 
inhibition of the previously seen GDF-9 associated increase in cellular adhesion (86.9±±4.76), 
suggesting that GDF-9 signals via Smad3 to exert its effects on prostate cancer cell adhesion, 
p=0.002 compared to PC-3 WT treated with rh-GDF-9, and p=0.027 compared to untreated 
control (Figure 7.5).
7.3.4 Smad3 and GDF-9 target gene expression
Furthermore, in order to establish whether GDF-9 up-regulation of adhesion molecules FAK 
and paxillin is due to Smad3 signalling, and thereby associated with prostate cancer cell 
adhesion, PC-3 cells were treated with either 20ng/ml rh-GDF-9, 3ng/ml Smad3 inhibitor, or 
both 20ng/ml rh-GDF-9 and 3ng/ml Smad3 inhibitor, respectively, for a time period of 2 hours.
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FAK and paxillin mRNA levels were analysed using both normal and Q-PCR, and protein 
levels were analysed using western blotting. The results of the RT-PCR and western blot 
showed that rh-GDF-9 mediated upregulation of FAK and paxillin mRNA and protein levels, 
that were inhibited in the presence of Smad3 inhibitor, suggesting that they are both Smad3 
gene targets (Figure 7.6).
Furthermore, the Q-PCR results demonstrated that when the PC-3 cells were treated with rh- 
GDF-9 alone, transcript levels of FAK (7.7xl04±1.04xl04) and paxillin (1.60xl07±2.15xl06) 
were increased when compared to the untreated controls. However, this up-regulation in FAK 
and paxillin transcript levels, was inhibited when PC-3 cells were treated with the Smad3 
inhibitor, p=0.18 for FAK transcripts (4.40xl03±5.30xl02) and p=0.43 for paxillin transcripts 
(5 .63x 105± 1.40x 105) compared to the rh-GDF-9 treated cells.
These levels were similar to those seen in the untreated control for FAK (2.72xl03±0.45) and 
paxillin (1.75xl06±5.86xl06). In addition, when these cells were treated with both the Smad3 
inhibitor and rh-GDF-9, FAK (4.52xl03±3.66xl03) and paxillin (2.62xl05±2.95xl04) levels 
remained low, p=0.08 for FAK and p=0.43 for paxillin compared to cells treated with rh-GDF-9 
alone (figure 7.7). This suggests that GDF-9 signals via Smad3 to up-regulate expression of 
these adhesion molecules.
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Figure 7.1: Expression o f FAK and paxillin in transfected prostate cancer cells using PCR. The 
expression o f A. paxillin and C. FAK was increased in the PC-3GDF~9exp cells compared to the 
controls and pc_3GDF-9nb3 cells. The mRNA levels o f B. paxillin and D. FAK were reduced in the 
DU-145GDF'9rib3 cells compared to the controls. Only D V-U S00^ 3 and pc-3GDF-9rib3 are analysed 
for their expression o f FAK and paxillin as they were shown to have the lowest expression levels of 
GDF-9.
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Figure 7.2: ICC staining o f FAK and paxillin in transfected PC-3 cells. The GDF-9 
overexpressing PC-3 cells were treated with anti-FAK and anti-paxillin primary antibodies, 
followed by treatment with the corresponding HRP-conjugated secondary antibodies, ABC 
complex, and DAB chromagen. The cell nuclei were then counterstained with Haematoxylin. The 
cytoplasmic staining for FAK and paxillin was enhanced in the pc_3GDF_9exp cells compared to the 
controls which showed weak staining for both proteins.
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Figure 7.3: Expression o f FAK and paxillin in PC-3 cells in response to 2 hours treatment with rh- 
GDF-9. A. There was an up-regulation in mRNA levels o f both FAK and paxillin in PC-3 cells 
treated with rh-GDF-9, compared to untreated controls. B. The protein levels of paxillin and FAK 
were up-regulated in response to rh-GDF-9 compared to the untreated controls. In addition, rh- 
GDF-9 treatment also resulted in an increase o f phosphorylated and therefore active levels of FAK 
and paxillin (p-FAK and p-paxillin).
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Figure 7.4: Q-PCR quantifying mRNA levels of FAK and paxillin in response to treatment with 
20ng/ml rh-GDF-9. A. An increase in the transcript levels of FAK was seen in the PC-3 cells treated 
with rh-GDF-9 compared to the untreated controls, p=0.07 for the cells treated with rh-GDF-9 for 24 
hours compared to untreated control. B. Transcript levels of paxillin were increased in PC-3 cells 
treated with rh-GDF-9 compared to the untreated controls, p=0.26 for the cells treated with rh-GDF-9 
for 24 hours compared to untreated control. Data shown is representative of 3 independent 
repeats. Error bars represent standard deviation.
242
N
um
be
r 
of 
ad
he
re
d 
ce
lls
90
80
70
60
50
40
20
10
0 PC-3 WT untreated PC-3 WT +rh-GDF-9 PC-3WT+Smad3 PC-3 WT +rti-GDF-9
inhibitor +Smad3 inhibitor
PC-3 WT  
untreated
<n=3)
PC-3 +rh-GDF-9 
(n=3)
PC-3 +Smad3 
inhibitor
(n=3)
PC-3+rh-GDF-9 
+Smad3 inhibitor 
(n=3)
Mean 55.4 86.9 65.9 33.1
SD 635 4.76 2.59 7.18
Figure 7.5: Effect o f Smad3 inhibitor (Calbiochem, Gibbstown, USA) on the adhesive 
capacity of PC-3 cells treated with rh-GDF-9. The PC-3 cells treated with either 3ng/ml 
Smad3 inhibitor, 20ng/ml rh-GDF-9, or both for a period of 40 minutes. Treatment with 
the Smad3 inhibitor resulted in an inhibition of the rh-GDF-9 associated enhanced 
adhesive capacity, *p=0.027 compared to the untreated control and *p=0.002 compared to 
PC-3 cells treated with rh-GDF-9 alone. Data shown is representative of 3 independent 
repeats. Error bars represent standard deviation.
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Figure 7.6: PC-3WT cells were treated either with 3ng/ml Smad3 inhibitor (Calbiochem,
Gibbstown, USA), 20ng/ml rh-GDF-9, or both for a period of two hours before carrying out 
PCR and western blotting using FAK and paxillin specific primers and antibodies. Treatment 
of PC-3 cells with 3ng/ml Smad3 inhibitor resulted in an inhibition in expression levels of rh- 
GDF-9 associated up-regulation of A. FAK and B. paxillin expression using western blot 
analysis. C. and D. demonstrate the same effect but in FAK and paxillin mRNA levels, using 
PCR.
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Figure 7.7: Q-PCR demonstrating quantification of FAK and paxillin mRNA levels in 
response to 2 hour treatment with Smad3 inhibitor. The cells treated with 3ng/ml Smad3 
inhibitor alone and along with 20ng/ml rh-GDF-9 demonstrated reduced levels of A. FAK, 
p=0.18 for cells treated with Smad3 inhibitor alone, and p=0.08 for cells treated with Smad3 
inhibitor and rh-GDF-9 compared to those treated with rh-GDF-9 alone. B. The same was 
true for the expression of paxillin, p=0.43 for cells treated with Smad3 inhibitor alone and 
along with rh-GDF-9, compared to those treated with rh-GDF-9 alone. Data shown is
representative of 3 independent repeats. Error bars represent standard deviation.
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7.3.4 The effect of endogenous GDF-9 on motility and EMT associated molecules
As previously mentioned, GDF-9 can promote the invasive and motile capacity of prostate 
cancer cells. Epithelial to mesenchymal transition (EMT) is a process involved in cancer 
metastasis that can promote the motility of tumour cells. Using IFC, the expression of SNAI1 
and RhoC was analysed in the transfected PC-3 cells (Figure 7.8). Nuclear staining for EMT 
associated molecule SNAI1 was increased in the pc_ 3 GDF-9exP cells, compared to the controls 
and PC-3GDF'9rib3 cells which showed no staining for SNAIl. SNAI1 is known for its inhibitory 
effect on the expression of E-cadherin. Similarly the pc-3GDF'9exp cells had increased 
membrane staining for RhoC compared to the control and knock-down cells.
Furthermore, using PCR, the mRNA levels of these molecules and other EMT associated 
molecules were analysed in the same cells. As can be seen in Figure 7.9, the mRNA levels of 
RhoC, SNAIl, and ROCK-1 were increased in the PC-3GDF'9exp cells compared to the controls 
and PC-3GDF'9rib3 cells. Additionally, ROCK-1 expression was reduced in the DU-145GDF 9rib3 
cells compared to the controls, while no expression of RhoC and SNAIl was detectable in DU- 
145 cells.
One characteristic of EMT is that the cells lose their expression of E-cadherin as they become 
more mesenchymal in nature and thereby start expressing N-cadherin. Accordingly, the 
expression of E-cadherin was down-regulated in the pc_3 GDF-9exP cens compared to the controls, 
while its expression was evident and similar to that of the controls both in the PC-3GDF'9nb3 cells 
and the DU-145GDF'9rib3 cells. N-cadherin mRNA levels meanwhile, were increased in the PC- 
3GDF'9exp cells compared to the controls which had low levels of N-cadherin, and the knock­
down cells which showed no expression. Meanwhile, no expression of N-cadherin was 
detected in the DU-145 cells (Figure 7.10).
7.3.5 The effect of rh-GDF-9 on motility and EMT associated molecules
In order to further confirm the role of GDF-9 on these molecules, PC-3 WT cells were treated 
with 20ng/ml rh-GDF-9 for varying amounts of time, and both normal and Q-PCR were used to
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analyse their expression levels. Treating the cells with rh-GDF-9 resulted in an up-regulation of 
the mRNA levels of N-Cadherin, SNAIl, TWIST, ROCK-1, and RhoC compared to the 
untreated controls, while levels of E-cadherin and SLUG remained relatively unchanged in 
response to rh-GDF-9 treatment (Figure 7.11). Protein levels of RhoC and SNAIl meanwhile, 
were also shown to be up-regulated in response to rh-GDF-9, while E-cadherin levels were 
reduced compared to the untreated controls (Figure 7.16).
Q-PCR analysis meanwhile, allowed for these mRNA levels to be quantified. Both ROCK-1 
and RhoC are molecules associated with cellular migration and motility and are frequently 
over-expressed in cancers. In the case of PC-3 cells treated with rh-GDF-9, levels of ROCK-1 
were up-regulated after about 24 hours (1.42xl09±1.82xl08), compared to the untreated control 
(2.97x 107±7.78x 106), p=0.40. The same was true for RhoC whose expression was also up- 
regulated in response to rh-GDF-9, except after just 30 minutes of exposure. Transcript levels 
of RhoC in the untreated cells were at 3.02xl06±1.81xl06, and after 24 hours treatment with rh- 
GDF-9 had increased to 4.45xl06±2.86xl06, p=0.19.
Furthermore, the rh-GDF-9 associated up-regulation of ROCK-1 mRNA levels 
( 1.19x 105± 1.02x 105) was demonstrated to be Smad3 dependent as treating these cells with 
Smad3 inhibitor (1.83xl04±1.66xl04), either alone or with rh-GDF-9 (6.5xl03±3.56xl03), 
resulted in an inhibition of ROCK-1 up-regulation, p=0.28 for cells treated with Smad3 
inhibitor alone, and p=0.33 for cells treated with both Smad3 inhibitor and rh-GDF-9 compared 
to cells treated with rh-GDF-9 alone (Figure 7.13).
As previously mentioned, transcript levels of E-Cadherin in PC-3 cells were decreased in 
response to rh-GDF-9 after just 30 minutes of treatment. Levels of E-cadherin were 
9.31x 109±3 .78x 108 in the untreated PC-3 cells and after 24 hours had reduced to 
2.43x 109±2 .98x 108, p=0.34. Levels of N-Cadherin meanwhile began to increase after an hour 
of treatment with rh-GDF-9 and had reached levels of 6.57xl05±6.25xl05 compared to the 
untreated control (1.08xl04±1.69xl03), p=0.72 (Figure 7.14). Finally, transcript levels of 
SLUG remained relatively unchanged while those of TWIST demonstrated a marginal increase
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in response to rh-GDF-9, with levels after 24 hours (6.58xl06±9.52xl05 and 
3.64x 106±5 .03x 105, respectively) being similar to those seen in the untreated cells 
(6.70x 106±7.06x 105 for SLUG and 3.44xl06±7.56xl05 for TWIST), p=0.78 for SLUG and 
p=0.19 for TWIST (Figure 7.15).
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Figure 7.8: Immunoflourescent staining of EMT molecules in GDF-9 over-expressing and 
knock-down PC-3 cells using anti-RhoC and anti-SNAIl antibodies. A. The PC-3GDF‘9exp cells 
demonstrated enhanced peripheral staining for RhoC compared to the controls and PC-3GDF‘9nb3 
cells. B. The PC-3GDF'9exp cells demonstrated increased nuclear staining for SNAIl compared 
to the controls and PC-3GDF"9rib3 cells.
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Figure 7.9: Expression of EMT molecules in transfected prostate cancer cells using PCR. 
The pc-3GDF"9exp cells demonstrated increased expression of A. RhoC and B. SNAIl 
compared to the controls and the PC-3GDF'9nb3 cells. No expression of SNAI1 or RhoC was 
found in the DU-145 cells. C. The pc-3GDF'9exp cells had increased mRNA levels of ROCK- 
1 compared to the controls and pc~3GDF-9nb2 cells. D. The DU-145GDF'9nb3 cells demonstrated 
decreased expression of ROCK-1 compared to controls.
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Figure 7.10: Expression of cadherins in transfected prostate cancer cells. A. The PC- 
G^DF-9exP ceps demonstrated increased levels of N-cadherin compared to the controls and the 
pC_3GDF-9rit>3 cells. B. No expression of N-cadherin was found in DU-145 cells. C. The 
PC-3GDF'9exp cells demonstrated decreased levels of E-cadherin compared to the controls 
and pc-3GDf'9rib3 cells. D. Decreased levels of E-cadherin were seen in the DU-145GDF'9rib3 
cells compared to the controls.
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Figure 7.11: Expression of EMT associated molecules in PC-3 cells treated with a time 
course of 20ng/ml rh-GDF-9 using PCR. The levels of RhoC, ROCK-1, N-cadherin, 
SNAIl, and TWIST were increased in response to rh-GDF-9, while those of E-Cadherin 
and apperared to SLUG remain unchanged throughout the time course.
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Figure 7.12: Quantified mRNA levels of ROCK-1 and RhoC in PC-3 cells treated with 
20ng/ml rh-GDF-9. A. ROCK-1 mRNA levels were increased in response to rh-GDF-9 
compared to the untreated controls, p=0.40 for cells treated with rh-GDF-9 for 24 hours 
compared to the untreated control. B. Expression levels of RhoC were increased in 
response to rh-GDF-9, p=0.19 for 24 hours of rh-GDF-9 treatment, compared to untreated 
control. Data shown is representative of 3 independent repeats. Error bars represent 
standard deviation.
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Figure 7.13: Quantified mRNA levels of ROCK-1 in PC-3 cells in response to 2 hour 
treatment with 3ng/ml Smad3 inhibitor (Calbiochem, Gibbstown, USA), using Q-PCR. 
The transcript levels of ROCK-1 were reduced in response to Smad3 inhibitor alone, and 
in conjunction with 20ng/ml rh-GDF-9, compared to the rh-GDF-9 treated cells, p=0.28 
for cells treated with Smad3 inhibitor alone, and p=0.33 for dual treated cells compared 
to rh-GDF-9 treated cells. Data shown is representative of 3 independent repeats. Error 
bars represent standard deviation.
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Figure 7.14: Quantified mRNA levels of E-cadherin and N-cadherin in PC-3 cells treated 
with a time course of 20ng/ml rh-GDF-9, using Q-PCR. A. E-cadherin mRNA levels were 
decreased in response to rh-GDF-9 compared to the untreated controls, p=0.34 for cells 
treated with rh-GDF-9 for 24 hours compared to the untreated control. B. Expression 
levels of N-Cadherin were increased in response to rh-GDF-9, p=0.72 for 24 hours of rh- 
GDF-9 treatment compared to untreated control. Data shown is representative of 3 
independent repeats. Error bars represent standard deviation.
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Figure 7.15: Quantified mRNA levels of SLUG and TWIST in PC-3 cells treated with a 
time course of 20ng/ml rh-GDF-9, using Q-PCR. A. SLUG mRNA levels remained 
relatively unchanged in response to rh-GDF-9, p=0.78 for cells treated with rh-GDF-9 for 
24 hours compared to the untreated control. B. Expression levels of TWIST were 
relatively increased in response to rh-GDF-9, p=0.19 for 24 hours of rh-GDF-9 treatment 
compared to untreated control. Data shown is representative of 3 independent repeats. 
Error bars represent standard deviation.
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Figure 7.16: Western blot demonstrating levels of EMT associated molecules in
response to a time course of 20ng/ml rh-GDF-9 in PC-3 WT cells. Protein levels of E- 
cadherin were reduced in response to rh-GDF-9, while SNAIl and RhoC levels were up- 
regulated.
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7.4 Discussion
In chapter 4, GDF-9 was demonstrated to be capable of promoting the adhesive, invasive, and 
motile capacity of prostate cancer cells, both endogenously and exogenously. These cellular 
properties are all required in order for a cancer cell to progress and thereby metastasise, and so 
cells either acquire mutations or over-express genes that will aid them in these processes. 
Several BMPs have been shown to influence cell motility and migration. Unlike GDF-9, over­
expression of BMP-9 and BMP-10 in PC-3 prostate cancer cells resulted in a decrease in cell 
matrix adhesion, invasion, and migration (Ye et al., 2008; Ye et al., 2009). BMP-2 and BMP-7 
meanwhile were shown to have an opposite effect on osteoblastic prostate cancer cell lines 
LAPC-4 and LAPC-9, where they were demonstrated to promote cell migration and invasion 
(Feeley et al., 2005).
FAK and paxillin are focal adhesion-associated proteins that transmit signals downstream of the 
integrins. These downstream integrin signals are important in regulating processes such as cell 
adhesion, migration, and survival. Cell motility is a process involving changes in actin filament 
dynamics and cell adhesion sites that lead to the formation of membrane protrusions and 
traction forces (Brakebusch and Fassler, 2003). FAK has been shown to influence the 
cytoskeleton, cell adhesion structure sites, and membrane protrusions to regulate cell movement 
(Mitra et al., 2005). Paxillin meanwhile interacts with FAK to recruit signal cascade molecules 
into close proximity in order to allow for efficient signal transduction (Turner, 1998).
Over-expressing GDF-9 in PC-3 cells as well as treating them with rh-GDF-9, resulted in an up- 
regulation of both FAK and paxillin mRNA and protein levels in a Smad3 dependent manner. 
Furthermore, treating the PC-3 cells with Smad3 inhibitor resulted in an inhibition of the GDF- 
9 associated increase in cell matrix adhesion, suggesting that GDF-9 signals via Smad3 to 
promote the adhesive capacity of prostate cancer cells via up-regulation of adhesion molecules 
FAK and paxillin, both of which appear to be GDF-9 target genes.
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In addition to up-regulating FAK and paxillin, GDF-9 also appeared to increase their 
phosphorylation and activation. Phosphorylation of these molecules normally occurs in 
response to integrin mediated cell adhesion and growth factor stimulation (Turner, 1998). This 
suggests that GDF-9 may act as a growth factor to stimulate up-regulation and activation of 
FAK and paxillin, resulting in increased prostate cancer cell adhesion and motility. Another 
BMP that has been reported to have an effect on these molecules is BMP-7. Primary cultures of 
chondrocytes treated with rh-BMP-7, demonstrated up-regulated levels of FAK and paxillin 
expression (Vinall et a l,  2002). In PC-3 prostate cancer cells however, knocking out BMP-7 
resulted in enhanced immuno-fluorescent staining of paxillin and FAK, and a promotion in cell 
matrix adhesion, invasion, and motility (Ye et a l,  2007).
Epithelial to mesenchymal transition (EMT) is a process involving a sequence of changes in 
gene-expression patterns, during which epithelial cells dissipate their epithelial features and 
acquire characteristics typical of mesenchymal cells. EMT has been shown to play an 
important role during tumour progression where the cells acquire mesenchymal cell properties 
in order to acquire enhanced motile and adhesive capacities, allowing them to spread and 
metastasise. The key changes during EMT include a loss of E-cadherin expression and an 
increase in expression of N-cadherin, SNAIl, SLUG (SNAI2), TWIST, vimentin, and 
fibronectin. Accordingly, many of these molecules have been shown to be deregulated in 
cancer (Thiery and Sleeman, 2006).
TGF-pl, 2, and 3 are renowned for regulating EMT of renal tubular cells, ventricular canal 
cells, and mammary ductal epithelial cells, respectively (Zavadil and Bottinger, 2005). More 
recently, BMPs have also been associated with EMT. BMP-4 for example, was demonstrated 
to induce EMT in ovarian cancer cells by up-regulating SNAIl and SLUG, and down- 
regulating E-cadherin, while BMP-7 was shown to reverse TGF-pl induced EMT by up- 
regulating E-cadherin in renal cells (Zeisberg et a l,  2003; Theriault et a l, 2007). These
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results now show that both endogenous and exogenous GDF-9 is capable of aiding in the 
process of EMT by up-regulating molecules including SNAIl, TWIST, and N-cadherin, and 
down-regulating E-cadherin expression. This may also help explain the positive effect of GDF- 
9 on prostate cancer cell adhesion, invasion, and motility.
Rho GTPases are molecular switches involved in cell motility, invasion, and survival, and their 
over-expression has also been associated with enhanced metastasis of several cancer types. 
RhoC for example has been shown to up-regulate the expression of angiogenic factors, promote 
cellular motility, and be vital for PC-3 cell invasion (Yao et al., 2006). Rho GTPases exert their 
effects via their effectors Rho kinases or ROCKs, whose actions are required for assembling 
integrins into focal adhesions which subsequently lead to ERK and FAK activation (Hauck et 
a l,  2002).
Furthermore, both Rho GTPases and ROCKs have been associated with the onset of EMT, 
acting as molecular switches for EMT morphology. BMP-4 induced EMT in ovarian cancer 
cells for example, was shown to be Rho dependent, while ROCK1 was up-regulated at the onset 
of EMT in early heart development, a process dependent on TGF-|33 and BMP-2 (Theriault et 
al., 2007; Sakabe et al., 2008). This study now shows an up-regulation of both RhoC and 
ROCK1 expression in PC-3 cells treated with rh-GDF-9, with ROCK-1 upregulation being 
Smad3 dependent. This suggests that GDF-9 may act as a growth factor to induce expression of 
these molecules which are in turn involved in the GDF-9 associated invasion and motility by 
inducing the onset of EMT leading to an up-regulation in the expression of EMT associated 
molecules.
However, as these results refer to only total protein levels and not phosphorylated and therefore 
active levels, these results are limited. It would therefore be of use to analyse levels of Rho 
regulators; Rho GTPase activating proteins (GAPs) and guanine nucleotide exchange factors 
(GEFs) in response to rh-GDF-9, as this would help determine if GDF-9 not only up-regulates 
Rho/ROCK levels but also results in their activation. Furthermore, LIMK1, a downstream
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effector of Rho GTPases that is responsible for phosphorylating and deactivating cofilin, an 
actin severing and depolymerisation factor, has been shown to associate with the tail region of 
BMPR-II. This suggests that BMPs may work with Rho GTPases to regulate actin dynamics 
and the thereby associated cellular motility and migration (Foletta et a l ,2003). It would 
therefore also be of interest to investigate the effect of GDF-9 on LIMK1, cofilin, and myosin 
light chain kinase (MLCK), an enzyme involved in actin contraction, which could help explain 
GDF-9 associated increased motility and invasion seen in PC-3 cells.
In conclusion, these results suggest that in prostate cancer cells, GDF-9 induced adhesion, 
invasion, and motility is due to a complex network of signalling molecules working together to 
induce the onset of EMT in a Smad-dependent manner, allowing the cancer cells to become 
more aggressive. However, more work is required on the role of Rhos in this process, and the 
associated changes in the actin cytoskeleton.
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Chapter 8 
General discussion
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GDF-9, a member of the BMP family, is known for its role as an oocyte derived growth factor 
vital in early ovarian folliculogenesis and female fertility. Here its actions include regulating 
interactions between oocytes and their surrounding granulosa cells, follicular development, 
granulosa cell proliferation, and cumulus cell expansion. As its expression was initially thought 
to be exclusive to the ovary, it has mainly been studied in the context of female fertility (Dong 
et a l, 1996). One of these studies demonstrated that mice with the GDF-9 gene knocked-out 
were not only infertile, but also developed ovarian tumours (Wu et a l,  2004). Apart from this 
observation, there has been little research carried out on the role of GDF-9 in human cancers.
This laboratory recently demonstrated that highly aggressive breast cancer samples from 
patients with poor prognosis lacked expression of GDF-9. This was in comparison to primary 
breast cancer samples from patients with good predicted prognosis including those who 
remained disease free after a 10 year follow up, which expressed significantly higher levels. 
Furthermore, when GDF-9 was over-expressed in a breast cancer cell line it reduced their 
invasive capacity suggesting that GDF-9 acts as a tumour suppressor in breast cancer (Hanavadi 
et a l, 2007). In contrast, another group reported GDF-9 up-regulation in oral squamous 
carcinoma cell lines more proliferative and less apoptotic in nature, suggesting a pro- 
tumourigenic for GDF-9 in this cancer type (Zhuang et a l, 2010). Finally, human lung 
adenocarcinoma cells with silenced mutant P53 demonstrated with an up-regulation of GDF-9 
expression suggesting that mutant P53 normally inhibits expression of GDF-9 due to its tumour 
suppressing role (Ma et a l,  2006).
Despite the abundance of literature on the role of BMPs in prostate cancer, no studies have 
investigated the role of GDF-9 in this prevalent cancer. Therefore, due to the well-established 
role of BMPs in carcinogenesis, as well as the previous success and experience of studying 
other BMPs in prostate cancer in this laboratory, this study aimed to determine a role for GDF-9 
in prostate cancer progression and metastasis. In addition, as previous studies have suggested 
possible roles for GDF-9 in cancer, as well as demonstrating its anti-apoptotic and pro-
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proliferative role in the ovary, suggested that GDF-9 could be an interesting candidate for 
prostate cancer progression.
The way we went about doing this firstly involved cloning of the coding sequence of human 
GDF-9 and over-expressing it in the prostate cancer cell line PC-3. This was followed by 
construction of ribozyme transgenes in order to knock-down its expression in both PC-3 and 
DU-145 cells. As GDF-9 is an oocyte growth-factor that is processed and secreted in a similar 
fashion to its BMP relatives, and the laboratory had previously shown GDF-9 expression in 
both normal and malignant prostate epithelial cells (unpublished data), it was hypothesised that 
prostate epithelial cells would be capable of secreting GDF-9. Therefore, by altering the 
endogenous expression of GDF-9 in prostate cancer cells, it was anticipated that the secretion of 
GDF-9 would be modified accordingly, allowing the stable transfectants to be used in 
functional assays in order to investigate the effect that altering GDF-9 expression would have 
on the biological properties of prostate cancer cells.
8.1 Effect of altering expression of GDF-9 on prostate cancer cell properties
The over-expression of GDF-9 in PC-3 cells resulted in a promotion in their growth, cell matrix 
adhesion, invasion, and motility compared to the controls. The opposite was observed in the 
GDF-9 knock-down cells, which displayed a decrease in all the aforementioned processes apart 
from invasion, which remained unchanged. The reason for this may be either that GDF-9 plays 
a less important role in prostate cancer cell invasion than it does on the other processes, or that 
when a gene is over-expressed in a cell it can dominate its resulting phenotype, whereas when it 
is silenced, other genes can take over in order to rectify the effect that its absence may have on 
the cell.
In order to ensure that it is actually GDF-9 exerting these effects and not some other factor that 
may have been altered during the incorporation of the GDF-9 plasmid into the cell genome, 
recombinant GDF-9 was generated using metal affinity chromatography, and used to treat the
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cells before carrying out further functional assays. Treating PC-3 WT cells with rh-GDF-9 
resulted in a promotion of their proliferative, adhesive, invasive, and motile capacity, further 
strengthening the evidence that GDF-9 itself does actually influence these processes.
8.2 Effect of GDF-9 on the cell cycle
One of the hallmarks of cancer cell progression is limitless replicative potential by being self 
sufficient in growth signals and insensitive to growth inhibitory signals, thereby allowing the 
tumour to grow and establish itself in its site of origin (Hanahan and Weinberg, 2000). Cancer 
cells mainly achieve this potential in one of two ways; by regulating genes involved either in 
the cell cycle, or those involved in apoptosis. Therefore, in order to establish a mechanism by 
which GDF-9 can promote prostate cancer cell growth, both the transfected cells and those 
treated with rh-GDF-9 underwent cell cycle and apoptotic analysis with the use of flow 
cytometry. In the case of the cell cycle, the pc_3GDF-9exP- cells demonstrated a significant 
increase in the fraction of cells present in the G2/M phase compared to the controls and PC- 
G^DF-9nh3 cejjs suggestjng GDF-9 may promote cells into the replicative stages of mitosis, 
only partially explaining its positive role on prostate cancer cell growth.
During the G1 phase of the cell cycle, cells respond to growth factor stimulation, mitogens, and 
cyclins to either commit to further division and thereby progress to the G2/M phase, or exiting 
the cycle into a resting state known as the GO phase. Cyclin D1 peaks during mid G1 phase 
where it binds to CDK4/6 resulting in phosphorylation and inhibition of Rb, thereby releasing 
the transcription factor E2F to activate the transcription of genes required for G1 to S phase 
transition, and hence cell cycle progression (Tashiro et a l, 2007). Furthermore, Cyclin D1 has 
been shown to have oncogenic potential and is often over-expressed in lymphomas and thyroid 
cancers. Tumour cells that overexpress Cyclin D1 overcome the Gl/S checkpoint as it 
competes with CDK inhibitor P16 for CDK4 binding, resulting in cell cycle progression despite 
DNA damage. Its oncogenic effects include VEGF production, promotion of anchorage-
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independent growth, and resistance to chemotherapeutic agents by protecting cells from Fas 
induced apoptosis (Shintani et al., 2002).
As GDF-9 was shown to promote cells into the G2/M phase of the cell cycle, PC-3 cells were 
treated with rh-GDF-9 in order to determine its effect on Cyclin D1 expression. This resulted in 
an increase of both the mRNA and protein levels of Cyclin D l, compared to the untreated 
control, suggesting that GDF-9 may promote cell cycle progression by up-regulation of Cyclin 
D l, which may further aid in prostate cancer cell progression. These results are in line with 
previous reports which demonstrated that GDF-9 promotes the proliferation of human granulosa 
cells by enhancing cell transition from G1 to S and G2/M phases, by up-regulating expression 
of cyclins D l and E, decreasing expression of CDK inhibitors P15 and P16, and activating Rb, 
via both Smad-dependent and Smad-independent pathways (Huang et al., 2009). In contrast, 
most other BMPs have been shown to have inhibitory effects on the cell cycle, with BMP-2 
stimulating levels of CDK inhibitor P21 and its association with cyclins D l and E, to induce 
inhibition of MDA-MB-231 breast cancer cell proliferation, and BMPs -6 and -7 inducing cell 
cycle arrest via induction of CDK inhibitors in keratinocytes and thyroid carcinoma cells, 
respectively (Ghosh-Choudhury et al., 2000; Franzen and Heldin, 2001; Gosselet et al., 2007).
8.3 Effect of GDF-9 on apoptosis
As the effect of GDF-9 on the cell cycle of prostate cancer cells was insufficient to explain the 
considerable induction of cell growth, the cells underwent apoptotic analysis with flow 
cytometry and Hoechst DNA staining. Both the p c _ 3GDF*9exP- ceps ancj pc-3 cells treated with 
rh-GDF-9 showed a significant reduction in the percentage of apoptotic cells under serum 
starvation, compared to the controls. Furthermore, p c _ 3GDF'9nb3 cells had around 15% more 
apoptotic cells than the controls, suggesting that GDF-9 may act as an anti-apoptotic factor 
protecting PC-3 cells from undergoing apoptosis.
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Apoptosis is orchestrated by a variety of molecules, including a family of cysteine proteases 
known as the caspases. Caspase 3 is known as an executioner caspase essential for cytochrome 
C action and DNA fragmentation. Caspase-3 is expressed as an inactive precursor, which is 
cleaved into mature caspase-3 subunits during apoptosis (Slee et a l,  2001). Due to the anti- 
apoptotic nature of GDF-9, pc_ 3 GDF-9exP demonstrated significantly lower expression levels of 
caspase-3 mature subunits compared to both the controls and the knock-down cells. In addition, 
protein levels of caspase-3 were gradually reduced over time when treated with rh-GDF-9, 
suggesting that GDF-9 may act as an anti-apoptotic factor in prostate cancer cells, protecting 
them from caspase-3 mediated apoptosis.
This anti-apoptotic effect of GDF-9 has also been demonstrated in granulosa cells where the 
cells are protected from undergoing ceramide induced apoptosis due to GDF-9 associated 
activation of the PI3K/AKT pathway promoting follicular cell growth and survival. 
Furthermore, GDF-9 antisense resulted in caspase-3 activation and induced apoptosis in 
granulosa cells of early antral follicles, suggesting that similarly to in prostate cancer cells, 
GDF-9 acts as an anti-apoptotic factor in preantral follicles (Orisaka et a l,  2006). In addition, 
its family member, BMP-2 was demonstrated to prevent an up-regulation of caspase-3 levels in 
MCF-7 breast cancer cells grown in serum free media (Clement et a l, 2000)
Other BMPs have been shown to regulate apoptosis through several signalling pathways. BMP- 
2 for example has been shown to induce apoptosis in medulloblastoma cells by activating the 
P38 mitogen-activated protein kinase (MAPK) pathway, while protecting MCF-7 cells from 
hypoxic cell death by activating the MAPK extracellular-signal-regulated kinases 1/2 (ERK1/2) 
pathways (Hallahan et a l,  2003; Raida et a l, 2005). BMP-9 meanwhile was previously shown 
to signal via BMPRIB and BMPRII to induce prostate cancer cell apoptosis in a Smad 1/5/8 
dependent manner via Par-4, while BMP-4, -5, -6, and -7 can induce apoptosis of myeloma 
cells through ALK3/6, ALK3, and ALK2, respectively (Ro et a l, 2004; Ye et a l, 2008).
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In order to determine which pathway GDF-9 uses to inhibit apoptosis, the PC-3 cells were 
treated with Smad3 inhibitor and analysed for proliferation, and then apoptosis. While the 
Smad3 inhibitor prevented GDF-9 associated increased growth, unexpectedly, it had no effect 
on the anti-apoptotic role of GDF-9, suggesting that while GDF-9 induced growth promotion is 
Smad3 dependent, its effects on apoptosis are not. This implies that GDF-9 may only signal via 
Smad3 to induce cell cycle progression to promote cell growth, and that a Smad-indepedent 
pathway may be responsible for its anti-apoptotic effects.
8.4 Signalling pathway of GDF-9 in prostate cancer cells
As previously mentioned, BMPs signal via two main pathways; the Smad-dependent, activated 
when the ligands bind to a preformed receptor complex, and Smad-independent, triggered when 
the ligand first binds the type I receptor, and then recruits the type-II receptor. In the ovary, 
GDF-9 has been shown to signal via ALK-5 and BMPR-II to activate Smads2 and 3 
(Mazerbourg et al., 2004). This study now shows that in prostate cancer, GDF-9 signals via 
ALK-5 to activate Smad3. Both the pc_3GDF-9exP cells and those treated with rh-GDF-9 
demonstrated increased protein levels of pSmad3, an effect that was inhibited by the Smad3 
inhibitor. In addition, levels of phosphorylated ALK-5 were also up-regulated in response to 
rh-GDF-9 suggesting that GDF-9 binds to ALK-5, and an as of yet unconfirmed type-II 
receptor, to phosphorylate and activate Smad3 in order to induce expression of its target genes.
Surprisingly, ALK-5 phosphorylation was inhibited by treatment with the Smad3 inhibitor. 
Smad7 is known to associate with Smurf following TGF-J3 stimulation, and ubiquitinates TGF-p 
receptors, resulting in their degradation. As Smad7 is a TGF-p target gene, this mechanism acts 
as a form of negative regulation, and while this form of regulation is more established, positive 
forms also exist (Moustakas and Heldin, 2009). For example, it has been shown that in some 
cell types, Smads are also capable of up-regulating BMP receptor expression in a positive
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feedback loop (Engel et al., 1999). Therefore, it is possible that GDF-9 acting via Smad3, can 
lead to up-regulation of its type-I receptor as a way of amplifying its downstream signalling.
The Smad-independent pathway involves ERK-1 and 2, P38, and JNK MAPKs, as well as RAS 
signalling (Nohe et al., 2002). Treating PC-3 cells with rh-GDF-9 resulted in increased levels 
of ERK and JNK, an effect that was Smad3 dependent in the case of JNK only. Furthermore, 
immunoprecipitating the cells with a serine/threonine phosphorylated antibody, resulted in 
elevated levels of active p-ERK and p-JNK, both of which were unaffected by the Smad3 
inhibitor. This suggests that while JNK itself may be a GDF-9 target gene, that GDF-9 
activates and signals via ERK and JNK independently of the Smads, thereby exerting MAPK 
associated effects on the PC-3 cells.
Although BMPs normally activate the MAPK pathway independently of the Smads, there has 
been proof of cross talk between the JNK and Smad dependent pathways. For example, JNK 
was shown to promote Smad signalling by phosphorylating Smad3 and inducing its nuclear 
translocation. Furthermore, this relationship was shown to be interdependent in that although 
the initial rapid induction of JNK is independent of the Smads, the sustained secondary JNK 
response is Smad dependent, and both require Rho GTPase (Engel et al., 1999). Therefore, it 
is possible that GDF-9 can not only signal via the MAPK pathway (shown by its induction of p- 
JNK and p-ERK), but that it can also up-regulate and activate JNK signalling via Smad3, and 
possibly RhoC.
The MAPK pathway is a major signalling pathway involved in cellular proliferation, affecting 
both apoptosis and the cell cycle. JNKs are a sub-family of the MAPK superfamily and have 
been shown to phosphorylate and regulate transcription factors including P53 and c-Myc, as 
well as members of the Bcl-2 family, in response to extracellular stimuli (Liu and Lin, 2005). 
The role of JNK in apoptosis is two-fold, as it has been demonstrated to exert both pro-, and 
anti-apoptotic functions, depending on cell type, the nature of the death stimulus, the extent of
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its activation, and cross talk with other signalling pathways. Its anti-apoptotic effects are 
induced by its capability o f phosphorylating pro-apoptotic molecule BAD, and thereby 
triggering its sequestration, and preventing inactivation of anti-apoptotic Bcl-2 (Liu and Lin, 
2005). Furthermore, BMP-7 was shown to protect LNCaP and C4-2B prostate cancer cells by 
stabilising survivin levels and restoring JNK activity (Yang et a l ,  2006). Apart from its anti- 
apoptotic roles, treating KB-3 carcinoma cells with JNK inhibitor resulted in an inhibition of 
cell growth with an increase of cells in the G2/M phase and apoptotic fractions, suggesting that 
JNK is involved in cellular proliferation as well as apoptosis (Du et al., 2004).
Similarly, ERK1 and 2 are members of the MAPK superfamily that can mediate cell 
proliferation and apoptosis in response to different growth signals. Accordingly, this pathway 
is frequently deregulated in several types of cancers. Like JNK, ERK can exert both pro- 
apoptotic and anti-apoptotic effects, depending on the cell and signal type (Mebratu and 
Tesfaigzi, 2009). For example, as previously mentioned, MCF-7 cells can be rescued from 
hypoxic cell death via BMP-2 induced ERK1/2 activation, while senescent cells treated with 
BMP-4, demonstrated reduced levels of ERK activation, VEGF, and Bcl-2, consistent with the 
less proliferative and more apoptotic nature of senescent cells (Buckley et al., 2004; Raida et 
al., 2005). This evidence makes it plausible that GDF-9 activation of ERK and JNK may be 
one of the ways in which it can promote prostate cancer cell growth via cell cycle progression 
and protection from apoptosis.
8.5 Effect of GDF-9 on FAK and paxillin mediated cell movement
As previously shown, GDF-9 can promote the adhesive, invasive, and motile capacity of 
prostate cancer cells, both endogenously and exogenously. In order to determine a mechanism 
by which GDF-9 exerts these effects, several motility associated molecules were screened as 
potential GDF-9 target genes. FAK and paxillin are focal adhesion-associated proteins that 
mediate integrin cellular properties, including; cell adhesion, migration, motility, and survival.
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Cell motility involves changes in the cytoskeleton as well as focal adhesion turnover, and FAK 
along with paxillin have been demonstrated to regulate cell movement via influences on the 
cytoskeleton and cell adhesion sites (Brakebusch and Fassler, 2003). Fibroblasts from FAK or 
paxillin knock-out mice exhibit reduced rates of migration and cell spreading, proving how vital 
FAK and paxillin are in these processes (Ilic et al., 1995). This therefore makes them worthy 
candidates as GDF-9 target genes. Indeed, both pc-3GDF'9exp cells and PC-3 WT cells treated 
with rh-GDF-9, resulted in an up-regulation of both inactive and active FAK and paxillin. As 
FAK and paxillin phosphorylation normally occurs in response to growth factor stimulation, 
this suggests that GDF-9 may act as a growth factor to induce their activation and up-regulation, 
in order to promote prostate cancer cell adhesion and motility.
Furthermore, the MAPK/ ERK pathway is a well known target of FAK-Src signalling whose 
activation is assisted by interaction with paxillin. A recent study showed that FAK, paxillin, 
and Src, along with ERK, are critical for adhesion turnover, a process that is central to cell 
migration (Webb et al., 2004). This implies that GDF-9 may up-regulate levels of active FAK, 
paxillin, and ERK, in order for them to interact and promote prostate cancer cell migration. 
This is not the first BMP found to affect FAK and paxillin levels. BMP-2 can act to enhance 
cell migration of osteosarcoma cells via focal adhesion formation induced by FAK 
phosphorylation, whereas BMP-7 was shown to up-regulate levels of paxillin and FAK in both 
bovine chondrocytes and prostate cancer cells, an effect that enhanced their adhesive, invasive, 
and motile capacity (Vinall et al., 2002; Sotobori et al., 2006; Ye et al., 2007).
8.6 Effect of GDF-9 on Rho GTPase and ROCK
Rho GTPases, and their most common effectors ROCKs, are important regulators of cellular 
processes including cell motility, proliferation, and apoptosis. They play a central role in cell 
adhesion and motility, by reorganising the actin cytoskeleton and regulating actomyosin 
contractility. Furthermore, Rho-ROCK interactions have been demonstrated to be involved in
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tumour invasion and metastasis by increasing cell motility through regulation of actomyosin 
driven amoeboid movement, disrupting epithelial sheet organisation, and promoting 
extracellular matrix (ECM) degradation through secretion of matrix-metalloproteinases 
(MMPS) (Itoh et a l ,  1999). Accordingly, RhoC has been associated with the invasive 
phenotype of cancers and was shown to be over-expressed in more aggressive and metastatic 
pancreatic ductal adenocarcinomas (Suwa et al., 1998). Futhermore, in melanomas it has been 
implicated as a metastasis gene, and in breast cancer by interacting with ROCK, RhoC been 
shown to induce expression of angiogenic factors (van Golen et a l ,  2000; Collisson et a l, 
2003). Consequently, ROCK has been implicated in increased breast cancer cell migration 
during tumour cell invasion and metastasis (Bourguignon et a l ,  1999).
These findings are of interest because this current study shows that GDF-9 can induce 
expression of both RhoC and ROCK-1. And while without measuring levels of their 
phosphorylated forms, or levels of their activators Rho GEFs or GAPs, these prelimary results 
suggest that GDF-9 may promote prostate cancer cell invasion and motility by induction and 
up-regulation of the Rho-ROCK pathway.
Furthermore, Rho and ROCK can induce changes in the expression, activation, and distribution 
of focal adhesion proteins, and are required for the assembly of integrins into focal adhesions 
resulting in activation of ERK1/2 and FAK (Sahai and Marshall, 2002). More specifically, high 
levels of RhoC in PC-3 cells can induce paxillin/PKL interaction resulting in increased cell 
motility, and knocking-out RhoC in these cells resulted in decreased levels of FAK and p- 
paxillin suggesting that RhoC can induce expression of these molecules to promote prostate 
cancer cell invasion and motility (Yao et a l ,  2006). Therefore, as GDF-9 has been shown to 
activate FAK and paxillin, these observations add to the claim that GDF-9 may be able to 
promote prostate cancer cell motility and adhesion via RhoC, possibly via activation of FAK 
and paxillin.
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Rho GTPases have also been implicated in cell proliferation, by affecting both the cell cycle 
and apoptosis. For example, RhoA along with RhoC has been shown to promote the 
proliferation of human gastric carcinoma cells by protecting them from apoptosis via activation 
of the PI3K/AKT pathway (Sun et al., 2007). Meanwhile, caspase-3 mediated cleavage and 
activation of ROCK1, is vital for the formation of membrane blebbing during apoptosis 
(Coleman et al., 2001). However, despite this pro-apoptotic role, ROCK mediated survival 
effects have been shown in cancer cells, epithelial cells, and endothelial cells. Inhibition of Rho 
and ROCK for example, triggered apoptosis of anaplastic thyroid cancer and glioma cells, by 
inducing the release of cytochrome C and activating caspases 3 and 9, whereas sole inhibition 
of ROCK by Y27632, reduced cardiomyocyte apoptosis by preventing down-regulation of Bcl- 
2 (Zhong et al., 2003; Bao et al., 2004; Rattan et al., 2006).
As this current study shows that GDF-9 results in down-regulation of caspase-3, these findings 
suggest that GDF-9 may exert its anti-apoptotic effects either by preventing caspase-3 mediated 
ROCK cleavage and thereby apoptosis, and/or by up-regulating and activating the Rho-ROCK 
pathway which thereby induce survival signals and reduce levels of caspase-3. Furthermore, 
another link exists between GDF-9 associated increased growth and the Rho-ROCK pathway. 
Rho signalling is vital for sustaining the ERK signal required for mid G1-phase, Cyclin D l up- 
regulation, and thereby promotion of cell cycle progression (Welsh et al., 2001). As PC-3 cells 
treated with rh-GDF-9 demonstrated increased levels of activated ERK and Cyclin D l, it adds 
to the idea that GDF-9 may signal via RhoC and ROCK to promote prostate cancer cell 
adhesion, motility, and growth. However, more work is required in order to make this claim 
conclusive.
8.7 Effect of GDF-9 on EMT associated molecules
Epithelial to mesenchymal transition is positively correlated with increased cell motility and 
invasion, and so it makes sense that cancer cells often manipulate this process in order to
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progress and metastasise. Adenocarcinoma invasion for example, involves the release of single 
cancer cells that have undergone EMT (Thiery, 2002).
One hallmark of EMT is the loss of E-cadherin expression, an epithelial cell marker involved in 
cell-cell adhesion and formation of adherens junctions, and the up-regulation in levels of N- 
cadherin which is a mesenchymal cell marker. Loss of E-cadherin expression is often observed 
in sites of EMT that occur during embryonic development and cancer progression (Cowin et al., 
2005). Several transcription factors have been implicated as repressors of E-cadherin 
expression, including; SN AIl, SLUG (SNAI2), and TWIST. They also act as molecular triggers 
of EMT, by acting to both repress epithelial cell markers, and induce expression of known 
promoters of EMT, including growth factors such as epidermal growth factor (EGF), hepatocyte 
growth factor (HGF), and TGF-0. As the loss o f E-cadherin is associated with tumour 
progression and hence poor clinical outcome, these E-cadherin repressors are considered as 
markers of malignancy (Gavert and Ben-Ze'ev, 2008).
This change in expression profile was also demonstrated in PC-3 cells in the presence of GDF- 
9, where GDF-9 induced expression of SNAIl, TWIST, and N-cadherin. E-Cadherin levels 
meanwhile were reduced compared to the untreated controls, while no changes were seen in the 
expression of SLUG. As the literature suggests that SNAIl and TWIST are capable of 
repressing E-cadherin expression, it implies that GDF-9 induces up-regulation of these 
transcription factors, resulting in E-cadherin repression and increased cell aggressiveness. 
However, in order to confirm this hypothesis, levels of the phosphorylated and thereby active 
forms of these transcription factors need to be assessed. Despite this, these observations along 
with the more mesenchymal like nature of the pc_3GDF'9exP cells, were all in line with the onset 
of EMT, suggesting that GDF-9 can induce EMT in PC-3 cells by up-regulating levels of EMT 
inducing molecules, resulting in a promotion of cell invasion and motility.
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Furthermore, SN AIl has also been demonstrated to act as a survival factor independently of its 
EMT inducing actions, by protecting cells from undergoing apoptosis, induced either by a 
deficit of survival factors or by direct apoptotic stimuli, and can also control cell adhesion and 
migration (Kajita et al., 2004). These characteristics of SNAIl match with the observations of 
GDF-9 made in this study, signifying that GDF-9 induced SNAIl up-regulation may, as well as 
aiding in induction of EMT, affect cell adhesion and migration, and protect the cells from 
undergoing apoptosis.
TGF-p is a powerful inducer o f EMT not only during embryonic development but also during 
tumour progression. For example, Smad2 and 3 over-expression induces EMT in a mammary 
epithelial model, where they can down-regulate levels of epithelial cell markers including E- 
Cadherin and ZO-1, while up-regulating levels of mesenchymal proteins such as fibronectin and 
vimentin, amongst others. In addition, several BMPs have also been implicated as inducers of 
EMT. BMP-2 signalling in gastric cancer cells for example, can promote EMT associated 
morphological changes including repression of E-cadherin, and induction of SNAIl and 
vimentin expression (Kang et a l) . BMP-4 meanwhile, induces EMT in primary epithelial 
ovarian cancer cells by up-regulating SNAIl and SLUG, and repressing E-cadherin expression 
while increasing cell adhesion, invasion, and motility (Theriault et al., 2007).
Ras, MAPK, and Rho/ROCK signalling pathways have been demonstrated to cooperate with 
TGF-p and BMPs to promote EMT. TGF-pi for example, activates Rho-ROCK signalling via 
ALK-5 to induce EMT in NMuMG breast cancer cells, while ROCK-1 was upregulated at the 
onset of TGF-P and BMP-2 induced EMT in early heart development (Bhowmick et al., 2001; 
Sakabe et al., 2008; Xu et a l ,  2009). In addition, Rho GTPases were highly expressed in the 
ovarian cancer cells that underwent BMP-4 induced EMT, suggesting that the process was 
mediated by Rho GTPase signalling (Theriault et a l ,  2007). Meanwhile, RhoA can mediate 
JNK and p38 activation in order to induce Smad mediated signalling and EMT associated 
characteristics, including delocalisation of E-cadherin from cell junctions, and elevation of N-
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cadherin levels, suggesting that both TGF-P Smad-dependent and independent signalling is 
required for EMT induction (Xu et a l ,  2009). These observations speculate that GDF-9 
induced EMT seen in PC-3 cells, may be partially dependent on Rho-ROCK signalling and that 
this pathway may interact with the Smad-dependent pathway in order to control the EMT 
process.
8.8 Main findings/significance of this study
This study is the first to reveal a role for GDF-9 in the progression of prostate cancer cells. This 
was initially achieved by altering the endogenous expression of GDF-9 via both over­
expression using cloning in PC-3 cells, and for reliability, gene silencing using ribozyme 
transgenes, in both PC-3 and DU-145 cells. These cells were then examined for any changes in 
their biological properties by carrying out functional assays that analyse the proliferative, 
adhesive, invasive, and motile capacity of these cells. Furthermore, recombinant GDF-9 was 
generated, in order to treat the cells and confirm the effect it has on prostate cancer cell 
biological properties, as well as any target genes and downstream signalling which would act as 
mechanisms for these effects.
Both endogenous and exogenous GDF-9 was capable of promoting prostate cancer cell 
adhesion, invasion, motility, and growth, an effect that was reversed in the GDF-9 knock-down 
cells. GDF-9 mediated growth promotion was shown to be associated both with an increase in 
cell cycle progression via up-regulation of Cyclin D l, and protection from apoptosis in a Smad- 
independent manner, possibly via a combination of SNAIl, Rho-ROCK, and/or ERK/JNK 
signalling all of which were activated by GDF-9. However, this requires further research into 
the activated forms of SNAIl and Rho/ROCK. Furthermore, GDF-9 associated cell adhesion, 
motility, and invasion appeared to be due to the interactions of FAK, paxillin, Rho-ROCK 
signalling, and the induction of EMT via its associated inducers, in a Smad-dependent and
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Smad-independent manner. All of these effects result in an increase in the aggressiveness of 
PC-3 cells, aiding in their progression and possibly metastasis.
Additionally, with the use of recombinant rh-GDF-9, GDF-9 was shown to signal via ALK-5 to 
activate Smad3 signalling in order to exert some of its effects on prostate cancer cells. FAK, 
paxillin, and ROCK-1 were shown to be Smad3 target genes, while GDF-9 associated growth 
and adhesion were also shown to be Smad-dependent. A type II BMP receptor was not able to 
be identified however, due to the lack of a specific anti-BMPR-II antibody, and hence needs 
further investigation. Apart from Smad dependent signalling, GDF-9 was capable of activating 
MAPK pathways including ERK and JNK, which contributed to some of the GDF-9 associated 
effects observed.
These results suggest that GDF-9 may play an important role in prostate cancer aggressiveness 
via activation of a complex network of signalling pathways and molecules. It provides 
researchers in the field of prostate cancer with further proof of the importance of BMP 
signalling, and suggests that perhaps novel treatments based on BMPs should be investigated. 
Manufacturing of drugs capable of blocking or altering BMP signalling may prove beneficial to 
the treatment of prostate cancer. In addition, some BMPs could perhaps be used as prognostic 
indicators of disease, aiding in diagnosis and treatment. Whether or not this would include 
GDF-9 requires further investigation.
8.9 Future work
Although this study gives an idea of the role of GDF-9 in prostate cancer, there are many loose 
ends that still need to be tied up in order to fully understand its importance in the field. For 
example, although we have demonstrated an anti-apoptotic role for GDF-9 in prostate cancer, 
the mechanisms still remain unclear. The literature suggests that in the ovary GDF-9 protects 
from cells from apoptosis by activating the PI3K/AKT pathway (Orisaka et al., 2006).
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In addition, Rho/ROCK signalling has been demonstrated to regulate both Bad and Bcl-2, and 
as GDF-9 can up-regulate RhoC and ROCK-1, the expression levels of these molecules should 
be investigated (Rattan et a i ,  2006). Furthermore, signalling molecules of the Smad- 
independent pathway with anti-apoptotic effects such as TAK-1 and XIAP, should also be 
analysed. Although Cyclin D1 appears to be one of the mechanisms behind the role of GDF-9 
in the cell cycle, a more precise mechanism needs to be determined. We found that oncogene 
C-myc, a known activator of Cyclin D1 was up-regulated by rh-GDF-9. However, this data was 
inconclusive and requires further study (Mateyak et al., 1999).
Meanwhile, while this study has proposed that GDF-9 may play a role in prostate cancer 
motility and has suggested several key players such as Rho/ROCK, EMT transcription factors, 
and MAPK signalling, little work was carried out on the phosphorylated, and hence activated 
levels of these proteins. It would therefore be of interest to analyse levels of Rho GTPase 
regulators Rho GAPs and GEFs, as well as their downstream regulators Wiskott-Aldrich 
syndrome proteins (WASPs) and WAVEs, in order to confirm the role that these proteins play 
in GDF-9 associated prostate cancer progression.
As previously mentioned, LIMK1 has been shown to bind to the tail region of BMPR-II to 
regulate cofilin, a regulator of actin dynamics, and therefore cell migration (Folleta et al., 
2003). As this has been shown to involve Rho GTPases, and GDF-9 signals via BMPR-II, 
analysis of activated levels of LIMK1, cofilin, Arp2/3, formin, and MLCK, would also be of 
use. In addition, as all these molecules are involved in actin dynamics, and relatively little 
microscopy work was carried out during this study due to several restrictions in equipment, it 
would be necessary to carry out some confocal microscopy to visualise the actin filaments and 
stress fibres via phalloidin and the proteins mentioned above, and focal adhesion complexes via 
FAK, paxillin, integrins, and Src, to further establish the role of GDF-9 in motility.
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Furthermore, although we have shown that GDF-9 can signal via ALK-5 to activate Smad3, 
immunoprecipitation and western blotting effects on determining a type-II receptor for GDF-9 
mediated signalling were unsuccessful. The literature suggests that the type-II receptor for 
GDF-9 is BMPR-II and so further attempts are required in order to confirm if this is also the 
case in prostate cancer cells. Although some of the target genes were found to be Smad3 
dependent, there was not enough time to determine the signalling pathway of the other target 
genes.
As this study portrays an interesting role for GDF-9 in prostate cancer, its role in prostate 
cancer metastasis and angiogenesis, as well as in the bone was not investigated. As several 
other BMPs have been implicated in aiding in bone metastasis from prostate cancer, it would be 
of interest to perhaps carry out some tubule formation assays, as well as analyse levels of 
VEGF. On the other side of the spectrum, it might also be appealing to see the effect of GDF-9 
on normal prostate epithelial cell lines such as PNT2C2 and PNT1A, and see if it would make 
them more aggressive. Unfortunately, there were problems in growing and transfecting these 
cell lines and hence this could not be done.
All of the experiments carried out in this study have been in vitro, therefore, in order to get a 
clearer role for GDF-9 in prostate cancer progression, the role of GDF-9 in vivo should also be 
studied, possibly in the form of GDF-9 knock-out mice. In addition, analysing GDF-9 
expression in clinical samples from patients with prostate cancer would also help in determining 
if any therapeutic or diagnostic value for GDF-9 in prostate cancer exists.
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lOOng/ml
(n=3)
Mean 0.70 0.80 0.84 1.01 1.03 1.35 1.60 1.71
SD 0.04 0.04 0.11 0.41 0.11 0.21 0.28 0.30
Figure A l: Growth assay on PC-3 WT cells treated with varying concentrations o f rh-GDF-9, 
following 4 days incubation. The cells were stained with crystal violet, and diluted with acetic 
acid before the absorption was measured using a spectrophotometer. The first concentration at 
which there was a statistically significant change in the absorbance and hence growth o f the 
cells was 20ng/ml rh-GDF-9, p=0.04 compared to untreated control. 20mg/ml rh-GDF-9 was 
then selected as the concentration at which to treat the cells in all further functional assays.
This data is representative o f three independent repeats. Error bars represent standard 
deviation.
